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Epithelial ovarian cancer (EOC) is clinically heterogeneous, comprising 
different histological and molecular subtypes. Multiple studies have implicated 
epithelial-mesenchymal transition (EMT), a biological process by which polarized 
epithelial cells convert into mesenchymal phenotype, to have significant contribution 
to the molecular heterogeneity of EOC. From the gene expression analysis of EOC 
tumours and EMT-characterized EOC cell lines, Grainyhead-like 2 (GRHL2) emerges 
as a transcription factor essential for the maintenance of epithelial phenotype. By 
validating the transcript and protein levels, the expression of GRHL2 was found to be 
exclusive in epithelial-like EOC cells, correlated positively with the expression of 
epithelial marker E-cadherin. In addition, EOC tumours with lower expression of 
GRHL2 showed poorer outcome and were associated with the Mes (mesenchymal) 
molecular subtype. shRNA-mediated loss-of-function experiments demonstrated that 
knockdown of GRHL2 in epithelial-like EOC cells resulted in partial or full EMT, 
accompanied by an increase in cell motility, migration and invasion. Knockdown of 
GRHL2 not only down-regulated E-cadherin expression, but also affected the stability 
of E-cadherin at cell-cell junctions, coupled with an up-regulation of mesenchymal 
markers vimentin and N-cadherin. This EMT-related function of GRHL2 in EOC is 
likely to involve a double negative feedback regulation between GRHL2 and ZEB1, a 
well-accepted EMT driver. By combining microarray analysis and chromatin-
immunoprecipitation sequencing (ChIP-seq), some of the putative direct targets of 
GRHL2 were identified and validated, including protein-coding and non-coding 
genes. Interestingly, this study showed that GRHL2 binds to the promoter of 
MIR203A and the previously characterized shared promoter of 
MIR200B/MIR200A/MIR429, suggesting the participation of microRNAs, GRHL2 
and other EMT transcription factors in a complex regulatory network. In conclusion, 
GRHL2 serves as a gatekeeper of the epithelial state of EOC and a negative regulator 
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1.1 Introduction to Ovarian Cancer 
Ovarian cancer, which includes all neoplasms originated from the ovaries, is 
one of the most fatal gynaecological malignancies in women. Due to the lack of early 
discernible symptoms, patients are often presented at advanced stages with poor 
prognosis (Coleman et al, 2013). In year 2012, global statistics listed 238,719 new 
cases being diagnosed and 151,905 cases being reported dead, ranking ovarian cancer 
as the seventh most common cancer and the eighth most common cause of cancer-
related death in women worldwide (Ferlay et al, 2013). In Singapore, 1646 new cases 
of ovarian cancer were diagnosed, while 583 patients died from the disease between 
year 2009 to 2013 (Singapore Cancer Registry, 2015). Studies have shown that 
ovarian cancers can arise from three main types of ovarian tissues: surface epthelial 
cells, sex cord-stromal tissues and germ cells (Scully, 1987; Chen et al, 2003). Of all 
malignant ovarian tumours, epithelial ovarian cancer (EOC), which consists of mostly 
carcinomas, is the most common type, accounting for about 90% of cases (Chuaqui et 
al, 1998).  
 
1.1.1 The origin of epithelial ovarian cancer (EOC) 
To date, the origin of EOC remains debatable. It has long been suggested that 
EOC originated from the ovarian surface epithelium (OSE), but recent findings 
propose the concept of extraovarian origin of EOC, of which high-grade serous 
carcinoma, the most common form of EOCs, are likely to arise from the fallopian 
tube fimbriae cells (Dubeau and Drapkin, 2013). Evidence-based analysis suggests to 
include both possibilities, that high-grade serous EOC can develop from either the 
OSE or the oviductal fimbriae (Auersperg, 2013).  
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 Four main hypotheses have been postulated to explain the pathogenesis of 
EOC. The first proposed hypothesis associates the occurrence of EOC with incessant 
ovulation. It is suggested that the repeated surface rupture and wounding of OSE after 
each round of ovulation is likely to increase the rate of somatic mutations and the risk 
of malignant transformation in OSE cells (Fathalla, 1971). This theory is supported by 
most epidemiological data that showed a significant reduced risk of EOC in women 
with lower rate of ovulation (through pregnancy, lactation, oral contraception, or early 
menopause) (Purdie et al, 2003). The second aetiological hypothesis of EOC proposes 
the involvement of gonadotropin secretion from the pituitary gland, which has a 
stimulatory effect on OSE cell proliferation (Cramer et al, 1983). A higher rate of 
EOC is shown in women at postmenopausal stage, during which the two 
gonadotropins (follicle-stimulating hormone and luteinizing hormone) are stably 
elevated (Choi et al, 2007). However, this hypothesis is challenged by inconclusive 
data that show gonadotropins could both inhibit and stimulate tumourigenesis in vitro 
and in vivo (Choi et al, 2007). The third hypothesis suggests a link between EOC risk 
and the levels of the sex-steroid hormones (Risch, 1998). Elevated androgen due to 
androgenic medication such as danazol increases the risk of developing EOC 
(Cottreau et al, 2003); whereas elevated progesterone due to intake of progestin oral 
contraceptive pills is associated with lower EOC risk (Rodriguez et al, 2002). The 
fourth hypothesis suggests that physiological inflammation in the ovary would lead to 
EOC development (Ness and Cottreau, 1999). This is supported by epidemiological 
studies that associate inflammatory conditions such as asbestos or talc exposure, 
pelvic inflammatory disease, ovarian cysts, endometriosis and hyperthyroidism with 
increased risk of EOC (Risch and Howe, 1995; Ness et al, 2000). Up-regulation of 
cytokines, chemokines and prostaglandins during inflammatory events is suggested to 
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promote mutagenesis that favors tumour growth (Ness and Cottreau, 1999).  
Infiltrating inflammatory cells are also found to be part of the spheroids of EOC cells 
circulating in the ascites (exudative fluid accumulated in the abdomen) (Burleson et al, 
2004). 
 
1.1.2 Screening, diagnosis and treatment of EOC 
The most common screening assay for early-stage EOC is the serum test of 
cancer antigen 125 (CA125). This test alone may not be sensitive when performed on 
single occasion, but is useful for sequential monitoring or used in combination with 
trans-vaginal sonography (TVS) (Bast et al, 2009). In addition to CA125, some new 
biomarkers such as WFDC2 (WAP Four-Disulfide Core Domain 2), also known as 
HE4, has been approved for diagnostics for EOC in combination with ROMA (risk of 
ovarian malignancy algorithm) (Moore et al, 2009). In general, early screening for 
EOC is more relevant to sporadic diseases that show stepwise progression from 
precursor lesions with preclinical CA125 increment; hereditary cases (BRCA1/2 or 
p53 mutated) that are aggressive and multifocal are likely to skip pre-invasive phase, 
thus defying early detection (Bast et al, 2009).  
EOC tumours are clinically staged by surgical exploration and subsequent 
histological examination on surgical specimens according to the FIGO system 
(International Federation of Gynecology and Obstetrics) listed in table I. The FIGO 
staging system is an important prognostic factor for the overall survival of EOC 
patients, with the median survival of EOC decreases from stage I to stage IV (Jayson 
et al, 2014). 
The current gold standard treatment for EOC patients is surgical debulking 
followed by taxane/platinum-based chemotherapy. Surgical cytoreduction is 
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necessary to remove maximal tumour volume to achieve zero residual disease (R0), 
especially tissues that may harbour chemoresistance (Bristow et al, 2002). Optimal 
cytoreduction that leaves < 1 cm diameter of minimal residual diseases is acceptable, 
although achieving R0 may offer better patient survival compared to having minimal 
residual diseases after optimal cytoreduction (Coleman et al, 2013). If primary 
debulking surgery is not feasible upon diagnosis, neoadjuvant chemotherapy 
(chemotherapy precedes surgery) accompanied by interval cytoreduction is the next 
preferred approach (Jayson et al, 2014). In first-line chemotherapeutic treatment, the 
current standard of care is six cycles of once-every-3-weeks of carboplatin combined 
with paclitaxel or docetaxel (Jayson et al, 2014). Despite these treatment regimens, 
over two-thirds of advanced EOC patients experience incurable recurrent disease 
(Coleman et al, 2013). Most patients with poor prognosis are noted to have platinum-
refractory disease (cancer progresses during platinum-based treatment) or platinum-
resistant disease (cancer recurs within 6 months after platinum-based treatment), thus 
highlighting the need for better therapeutic strategies (Jayson et al, 2014). A recent 
phase III study proposed a dose-dense weekly administration of paclitaxel and 
showed encouraging results in dose intensification with enhanced progression-free 
survival (PFS) and overall survival (OS) (Katsumata et al, 2009). Some potential new 
drugs for EOC treatment have been suggested, including the two anti-angiogenic 
reagents bevacizumab and pazopanib (Perren et al, 2011; du Bois et al, 2014). Results 
from clinical trials have shown that the combination of bevacizumab with 
chemotherapy improves the progression-free survival (PFS) of EOC patients at 
advanced stages (Perren et al, 2011; Aghajanian et al, 2012; Burger et al, 2011). 
Besides the anti-angiogenic VEGF inhibitors, a recent trial of maintenance therapy 
with poly ADP-ribose polymerase (PARP) inhibitor olaparib has also been shown to 
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significantly improve the PFS of EOC patients with platinum-sensitive relapse, thus 
providing a new potential therapeutic strategy (Ledermann et al, 2014). 
 
 
Table I. The FIGO staging of EOC 
EOC tumours are classified into four different stages based on the size of tumour 
growth, involvement of other tissues/lymph nodes, and the extent of metastasis. 
 
Stage I Tumour limited to the ovaries only 
 IA  Tumour limited to one ovary (capsule intact), no tumour on ovarian surface, 
no malignant cells in the ascites or peritoneal washings 
 IB  Tumour limited to both ovaries (capsules intact), no tumour on ovarian 
surface, no malignant cells in the ascites or peritoneal washings 
 IC  Tumour limited to one or both ovaries, with any of the following: 
IC1: Surgical spill 
IC2: Capsule ruptured or tumour on ovarian surface 
IC3: Malignant cells detected in the ascites or peritoneal washings 
Stage II Tumour involving one or both ovaries with pelvic extension 
 IIA  Disease extending to uterus and/or fallopian tubes 
 IIB  Disease extending to other pelvic intraperitoneal tissues 
Stage III Tumour involving one or both ovaries extending to the peritoneum outside the 
pelvis and/or the retroperitoneal lymph nodes 
 IIIA1  Positive retroperitoneal lymph nodes only 
(i) disease up to 10 mm diameter        (ii) disease > 10 mm diameter 
 IIIA2 Microscopic extrapelvic peritoneal involvement  
 IIIB  Peritoneal metastasis beyond the pelvis, disease up to 2 cm diameter 
 IIIC Peritoneal metastasis beyond the pelvis, disease > 2 cm diameter 
Stage IV Distant metastasis beyond peritoneal metastases 
 IVA  Cytology positive pleural effusion 
 IVB Parenchymal metastases to extra-abdominal organs  
  Adapted from (Prat and FIGO Committee on Gynecologic Oncology, 2014)  
 
 14 
1.1.3 Histopathology and molecular pathology of EOC 
EOC has long been regarded as one disease entity. However, it is clear now 
that EOC is very diverse and heterogeneous reflected by its histology and molecular 
pathology. Conventionally, epithelial ovarian tumours are divided into five main 
histotypes based on their histopathological features: serous, mucinous, endometrioid, 
clear cell and transitional/Brenner type (Scully, 1987). Within each histotype, the 
tumours are classified as benign if they lack profuse proliferative and invasive 
behaviour; as borderline (low malignant potential) if they show exuberant growth but 
limited invasiveness; and as malignant if there is extensive proliferation coupled with 
invasive behaviour (Chen et al, 2003). Besides histologic subtyping, EOC tumours 
are also graded from low to high by the extent of tumour differentiation: well-
differentiated, moderately differentiated, poorly differentiated, or undifferentiated 
(Chen et al, 2003). Some EOC tumours may show mixed or undifferentiated 
histotypes and these less common undifferentiated tumours are often the most 
aggressive types (Hennessy et al, 2009). In recent years, a proposed classification 
system divides EOC tumours into two broad categories named type I and type II 
tumours based on two molecular pathways of tumourigenesis (Shih and Kurman, 
2004; Jayson et al, 2014) Type I comprises mainly low-grade tumours which include 
low-grade serous carcinoma (LGSC), mucinous, endometrioid, clear cell and 
malignant Brenner tumours; while type II consists of high-grade tumours such as the 
most common high-grade serous carcinomas (HGSC), carcinosarcomas and 
undifferentiated carcinomas (Shih and Kurman, 2004). Most type I tumours develop 
stepwise from recognizable precursors, such as cystadenomas, adenofibromas or 
borderline tumors; while most type II tumours may develop de novo from the 
epithelial inclusion cysts of the ovary or from tubal intraepithelial carcinoma (Table 
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II). Despite having the same histotype, LGSC and HGSC vary in their genetic 
mutations, with BRAF or KRAS mutations (65%) mainly found in LGSC while TP53 
mutations (50-80%) mostly occuring in HGSC (Shih and Kurman, 2004). Tumours of 
patients with germline BRCA1/2 mutations are almost invariably HGSC (Prat, 2012). 
Moreover, these tumours show different responses to treatment, with LGSCs 
(generally not highly proliferative) respond poorly to chemotherapy whereas HGSCs 
(highly proliferative) respond well to chemotherapy but with high recurrence (Shih 
and Kurman, 2004). 
 
Table II. Type I and Type II EOC tumours. 
Type I and type II EOC are listed based on their histotypes, precursor lesions and 
some of the associated genetic abnormalities. 
 
Classes Histotype (Percentage) Precursors Genetic abnormalities 
Type I Low-grade serous carcinomas 
(<5%) 
Serous cystadenoma/adenofibroma 
Borderline serous tumour  
Noninvasive serous carcinoma 











Atypical endometriosis  
Endometrioid adenofibroma 
Borderline endometrioid tumour  
Intraepithelial carcinoma 
PTEN mutations/LOH 
CTNNB1, KRAS, PIK3CA, 
PPP2R1A, ARID1A mutations 
Microsatellite instability 
MMR deficiency 
Clear cell carcinomas 
(10%) 
Atypical endometriosis  
Clear cell adenofibroma 
Borderline clear cell tumour  
Intraepithelial carcinoma 
KRAS, HNF1, ARID1A, 




Malignant Brenner tumours Brenner tumour  
Borderline Brenner tumour 
Not yet identified 
Type II High-grade serous carcinomas 
(70%) 
De novo in epithelial inclusion 
cysts 
Tubal intraepithelial carcinoma 
 
TP53, BRCA1/2 mutations 
ERBB2 amplification 
AKT2 amplification  
CDKN2A inactivation 
NF1, CDK12 mutations 




  Malignant mixed mesodermal 
tumours (carcinosarcomas) 
Not yet identified TP53 mutations 
 
 Undifferentiated carcinoma Not yet identified Not yet identified 
Adapted from (Hennessy et al, 2009; Jayson et al, 2014; Prat, 2012; Shih and Kurman, 2004) 
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1.1.3.1 Molecular subtypes of EOC 
EOC is genetically heterogeneous, as demonstrated by the different 
histopathological subtypes associated with distinctive genetic aberrations (Table II). 
Besides dissecting the heterogeneity of EOC by genetic mutations, increasing number 
of studies are now profiling EOC at the molecular level by large-scale gene 
expression analysis. From the gene expression and clinical data of 285 serous and 
endometrioid tumours, Tothill et al reported six molecular subtypes of EOC (C1 to 
C6), of which four subtypes exist in HGSCs with distinguishable molecular 
differences: C1 (reactive stroma), C2 (immune-related), C4 (low stromal response) 
and C5 (mesenchymal) (Tothill et al, 2008). Integrated genomic analyses by The 
Cancer Genome Atlas Research Network (TCGA) on 489 high-grade serous EOC 
also yielded four transcriptional subtypes, namely Immunoreactive, Differentiated, 
Proliferative and Mesenchymal, as well as three miRNA subtypes and four promoter 
methylation subtypes (Cancer Genome Atlas Research Network, 2011).  In a separate 
study, meta-analysis of a large collection of 1538 EOC samples identified five 
molecular subtypes, Epi-A, Epi-B, Mes, Stem-A and Stem-B, with distinct expression 
signatures and clinical prognosis (Tan et al, 2013). Notably, all three independent 
studies identified a mesenchymal subtype in EOC that is associated with genes 
involved in an evolutionarily conserved developmental pathway - epithelial-




1.2 Epithelial-Mesenchymal Transition (EMT) 
 Epithelial-mesenchymal transition (EMT) is an important cellular mechanism 
by which stationary epithelial cells convert their phenotype into the more migratory 
mesenchymal state (Greenburg and Hay, 1982). In metazoans, epithelial cells and 
mesenchymal cells form morphologically distinctive tissues. Epithelial cells are 
apical-basal polarized, and typically adhere to one another to form epithelial sheets 
underlined by a basement membrane; whereas migratory mesenchymal cells adopt 
front-rear polarity that allow persistent, directional movement within their 
surrounding extracellular matrix (Nelson, 2009). During EMT, epithelial cells lose 
their epithelial characteristics while acquiring mesenchymal features. The entire 
process is achieved through complex coordinated signalling pathways and 
transcriptional regulation of cell adhesion components and cytoskeletal proteins 
(Thiery and Sleeman, 2006; Zeisberg and Neilson, 2009) The transition is also likely 
to be sequential, involving intermediate stages considered as “partial EMT” state 
before achieving a “full EMT” state (Huang et al, 2012a). The early events of EMT in 
epithelial cells include the disassembly of cell-cell junctions (tight junctions, adherens 
junctions and desmosomes), which is hallmarked by the loss of E-cadherin, an 
important cell adhesion molecule (Thiery, 2002) In the course of transition, cells that 
have undergone partial EMT may display enhanced plasticity and appear as 
intermediate phenotypes that co-express both epithelial and mesenchymal traits 
(Leroy and Mostov, 2007; Huang et al, 2012a). The gain of the mesenchymal traits 
includes an up-regulation of various mesenchymal markers such as vimentin, 
fibroblast-specific protein-1 (FSP1/S100A4) and alpha smooth muscle actin (α-SMA) 
(Thiery and Sleeman, 2006; Kalluri and Weinberg, 2009). If full-blown EMT is 
achieved, epithelial features will be further suppressed or completely lost, resulting 
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into a predominantly mesenchymal trait. Although terminally differentiated cells are 
presumably morphologically stable, epithelial and mesenchymal states are 
interchangeable via repeated rounds of EMT and MET (the reversal of EMT), 
especially during organogenesis in embryonic development (Lim and Thiery, 2012). 
 
1.2.1 EMT in development 
 The roles of EMT in development are evolutionarily conserved. Multiple 
studies have confirmed the significance of EMT during gastrulation in invertebrates 
such as sea urchin and drosophila, as well as in vertebrates such as chicken and 
mouse (Thiery et al, 2009). In amniotes, four successive waves of EMT/MET cycles 
have been implicated as fundamental events in gastrulation, neural crest delamination, 
and morphogenesis of major organs such as the heart and the kidney (Lim and Thiery, 
2012). As early as the stage of blastocyst implantation onto the uterus, EMT takes 
place in primitive endoderm cells and trophectoderm to form parietal endoderm and 
giant trophoblast respectively (Veltmaat et al, 2000; Vićovac and Aplin, 1996). 
During gastrulation, EMT is adopted by epiblast at primitive streak for cell ingression, 
which subsequently give rise to mesodermal and endodermal cells (Nieto et al, 1994). 
EMT is also involved in the delamination of neural crest cells, which migrate as 
mesenchymal-like cells before differentiating into mesectoderm and other derivatives 
(Suzuki et al, 2010). In later embryonic stages of organogenesis, successive cycles of 
EMT/MET allow fated cardiac cells to form the heart primordium, endocardial layer, 
endocardial cushion, epicardium, and epicardial-derived cells (Chua et al, 2011). 
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1.2.2 EMT in normal homeostasis and tissue fibrosis 
 Besides being a crucial mechanism in development, EMT also occurs in 
mature organisms during physiological homeostasis. During cutaneous wound healing, 
the re-epithelialization of keratinocytes involves loosening of cell-cell adhesion and 
collective cell migration, resembling the partial EMT mechanisms (invagination or 
involution) observed in gastrulation (Arnoux et al, 2008). In the ovaries, EMT has 
also been suggested to take place after each round of ovulation, as wounded OSE cells 
acquire fibroblast-like phenotype to integrate into the stromal cortex (Ahmed et al, 
2007). Besides being involved in normal homeostasis, the EMT mechanism is also 
implicated as one of the driving mechanisms during pathophysiological circumstances 
(Thiery et al, 2009). One example of pathological EMT is the conversion of epithelial 
cells to fibroblasts during tissue fibrosis. Studies have shown that hepatocytes, lung 
epithelium, lens epithelium, renal epithelial cells and cardiomyocytes, can all serve as 
the progenitors of fibroblasts (Thiery et al, 2009). Organ fibrosis may occur as a 
result of the accumulation of fibroblasts originated from epithelial cells of the 
respective tissue type. These events have been well-documented in hepatocytes, 
which undergo EMT to form activated fibroblasts during liver fibrosis (Zeisberg et al, 
2007a). Alveolar epithelial cells in the lung have also been demonstrated to be the 
main source of fibroblasts expansion during pulmonary fibrosis (Kim et al, 2006). 
Besides epithelial cells, endothelial cells are capable of forming fibroblasts by a 
similar process knowned as EndMT and may contribute to cardiac fibrosis (Zeisberg 






1.2.3 EMT in cancer 
One of the major hallmarks of cancer is the acquired capability of tissue 
invasion and metastasis (Hanahan and Weinberg, 2011). Hence, a certain extent of 
morphological modification could have involved during cancer dissemination. More 
than a decade ago, it was hypothesized that malignant carcinomas may reactivate the 
reversible EMT/MET programme to promote tumor invasion and metastasis (Thiery, 
2002). To date, the role of EMT in cancer progression is still debated (Tarin et al, 
2005; Chui, 2013), due to difficulties in demonstrating intermediary events of 
EMT/MET in metastasized carcinomas that display epithelial characteristics, similar 
to the primary tumours they derived from. However, increasing evidence from in vitro, 
in vivo and clinical findings are supporting the roles of EMT/MET in cancer. In 
clinical samples of colorectal carcinoma, the cancer cells at the invasive front (but not 
the central region of tumour) show a gradient of morphological changes into 
dissociated, mesenchymal-like cells with enhanced nuclear β-catenin expression, 
demonstrating the occurrence of EMT during local invasion (Brabletz et al, 2005). 
Moreover, the loss of E-cadherin, the main feature of EMT, has long been associated 
with increased tumour invasiveness (Vleminckx et al, 1991; Moll et al, 1993). 
Induction of EMT has also been shown to up-regulate matrix metalloproteinase 
(MMPs) that are required by carcinoma cells to degrade their surrounding 
extracellular matrix during invasion (Miyoshi et al, 2005) or intravasation into the 
blood vessels for systemic dissemination (Ota et al, 2009). In addition, a mouse study 
of squamous cell carcinoma shows that Twist1-induced EMT significantly increases 
circulating tumour cells (CTCs) in blood circulation, and these CTCs exhibit down-
regulated E-cadherin and up-regulated vimentin (Tsai et al, 2012). Interestingly, 
Twist1 is then depleted at distant metastases, supporting the hypothesis that MET 
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takes place at metastatic sites to allow secondary tumour proliferation (Tsai et al, 
2012).  
Besides having roles in tumour dissemination, EMT may promote cancer 
stemness, as demonstrated by the acquisition of stem cell features 
(CD44high/CD24Low) in mammary epithelial cells that have undergone EMT (Mani et 
al, 2008). It has been reported that TWIST1 is able to suppress CD24 expression 
(Vesuna et al, 2009); whereas the chromatin state of ZEB1 promoter, another EMT 
driver, is crucial in the conversion of cancer stem cells (CSCs) from non-CSCs 
(Chaffer et al, 2011). Emerging findings have also implicated EMT in drug resistance 
and immune escape. For example, SNAI1-induced EMT in colorectal cell lines 
resulted in higher chemoresistance to 5-fluorouracil treatment (Hoshino et al, 2009). 
Apart from chemotherapeutics, EMT confers resistance to radiotherapy through 
WNT/β-catenin signalling (Woodward et al, 2007), and even to targeted therapeutic 
drugs such as EGFR inhibitors (Barr et al, 2008). Meanwhile, the role of EMT in 
immunosuppression is demonstrated by a study of melanoma cells, in which Snail-
induced EMT activates regulatory T cells but deactivates dendritic cells, thus 
allowing cancer cells to escape immune surveillance (Kudo-Saito et al, 2009).  
	  
1.2.3.1 EMT in EOC 
Similar to other solid tumours, metastatic diseases remain the main causes of 
EOC-associated deaths (Jayson et al, 2014). The dissemination of EOC may involve 
EMT and its reverse process MET. Studies have shown that EOC cells can 
metastasize hematogenously (Pradeep et al, 2014), directly via peritoneal circulation 
(often manifested as ascites), or through lymphatic transport (Naora and Montell, 
2005). Hematogenous metastasis of carcinoma cells has long been suggested to 
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involve EMT/MET at different stages, often explained by a stepwise model: the loss 
of epithelial phenotype, detachment from basement membrane, intravasation into 
blood vessels, extravasation at remote sites, and the establishment of micro- or macro-
metastases (Thiery, 2002; Kalluri and Weinberg, 2009; Gupta and Massagué, 2006). 
Unlike hematogenous dissemination, the direct intraperitoneal spread of EOC may not 
be limited much by anatomical barrier, as shedded EOC cells were carried by 
circulation of the peritoneal fluid (often manifested as ascites) (Naora and Montell, 
2005). This direct mode of spreading has also been suggested to involve EMT and 
MET when the metastatic cells detach from primary sites, circulate as aggregates or 
spheroids in the peritoneal fluid, and subsequently attach onto the mesothelium 
(Ahmed et al, 2007). Increasing evidence suggests that multiple pathways leading to 
EMT may contribute to tumour invasiveness, chemoresistance and cancer stem cell 
properties of EOC (Huang et al, 2012b). These EMT pathways can be induced by 
various signalling molecules, including ET-1 (endothelin-1), TGF-β (transforming 
growth factor-β), BMP4 (bone morphogenetic protein 4), epidermal growth factor 
(EGF), hepatocyte growth factor (HGF) and glycoprotein MUC4 (Vergara et al, 
2010; Huang et al, 2012b). They have been shown, respectively, to induce EMT in 
EOC cells through downstream activation of key EMT transcription factors such as 






1.2.4 Regulation of EMT 
1.2.4.1 EMT-inducing signals 
 EMT can be triggered by a number of signalling pathways, many of which are 
crucial during development. One of the primary EMT inducing pathways is the 
signalling of TGF-β superfamily, which includes the cytokine TGF-β and bone 
morphogenetic proteins (BMPs) (Yang and Weinberg, 2008). Upon activation by 
TGF-β or BMPs, TGF-β receptors TGFβRI and TGFβRII bind to and activate polarity 
proteins such as occludin and Par6, resulting in cytoskeleton remodelling and 
disruption of epithelial polarity (Lim and Thiery, 2012). TGF-β and BMPs also 
phosphoactivate various SMAD factors to induce key EMT transcription drivers such 
as SNAI1/2 and ZEB1/2 (Thiery et al, 2009). During EMT, the TGF-β/Smad 
signalling may crosstalk with other EMT pathways such as Wnt/β-catenin, Notch, and 
Receptor Tyrosine Kinases/Ras cascade (Yang and Weinberg, 2008). In tumour 
microenvironment, cancer cells are likely to obtain TGF-β stimuli from the 
surrounding stromal fibroblasts (Hanahan and Weinberg, 2011). 
Besides TGF-β, a myriad of growth factors such as EGF, FGF, HGF, SCF, 
VEGF, IGF and PDGF activate EMT during development and cancer. These growth 
factors bind to their respective receptor tyrosine kinases (RTKs) and stimulate 
signalling cascades (such as PI3K/Akt, Ras/MAPK or Rac/Cdc42) that mostly 
converge at the activation of EMT transcription factors, leading to the down-
regulation of epithelial markers or up-regulation of mesenchymal proteins (Yang and 
Weinberg, 2008). Apart from the RTK signalling cascade, IGF may induce EMT 
through the NFkB-SNAI2 axis while both Notch and Sonic hedgehog (Shh) signalling 
induce EMT by activating SNAI1 (Thiery et al, 2009). In addition, inflammation and 
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hypoxia are also EMT stimuli that can activate SNAI1 and TWIST1 through NFkB 
and JAK/STAT pathways respectively (Tsai and Yang, 2013). 
 
1.2.4.2 EMT-inducing transcription factors 
EMT is activated through the interplay of various transcription factors, most 
of which repress E-cadherin, either by direct binding to the promoter or via indirect 
regulation. The direct repressors of E-cadherin include the Snail and ZEB families, 
TCF3/E47, and KLF8 (Kruppel-Like Factor 8); while the indirect repressors include 
Twist, Goosecoid, TCF4/E2-2 and FoxC2 (Thiery et al, 2009). Both SNAI1 and 
SNAI2 from the Snail zinc finger family are important EMT inducers in development, 
fibrosis and cancer (Peinado et al, 2007). Through direct binding to E-boxes in 
promoters, they recruit polycomb repressive complex 2 (PRC2) to repress 
transcription of E-cadherin and other epithelial genes (Herranz et al, 2008). Acting 
downstream of TGF-β, SNAI1 forms complex with SMAD3 and SMAD4 (Vincent et 
al, 2009). Interestingly, SNAI1 indirectly activates ZEB1, another important EMT 
driver (Peinado et al, 2007).  
ZEB1 and ZEB2 are zinc finger homeobox proteins that also directly interact 
with E-boxes, along with co-repressor CtBPs, for E-cadherin repression (Eger et al, 
2005; Postigo and Dean, 1999). Besides E-cadherin, ZEB1/2 down-regulate other 
epithelial markers such as Claudins, Connexin 26/31 and Crumbs3 while up-regulate 
mesenchymal proteins such as vimentin, N-cadherin and MMP1/2 via direct or 
indirect regulation (Thiery et al, 2009 supplementary table). Another group of EMT 
transcription inducers, which include TWIST1, TWIST2 and TCF3/E47 belong to the 
basic helix–loop–helix (bHLH) family (Peinado et al, 2007). TWIST1, in particular, 
has been associated with cancer stemness (Vesuna et al, 2009) and invasiveness in 
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breast cancer, prostate cancer, gastric cancer and melanomas (Peinado et al, 2007). 
Other trancriptional EMT drivers include Kruppel-like factor 8 (KFL8) which directly 
represses E-cadherin through binding to GT boxes; Goosecoid which down-regulates 
E-cadherin indirectly; and FOXC2 which regulates post-translational localization of 
E-cadherin (Thiery et al, 2009; Yang and Weinberg, 2008). Among the well-studied 
EMT transcriptional regulators, SNAI1 plays a more prominent role for EMT 
induction, whereas other transcription factors are likely to be involved in maintaining 
the post-EMT mesenchymal phenotype (Peinado et al, 2007).  
 
Table III. Positive regulators and effectors of EMT  
A plethora of signals induce EMT by activating transcription factors that regulate the 
expression of various EMT effectors/markers. 
 
 














































Adapted from  (Thiery et al, 2009; Yang and Weinberg, 2008; Kalluri and Weinberg, 2009) 
 
 
1.2.4.3 Negative regulators of EMT 
 In contrast to the extensively studied EMT inducers, relatively little is known 
about the negative regulators of EMT or the inducers of MET. Among the 
aforementioned EMT inducers, BMP2 from the BMP family is required for activating 
EMT whereas, BMP7 is recently shown to suppress EMT by antagonizing TGF-β1 
signalling (Zeisberg et al, 2003), and by activating microRNAs miR-200 family and 
miR-205 (Samavarchi-Tehrani et al, 2010). This suggests that different members of 
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the BMPs are likely to regulate EMT/MET differently. A number of microRNAs have 
been demonstrated to negatively regulate EMT. The miR-200 family (consisting of 
miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 have been 
shown to induce MET or suppress EMT by targeting ZEB1 and ZEB2 (Gregory et al, 
2008). In fact, a negative feedback loop exists between the miR-200 family members 
and ZEB factors, and this loop is likely to be important for the regulation of cellular 
plasticity (Brabletz and Brabletz, 2010). On the other hand, two microRNAs miR-30a 
and miR-203 have been shown to negatively regulate EMT through inhibiting SNAI1 
(Kumarswamy et al, 2012; Moes et al, 2012). Thus far, most of the negative 
regulators of EMT are found to operate through inhibiting EMT transcription drivers. 




1.3 Grainyhead-like 2 (GRHL2) 
1.3.1 Grainyhead (Grh) transcription factor family  
GRHL2 belongs to the transcription factor family of Grainyhead (Grh), which 
is subdivided into two branches, the Grh subfamily and the LSF/CP2 subfamily 
(Wilanowski et al, 2002; Venkatesan et al, 2003). The ancestral gene of the Grh 
subfamily, grainyhead (grh) was first documented in Drosophila as an embryonic 
lethal locus (Nusslein-Volhard et al, 1984). Mutations in this gene in Drosophila 
showed phenotypes of immature epidermal cuticle, patchy tracheal tubes and most 
notably, granular head skeleton (Bray and Kafatos, 1991). This grh gene was later 
discovered to encode the previously knowned Elf-1 or NTF-1, a factor that binds to 
cis-acting elements and modulates transcription of several key developmental genes 
in Drosophila, such as DOPA decarboxylase (Ddc), Ultrabithorax (Ubx), engrailed 
(en), fushi tarazu (ftz) and proliferating cell nuclear antigen (PCNA) (Bray et al, 
1988; Bray et al, 1989; Biggin and Tjian, 1988; Soeller et al, 1988; Dynlacht et al, 
1989; Hayashi et al, 1999).    
Evolutionarily conserved from fly to human, the single gene grh in 
Drosophila and C. elegans gave rise to multiple orthologous genes in the vertebrates, 
which are named as the grainyhead-like (grhl) genes. From phylogenetic analysis, 
three mammalian orthologues of grainyhead have been identified: Grainyhead-like 1 
(GRHL1), Grainyhead-like 2 (GRHL2) and Grainyhead-like 3 (GRHL3) (Wilanowski 
et al, 2002; Kudryavtseva et al, 2003; Ting et al, 2003a). In the second subfamily 
LSF/CP2, mammals including humans have also evolved three orthologues named 
TFCP2, TFCP2L1 and UBP1 from the ancestral gene gemini (or dCP2) in Drosophila 
(Wu et al, 1988; Lim et al, 1992; Shirra et al, 1994; Yoon et al, 1994; Rodda et al, 
2001; Wilanowski et al, 2002; Venkatesan et al, 2003). The three Grainyhead-like 
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factors were shown to form dimers with members within their subfamily, but not with 
members of the LSF/CP2 subfamily (Wilanowski et al, 2002; Ting et al, 2003a). 
 
Table IV. The two subfamilies of Grainyhead transcription factor family.  
The mammalian orthologues of Grainyhead family genes are shown together with 
their aliases and amino acid sequence homology (% identity as target/query) with 
respect to GRHL2. 
 
Subfamilies Drosophila Homo sapiens Aliases 
Amino acid  
sequence homology 
(% identity to GRHL2) 
Grh grainyhead 
(grh) 
GRHL1 MGR, TFCP2L2, LBP32 55 or 56% 
 GRHL2 BOM, TFCP2L3, DFNA28 - 
 GRHL3 SOM, TFCP2L4, GET-1 42% 
LSF/CP2 gemini 
(gem) 
TFCP2 LBP1C, LSF, TFCP2C 15 or 18% 
  TFCP2L1 LBP9, CRTR1 15 or 19% 
 UBP1 LBP1, LBP1A, LBP1B 13 or 15% 
Data source: ENSEMBL (Flicek et al, 2014) 
 
1.3.2 Structure of the GRHL2 gene and protein  
The human GRHL2 gene is located on the forward strand of chromosome 
8q22.3, ranging from 102,504,660 to 102,681,954 (GRCh37/hg19). It encodes a full-
length transcript that contains 16 exons (Flicek et al, 2014). Through alternate 
splicing at exon 1, GRHL2 generates two protein isoforms. The canonical isoform 1 
contains 625 amino acids in length, of which the first 16 residues are missing in the 
shorter isoform 2 (Uniprot database). Based on the canonical protein sequence, three 
functional domains have been annotated: a transcriptional activation domain (TAD) at 
the N-terminus; a DNA-binding domain (DBD) and a dimerization domain (DD) at 
the C-terminus (Figure A). These three domains are highly conserved in all three 
mammalian GRHL factors (Wilanowski et al, 2002; Ting et al, 2003a). Among the 
three domains, the DBD and DD of GRHL proteins share striking similarities with the 
respective domains in Drosophila Grh. However, the isoleucine-rich TAD identified 
in Grh is not conserved in the mammalian orthologues (Attardi and Tjian, 
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1993; Wilanowski et al, 2002). Studies of Drosophila Grh, Xenopus Grhl1 and mouse 
Grhl2 showed that deletion of the TAD would generate dominant-negative mutant 
proteins that compete with and inhibit the transcriptional functions of endogenous 
wild-type Grainyhead/Grainyhead-like proteins (Attardi and Tjian, 1993; Tao et al, 







Figure A. Schematic structure of GRHL2 protein (human).  
The predicted structure of human GRHL2 consists of a transcriptional activation 
domain (TAD), a DNA-binding domain (DBD) and a dimerization domain (DD). The 
numbers annotate the positions of amino acid residues in each of the three domains. 
 
 
1.3.3 Molecular functions of GRHL2 
1.3.3.1 Oligomerization and DNA-binding of Grh/GRHL 
The initial study of Grh in Drosophila revealed an unusually large, combined 
DNA-binding/dimerization domain of about 400 residues (Attardi and Tjian, 1993), 
which suggested the requirement of Grh dimerization for DNA-binding. Subsequent 
research later identified a smaller (~ 100 residues), major dimerization domain that is 
separated from the DNA-binding domain (~ 233 residues) (Uv et al, 1994). Although 
Grh can bind to DNA either as monomer or dimers, Grh was shown to form dimers 
readily and this dimerization would significantly stabilize their binding to DNA (Uv 
et al, 1994). This is particularly relevant in the mammalian system, as all three GRHL 
factors (GRHL1, GRHL2 and GRHL3) are able to form not only homodimers, but 
also heterodimers with each other or with other proteins (Wilanowski et al, 
2002; Ting et al, 2003a). The state of oligomerization has also been suggested to be 
1-16  
not found in isoform 2  
TAD  DD DBD 
244-494 520-625 1-93 
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important for Grainyhead transcription factors to recognize their DNA-binding sites 
specifically. One example is the differential DNA-binding affinity between Grh and 
TFCP2. Although both factors recognize a conserved DNA-binding motif, Grh binds 
DNA as a dimer while TFCP2 requires a tetrameric oligomerization to form a stable 
complex with DNA (Shirra and Hansen, 1998).  
 The DNA-binding sites of Grainyhead members have been studied in different 
species. In Drosophila, DNase footprint experiments showed that Grh recognizes 
DNA regulatory sequences upstream of genes Ddc (TGAACCGGTCCTGCGG) and 
engrailed (GTGAGCCGGCGAAACCGGTT) (Bray et al, 1988; Soeller et al, 1988). 
As Grh also binds to the promoters of Ubx and ftz, a sequence alignment of the Grh 
binding regions in Ddc, Ubx and ftz promoters generated a binding motif of 
(T/C)NAAC(C/T)GGT(T/C) (Dynlacht et al, 1989). Besides Drosophila, Ce-Grh-1 
of C. elegans was also shown to recognize promoters of dbl-1, mab-5 and Ce-Ddc 
(homologs of Drosophila Dpp, Ubx and Ddc) at sequences with a less stringent, yet 
similar motif (A/T)C(T/C/A)(G/T)GTT (Venkatesan et al, 2003). This Grh binding 
motif is conserved in the mammalian Grainyhead-like factors, as evinced by: the 
binding of human GRHL1 to the AACCGGCA motif at the promoter Engrailed-1 
gene (Wilanowski et al, 2002); the binding of rat Grhl2 to Grh consensus sequence 
(Boglev et al, 2011); as well as the binding of mouse Grhl3 to Grh consensus 
sequence (A/T)AAACCGGTT(T/A)(T/A)(T/A) in A431 cell extracts (Ting et al, 
2005). Although Grh binding consensus has previously been defined as AACCGGTT 
based on a few target genes, more recent findings suggest a considerable variability in 
the Grh/Grhl recognition sites, thus questioning the strength of the 8-sequence 
consensus motif (Harrison et al, 2010). In particular, the regulatory binding of human 
GRHL2 to the TERT promoter was found to reside within the sequence of 
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TCTCCTCGCG, which varies greatly from the known Grh binding consensus (Chen 
et al, 2010). Moreover, the Grhl2 binding sites at the intron 2 of Cdh1 gene 
(AAACCAGTCAAACCAGTT) and the promoter of Cldn4 gene 
(AATCCAGAGAAACTGGTC) consist of two similar, repeated motifs (in bold), 
and both are required for Grhl2 binding (Werth et al, 2010). 
 
1.3.3.2 Transcriptional targets of Grh/GRHL 
The Grh/GRHL transcription factors have been shown to directly regulate a 
variety of genes (Table V). Through binding to promoters, enhancers or intronic 
regions, Grh/GRHL factors are capable of activating or repressing the transcription of 
their target genes. As the DNA-binding properties of Grh/GRHL are conserved from 
fly to human, Grh/GRHL factors in different species may share homologous 
transcriptional targets. For instance, the Drosophila gene engrailed is regulated by 
Grh, while its orthologous counterparts engrailed2a (in zebrafish) and EN1 (in 
human) are regulated by Grhl2b and GRHL1 respectively (Dworkin et al, 
2012; Soeller et al, 1988; Wilanowski et al, 2002). Compared to the relatively simpler 
system of the invertebrates, the multiple GRHL factors in the vertebrates showed a 
more complex regulatory system. Besides sharing some common transcriptional 
targets, each GRHL factor has its own unique targets with different binding 
specificity. For example, GRHL2 and GRHL3 but not GRHL1 were shown to bind to 
the promoter of ARHGEF19 gene for transcriptional regulation; while only GRHL3 
(but not GRHL1 or GRHL2) was shown to bind to the promoter of TGM1 (TGase1) 
for transcriptional regulation (Boglev et al, 2011). The transcriptional targets 
specifically regulated by GRHL2 are listed in Table V. 
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Table V. The transcriptional targets of Grh/GRHL factors.  
The identified transcriptional targets of Grh/GRHL factors in published literature are 
listed along with the information on Grh/GRHL binding region, species studied, 
nature of regulation and respective references. The list is non-exhaustive. 
 
Transcriptional targets of Grh 











Activation Bray et al, 1988; Johnson et al, 
1989; Venkatesan et al, 2003 
Ubx / mab-5 
(Ultrabithorax) 
Promoter Drosophila & 
C. elegans 
Activation  Biggin and Tjian, 1988; Dynlacht et 
al, 1989; Venkatesan et al, 2003 
ftz 
(fushi tarazu) 
Promoter Drosophila N/A  Dynlacht et al, 1989 
en 
(engrailed) 
Promoter Drosophila Activation  Soeller et al, 1988 
dpp / dbl-1 
(decapentaplegic) 
Intron 2 Drosophila & 
C. elegans 
Repression  Huang et al, 1995;  
Venkatesan et al, 2003 
zen 
(zerknüllt) 
Promoter Drosophila Repression  Huang et al, 1995;  
Harrison et al, 2010 
tll 
(tailless) 
Promoter Drosophila Repression  Liaw et al, 1995 
sc 
(scute) 
Promoter Drosophila Repression  Harrison et al, 2010 
Sxl 
(Sex lethal) 
Promoter Drosophila Repression  Harrison et al, 2010 
PCNA 
(Proliferating Cell Nuclear 
Antigen) 
Promoter Drosophila Activation  Hayashi et al, 1999 
stan 
(starry night) 
N/A Drosophila Activation  Lee and Adler, 2004 
shg 
(E-cadherin) 
Intron Drosophila Activation  Almeida and Bray, 2005 
fas3 
(fasciclin 3) 
Intron 1 Drosophila Activation  Narasimha et al, 2008 
cora 
(coracle) 
Intron 1 Drosophila Activation  Narasimha et al, 2008 
sinu 
(sinuous) 
N/A Drosophila Activation  Narasimha et al, 2008 
msn 
(misshapen) 
Intron 3 Drosophila Activation  Pearson et al, 2009 
ple 
(pale) 
Enhancer Drosophila N/A  Pearson et al, 2009 
stit 
(stitcher) 
Intron 2 Drosophila Activation  Wang et al, 2009 
 
Transcriptional targets of Grainyhead-like 1 







Promoter  Human Activation Wilanowski et al, 2002 
 
XK81A1 
(Keratin, type I cytoskeletal) 




Promoter Human Repression Henderson et al, 2007 
DSG1 
(Desmoglein 1) 
Promoter Human & 
Mouse 
Activation Wilanowski et al, 2008 
 
Transcriptional targets of Grainyhead-like 2 







Enhancer Zebrafish Activation  Han et al, 2011 
epcam 
(epithelial cell adhesion molecule) 
Enhancer Zebrafish Activation  Han et al, 2011 
eng2a 
(engrailed 2a) 
Promoter Zebrafish Activation Dworkin et al, 2012 
cdc42se1 
(CDC42 small effector 1) 
Promoter Zebrafish Activation Dworkin et al, 2012 
TERT 
(Telomerase reverse transcriptase) 
Promoter Human Activation Kang et al, 2009;  
Chen et al, 2010 
Cdh1 
(E-cadherin) 
Intron 2 Mouse Activation Werth et al, 2010 
Cldn4 
(Claudin 4) 
Promoter Mouse Activation Werth et al, 2010 
ARHGEF19 
(Rho Guanine Nucleotide 
Exchange Factor 19) 
Promoter Human & 
Mouse 
Activation Boglev et al, 2011;  
Gao et al, 2013a 
ZEB1 
(Zinc Finger E-Box Binding 
Homeobox 1)  
Promoter Human Repression Cieply et al, 2012 
ERBB3 
(v-erb-b2 avian erythroblastic 
leukemia viral oncogene homolog 
3)  
Promoter Human & 
Mouse 
Activation Werner et al, 2013 
RAB25 
(member RAS oncogene family) 
Promoter Human & 
Mouse 
Activation Senga et al, 2012;  
Gao et al, 2013a 
Nkx2-1 
(NK2 Homeobox 1) 
Promoter Mouse Activation Varma et al, 2012 
 
Transcriptional targets of Grainyhead-like 3 







Promoter Human & 
Mouse 
Activation Ting et al, 2005;  
Boglev et al, 2011 
UpkII 
(Uroplakin 2) 
Promoter Mouse Activation Yu et al, 2009 
PTEN 
(Phosphatase And Tensin 
Homolog) 
Promoter Human & 
Mouse 
Activation Darido et al, 2011 
ARHGEF19 
(Rho Guanine Nucleotide 
Exchange Factor 19) 
Promoter Human & 
Mouse 
Activation Boglev et al, 2011;  
Caddy et al, 2010 
MIR-21 
(MicroRNA 21) 
Promoter Human & 
Mouse 
Repression Bhandari et al, 2013 
N/A: Information not available or inconclusive 
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1.3.4 Biological and pathophysiological functions of Grhl2/GRHL2 
1.3.4.1 Roles of Grh and Grhl factors in development 
 The Grh/GRHL factors are key regulators in embryonic development. In both 
Drosophila and C. elegans, loss of Grh/Ce-Grh-1 function resulted in embryonic 
lethality accompanied by cutical defects (Bray and Kafatos, 1991; Venkatesan et al, 
2003). A myriad of genes required for Drosophila early embryonic development, 
including dpp, tll, Ubx, en, ftz, zen and sxl, have been shown to be regulated by Grh 
(Dynlacht et al, 1989; Harrison et al, 2010; Huang et al, 1995; Liaw et al, 
1995; Soeller et al, 1988). On the other hand, the cuticle malformation and defective 
epidermal wound healing observed in Grh-deficient flies suggested the importance of 
Grh in epidermal barrier formation and repair through its direct regulation of Ddc, ple, 
stit and msn (Bray and Kafatos, 1991; Mace et al, 2005; Pearson et al, 2009; Wang 
and Samakovlis, 2012). This function has been shown well-conserved in the worm, 
frog and mouse (Venkatesan et al, 2003; Tao et al, 2005; Gustavsson et al, 2008). In 
Xenopus, inhibition of XGrhl1 activity led to impaired head and trunk formation, 
along with global defects in terminal epidermal differentiation (Tao et al, 2005). The 
regulatory role of XGrhl1 in epidermal fate is BMP4 signaling-dependent, and is 
achieved in part through direct transactivation of epidermal keratin gene XK81A1 
(Tao et al, 2005).  
In the mammalian system, the functions of Grhl factors in development have 
been examined in gene knockout mice. Homozygous Grhl1-null mice are viable, and 
they display alopecia or sparse hair, defective hair shaft anchoring, palmoplanter 
keratoderma, and postnatal temporary growth retardation (Wilanowski et al, 2008). 
The gene Desmoglein 1 (Dsg1), which encodes an important adhesion molecule in the 
formation of desmosomes, has been identified as a direct transcriptional target of 
 35 
Grhl1 and down-regulated expression of Dsg1 in Grhl1-deficient mutants is likely to 
have caused the defective hair anchorage and abnormal epidermal differentiation 
phenotype (Wilanowski et al, 2008).  
In the gene knockout studies of Grhl2, homozygous null mice are embryonic 
lethal, showing severe defects in organogenesis and neural tube closure (Werth et al, 
2010; Rifat et al, 2010). The failure of cranial neural tube closure in these mutants 
resulted in anterior spina bifida, defective neural fold elevation, cranioschisis and 
exencephaly; while the failure of posterior neural tube closure led to lumbosacral 
spina bifida (open neuropore) and a curled tail phenotype (Werth et al, 2010; Rifat et 
al, 2010). Although Grhl2 is crucial in proper neural tube closure, the expression of 
Grhl2 in normal mice is not found in the neural tube, but in the adjacent surface 
ectoderm and in the gut endoderm (Werth et al, 2010). In the Grhl2-null mutants, the 
expression levels of two Grhl2 direct targets, E-cadherin (Cdh1) and Claudin 4 
(Cldn4), are significantly reduced in the major epithelia including foregut endoderm, 
surface ectoderm and otic epithelium (Werth et al, 2010). Hence, Grhl2 functions as 
an important regulator of apical junction formation during epithelial differentiation 
(Werth et al, 2010). 
On the other hand, homozygous Grhl3-null mice die neonatally, and they 
exhibit both perturbed epidermal barrier formation and impaired neural tube closure 
(Ting et al, 2003b; Ting et al, 2005; Yu et al, 2006). The defects in epidermal barrier 
are marked by impaired formation of stratum corneum (skin barrier), failure in wound 
repair, and incomplete eyelid closure (Ting et al, 2005; Yu et al, 2006; Yu et al, 
2008). A Grhl3 transcriptional target transglutaminase 1 (Tgm1) has been suggested 
as one of the effectors downstream of Grhl3 in regulating epidermal differentiation 
and repair by cross-linking structural components of the epidermis (Ting et al, 2005). 
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The interaction between Grhl3 with LIM domain-only protein LMO4 in regulating 
actin polymerization is also thought to play a part (Yu et al, 2006; Hislop et al, 2008). 
Meanwhile, the failure of eyelid closure could be due to perturbed cytoskeletal 
organization, a result of down-regulated TGF-α activity upon the EGFR/ERK 
pathway in Grhl3-null condition (Yu et al, 2008). Besides epidermal defects, the 
Grhl3-null mice showed immature urothelium formation (Yu et al, 2009). One of the 
genes encoding the components of urothelium differentiation uroplakin II (UpkII) is a 
direct target of Grhl3, and the selective Grhl3 transactivation of UpkII in urothelial 
cells is required for urothelial membrane formation (Yu et al, 2009). Interestingly, 
Grhl2 and Grhl3 are likely to be functional redundant in eyelid fusion, but their roles 
in epidermal barrier formation are non-redundant (Boglev et al, 2011). 
Overall, gene-targeting studies in mice revealed that Grhl1, Grhl2 and Grhl3 
have related yet notably different functions in embryonic development. The unique 
roles of each factor in embryogenesis are most likely dependent on their differential 
spatio-temporal expression patterns (Auden et al, 2006). A detailed study by Auden et 
al showed that at embryonic stage E8.5, Grhl2 expression is observed throughout the 
surface ectoderm, while Grhl3 is only found in a small fraction of non-neural 
ectoderm cells. Subsequently, the expression of Grhl3 increases to encompass the 
entire surface ectoderm and is maintained from E10.5 onwards. Meanwhile, from 
E10.5 to E17.5, the level of Grhl2 gradually decreases and is followed by a surge in 
Grhl1 expression from E15.5 onwards (Auden et al, 2006). Although both Grhl1 and 
Grhl3 have prominent epidermal expression from E15.5, they exhibit no functional 
redundancy in barrier establishment (Boglev et al, 2011). Moreover, Grhl2 is unable 
to rescue the phenotype of Grhl3 deficiency in epidermal barrier formation (Boglev et 
al, 2011). Apart from the ectoderm, differential expression levels of Grhl1, Grhl2 and 
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Grhl3 are also observed in non-ectodermal tissues including the heart, lung and 
kidney (Auden et al, 2006). Therefore, the timely and spatially regulated expression 
of multiple Grhl factors is crucial for their non-overlapping roles in development.  
 
1.3.4.2 Roles of Grhl2 in neural tube defects and spina bifida  
Neural tube defects (NTDs) are severe congenital malformations that include 
spina bifida and anencephaly, occuring at a high rate of 1 in every 1000 human 
pregnancies (Mitchell, 2005). Gene-targeting studies in mice revealed the importance 
of Grhl2 in neural tube closure (Werth et al, 2010; Rifat et al, 2010; Pyrgaki et al, 
2011). Since both Grhl2 and Grhl3 are required for complete neural tube closure, the 
two genes may share functional roles in neurulation. Rifat et al demonstrated that 
Grhl2 and Grhl3 exhibit cooperative activity during spinal closure from mid to lower 
thoracic region and neurulation closure 2 at the forebrain/midbrain boundary (Rifat et 
al, 2010). In the posterior neuropore closure, the functions of the two genes 
overlapped, but are non-cooperative (Rifat et al, 2010). On the other hand, Grhl2 
showed unique function in neurulation closure 3; while Grhl3 alone is implicated in 
spinal closure at the lower thoracic site (Rifat et al, 2010). It has been suggested that 
the combined loss of multiple adhesion and junctional molecules including E-
cadherin in Grhl2 deficient mice is responsible for the neural tube defects (Rifat et al, 
2010; Pyrgaki et al, 2011). Contrary to Grhl2-deficient neural tube defects, 
overexpression of Grhl2 could also be the underlying cause of defective neural tube 
closure in Axial defects mouse (Brouns et al, 2011). Therefore, tightly regulated 
expression of Grhl2 is crucial for its proper functions in neural tube closure.  
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1.3.4.3 Roles of GRHL2 in epithelial organogenesis and epidermal differentiation 
 Besides regulating epithelial differentiation in early embryonic development, 
GRHL2 is also required for epithelial morphogenesis in lung epithelium and bile duct 
(Varma et al, 2012; Gao et al, 2013a; Senga et al, 2012). Based on a study of lung 
epithelial cells in mouse, Grhl2 and Nkx2-1, a homeobox transcription factor, form a 
postive regulatory feedback loop (Varma et al, 2012). Both transcription factors are 
direct targets of each other and the regulatory loop is essential for the the maintenance 
of cell morphology, migratory properties and cell-cell interactions in lung epithelium 
(Varma et al, 2012). A separate study on human bronchial epithelium also suggested 
the roles of GRHL2 in establishing and maintaining the epithelial barrier of 
mucociliary airway, which are likely to involve direct or indirect regulation of 
components required for junction assembly and cell polarity, such as CDH1, TJP1, 
RAB25, PVRL4, VAV1, and ESRP1/2 (Gao et al, 2013a). Besides lung epithelium, in 
vitro experiments of mouse liver progenitor cells HPPL showed that Grhl2 is able to 
induce lumen expansion through direct activation of Rab25, which leads to up-
regulation of Cldn3 and Cldn4 at tight junctions (Senga et al, 2012). 
 Although Grhl2 does not regulate transglutaminase 1 (TGM1), the crucial 
Grhl3 target required for epidermal barrier formation (Boglev et al, 2011), GRHL2 
does have important roles in keratinocyte differentiation (Chen et al, 2012). In NHEK 
cells (human epidermal keratinocytes), Chen et al demonstrated that GRHL2 inhibits 
human keratinocyte differentiation by transcriptionally repressing multiple genes of 
the epidermal differentiation complex (EDC) (Chen et al, 2012). Besides direct 
regulation, GRHL2 also represses the expression of EDC genes through epigenetic 
modification (Chen et al, 2012). This is supported by the observation that GRHL2 
overexpression resulted in an increased level of histone 3 Lys 27 trimethylation at the 
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promoters of EDC genes, possibly through inhibiting the recruitment of histone 
demethylase Jmjd3 (Chen et al, 2012). Moreover, compared to normal skin, up-
regulation of GRHL2 is observed in atopic dermatitis and psoriasis, suggesting the 
pathological roles of GRHL2 in skin anomalies (Chen et al, 2012). 
 
1.3.4.4 Roles of GRHL2 in hearing impairment 
Two mutations found in the human GRHL2 gene are associated with non-
syndromic sensorineural deafness autosomal dominant type 28 (DFNA28) (Peters et 
al, 2002; Vona et al, 2013). The first identified mutation 1609-1610insC is a 
frameshift mutation that generates a transcript with a premature stop codon in exon 14 
(Peters et al, 2002). The transcript may be subjected to nonsense-mediated mRNA 
decay, or upon translation, would produce a GRHL2 protein that lacks most of the 
dimerization domain (Peters et al, 2002). The latter is suggested to be an unlikely 
event as no such isoform of GRHL2 protein has been detected (Peters et al, 2002). 
The second DFNA28-causing mutation c.1258-1G>A is a novel splice site mutation 
that resulted in p. Gly420Glufs0111 frameshift mutation in exon 10 of GRHL2 (Vona 
et al, 2013). Both GRHL2 mutations are likely to negatively impact the protein 
expression and thus suggesting the loss of GRHL2 activity as a genetic risk factor for 
DFNA28 (Peters et al, 2002; Vona et al, 2013). The underlying mechanism has been 
studied in a zebrafish grhl2bT086 mutant line generated by Tol2 transposon insertion 
(Han et al, 2011). The grhl2b-null mutants display inner ear defects, impaired hearing 
ability and imbalanced swimming behaviour, which can be rescued by injection of 
wild type human GRHL2 mRNA (Han et al, 2011). Further analysis uncover that 
depletion of Grhl2b in the mutants has led to significant down-regulation of junctional 
proteins claudin b and epcam, which eventually resulted in perturbed otic 
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development and hearing impairment (Han et al, 2011). Besides DFNA28, GRHL2 
has also been implicated in age-related hearing impairment (ARHI), whereby one 
among several SNPs (single nucleotide polymorphism) identified in the intron 1 of 
GRHL2 gene is significantly associated with the disease (Van Laer et al, 2008). In 
contrast to the European populations, the association of GRHL2 with ARHI is not 
observed in the Han Chinese (Lin et al, 2011).  
 
1.3.4.5 Roles of GRHL2 in cancer 
 The roles of GRHL2 in cancer progression has been implicated in oral 
squamous cell carcinoma (OSCC), hepatocellular carcinoma, breast cancer, colorectal 
cancer and gastric cancer. Compared to normal oral keratinocytes, GRHL2 is 
overexpressed in human OSCC cells and the transcription factor is capable of  
inducing human telomerase (TERT) activity through direct binding at its promoter 
(Kang et al, 2009).  Besides direct regulation, GRHL2 is also likely to control hTERT 
expression by inhibiting DNA methylation at the 5’ CpG island, a mechanism 
demonstrated in human keratinocytes (Chen et al, 2010). In hepatocellular carcinoma 
(HCC), GRHL2 gene in 8q22.3 is found to be frequently amplified compared to 
normal tissues, and the amplification is significantly associated with poorer prognosis 
and early recurrence of the disease (Tanaka et al, 2008). This finding is in line with 
the genome-wide RNAi screening performed on fibrosarcoma, which identified 
GRHL2 among the 8q22 gene cluster that negatively regulates death receptor-
mediated apoptosis (Dompe et al, 2011). The 8q22 region is also shown frequently 
amplified in breast, lung, ovarian, and melanoma tumours (Dompe et al, 2011). 
However, the amplification of GRHL2 in breast cancer does not reflect gene up-
regulation in all subclasses, as the expression levels of GRHL2 are found to be 
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significantly lower in the claudin-low and basal-B cell lines that are associated with 
mesenchymal phenotype and poor prognosis (Cieply et al, 2012). This expression 
pattern is related to the functional roles of GRHL2 in suppressing oncogenic EMT, 
promoting anoikis-sensitivity and inhibiting mammosphere formation in breast cancer 
cells through the repression of TGF-β/Smad pathway and the EMT driver ZEB1 
(Cieply et al, 2012).  
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1.4 Aims and hypothesis 
 The heterogeneity of EOC remains a challenge that continues to impede 
diagnosis, management and treatment of the disease. From histological 
subclassification (Scully, 1987) to mutation-based progression model (Shih and 
Kurman, 2004), and the more recent molecular subclassifications of EOC (Tothill et 
al, 2008; Cancer Genome Atlas Research Network, 2011; Tan et al, 2013), efforts in 
dissecting the heterogeneity of EOC have improved the understanding of the biology 
that underlies EOC progression. Among the suggested molecular subtypes, tumours  
with EMT features (Mes subgroup) were significantly associated with poor prognosis 
(Tan et al, 2013). Increasing evidence also suggested that multiple EMT pathways 
contribute to the migratory/invasive properties, cancer stemness and chemoresistance 
of EOC (Huang et al, 2012b). Hence, this study seeks to explore potential novel EMT 
players in EOC. By analyzing subclassified EOC tumours and a panel of 42 
phenotypically-characterized EOC cell lines, a candidate approach identified GRHL2 
as an EMT-associated transcription factor in EOC (Huang et al, 2013). Thus the 
hypothesis of this project is that GRHL2 serves as an EMT suppressor required for 
the maintenance of epithelial phenotype in EOC.  
To test the hypothesis, the first aim of this project is to examine the EMT-
related functional roles of GRHL2 in EOC, which will be elaborated in chapter III. 
The expression levels of GRHL2 in EOC cell lines and patient samples are to be 
validated, and the functions of GRHL2 in regulating cell phenotype, motility, 
migration and invasiveness will be examined. The second aim of this study is to 
identify transcriptional targets directly regulated by GRHL2 in EOC. The 
involvement of the downstream targets corresponding to the functional roles of 








2.1 EOC cell lines and cultures 
42 EOC cell lines from the SGOCL library (Huang et al, 2013) were used in 
this study. The cell lines were previously characterized into four EMT phenotypes 
(Huang et al, 2013) and were maintained in their respective culture media (Table VI). 
 
Table VI. EOC cell lines with their respective phenotypes and culture media.  
 
Cell lines EMT Phenotype Media 
A1847 Mesenchymal RPMI 1640, 10% FBS, 10 µg/ml insulin 
A2008 Epithelial RPMI 1640, 10% FBS 
A2780 Mesenchymal RPMI 1640, 10% FBS 
BG1 Intermediate Mesenchymal DMEM, 10% FBS, 1 µg/ml insulin 
C13 Epithelial RPMI 1640, 10% FBS 
Caov2 Intermediate Epithelial RPMI 1640, 10% FBS 
Caov3 Epithelial DMEM, 10% FBS 
CH1 Intermediate Mesenchymal DMEM, 10% FBS 
COLO720E Mesenchymal RPMI 1640, 10% FBS 
DOV13 Intermediate Mesenchymal DMEM, 10% FBS 
EFO21 Intermediate Epithelial RPMI 1640, 20% FBS, 1x NEAA 
FUOV1 Intermediate Epithelial DMEM/F12 (1:1), 10% FBS 
Hey Intermediate Mesenchymal RPMI 1640, 10% FBS 
HeyA8 Mesenchymal RPMI 1640, 10% FBS 
HeyC2 Intermediate Mesenchymal RPMI 1640, 10% FBS 
IGROV1 Intermediate Epithelial RPMI 1640, 10% FBS 
JHOS2 Intermediate Epithelial DMEM/F12 (1:1), 10% FBS, 0.1 mM NEAA 
JHOS3 Intermediate Epithelial DMEM/F12 (1:1), 10% FBS, 0.1 mM NEAA 
JHOS4 Intermediate Epithelial DMEM/F12 (1:1), 10% FBS, 0.1 mM NEAA 
OAW28 Intermediate Epithelial DMEM, 10% FBS, 0.7 µg/ml insulin 
OAW42 Intermediate Epithelial DMEM, 10% FBS, 0.7 µg/ml insulin 
OV17R Intermediate Epithelial DMEM/F12 (1:1), 5% FBS, 0.4 µg/ml hyrocortisone, 10 µg/ml insulin 
OV2008 Epithelial RPMI 1640, 10% FBS, 1x NEAA 
OV56 Intermediate Epithelial DMEM/F12 (1:1), 5% FBS, 0.5 µg/ml hyrocortisone, 10 µg/ml insulin 
OV7 Intermediate Mesenchymal DMEM/F12 (1:1), 5% FBS, 0.5 µg/ml hyrocortisone, 10 µg/ml insulin 
OV90 Epithelial MCDB105/M199 (1:1), 10% FBS 
OVCA420 Epithelial DMEM, 10% FBS 
OVCA429 Intermediate Epithelial DMEM, 10% FBS 
OVCA432 Intermediate Epithelial DMEM, 10% FBS 
OVCA433 Intermediate Epithelial DMEM, 10% FBS 
OVCAR10 Mesenchymal RPMI 1640, 10% FBS, 10 µg/ml insulin 
OVCAR2 Intermediate Epithelial RPMI 1640, 10% FBS, 10 µg/ml insulin 
OVCAR3 Epithelial RPMI 1640, 20% FBS, 10 µg/ml insulin 
OVCAR5 Intermediate Epithelial RPMI 1640, 10% FBS, 10 µg/ml insulin 
OVCAR8 Epithelial RPMI 1640, 10% FBS, 10 µg/ml insulin 
OVK18 Mesenchymal DMEM, 10% FBS 
PEO1 Epithelial RPMI 1640, 10% FBS 
PEO4 Intermediate Epithelial RPMI 1640, 10% FBS, 2.5 µg/ml insulin, 1x NEAA 
SKOV3 Intermediate Mesenchymal DMEM, 10% FBS 
TOV112D Mesenchymal MCDB105/M199 (1:1), 10% FBS 





RPMI 1640/ MEGM (1:1), 3% FBS 
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2.2 EOC patient samples 
A collection of archived frozen EOC patient samples were obtained from the 
Department of Gynecology & Obstetrics, Kyoto University Graduate School of 
Medicine, Japan and Department of Obstetrics & Gynecology, Tri-Service General 
Hospital, Taiwan (Huang et al, 2012). From the collection, 44 samples have been 
subclassified into different molecular subgroups (Tan et al, 2013) (Table VII). RNAs 
extracted from these samples were used for RT-qPCR analysis in this study. 
 
Table VII. 44 EOC patient samples with their respective molecular subtypes  
 
Tumour Sample Molecular Subtype   Tumour Sample Molecular Subtype  
JPKO 001 EpiA  JPKO 063 StemB 
JPKO 002 StemA  JPKO 064 StemB 
JPKO 005 Mes  JPKO 065 EpiB 
JPKO 007 StemB  JPKO 069 StemA 
JPKO 008 EpiA  JPKO 070 EpiA 
JPKO 009 EpiA  JPKO 079 Mes 
JPKO 010 EpiA  JPKO 080 StemA 
JPKO 013 StemB  JPKO 081 StemA 
JPKO 021 StemB  JPKO 082 EpiB 
JPKO 023 StemB  JPKO 083 Mes 
JPKO 024 EpiA  JPKO 085 EpiB 
JPKO 025 EpiA  JPKO 089 Mes 
JPKO 027 EpiA  JPKO 095 StemB 
JPKO 031 StemB  JPKO 098 Mes 
JPKO 033 StemB  JPKO 099 StemA 
JPKO 036 StemA  JPKO 101 Mes 
JPKO 045 StemA  JPKO 102 Mes 
JPKO 049 StemA  JPKO 103 EpiB 
JPKO 055 EpiA  JPKO 104 Mes 
JPKO 056 EpiA  JPKO 105 Mes 
JPKO 060 StemB  JPKO 106 EpiB 









2.3 Generation of stable GRHL2-knockdown cell lines  
For loss-of-function studies, two lentiviral plasmids, each encodes a unique 
short hairpin RNA (shRNA) sequences targeting human GRHL2 (TRCN0000015810 
and TRCN0000015812) (Sigma-Aldrich) were used. Luciferase shRNA and non-
target shRNA (#SHC007, #SHC016) were used as the negative controls. shRNA 
plasmids were incubated with MISSION® Lentiviral Packaging Mix (#SHP001, 
Sigma-Aldrich) and transfection reagent Fugene 6 (#11814443001, Roche) before 
added to 293T cells at 60% confluency. For infection, viral supernatants were 
harvested at 48 or 72 hours post-transfection, filtered and added to the media of 
PEO1, OVCA420 and OVCA429 cells together with 8 µg/ml polybrene (Sigma-
Aldrich). At 48 hours post-infection, the cells were subjected to puromycin selection 
at a concentration of 6 to 7 µg/ml. Stable cell lines were maintained with 4 µg/ml of 
puromycin.  
 
2.4 Generation of stable ZEB1-overexpressing cell lines  
Plasmid pCMV6-AC-GFP-ZEB1 was generated by molecular cloning from 
pCMV6-Entry-ZEB1 (RC217704, Origene). Stable ZEB1-overexpressing cell lines 
were generated by colleague Ms. Tan Ming via transfection of the pCMV6-AC-GFP-
ZEB1 plasmid into PEO1 and OVCA429 cells. Transfected cells were selected by 
G418 (#10131027, Life Technologies) at 300 µg/ml and maintained at 250 µg/ml 
concentration. 
 
2.5 Reverse transcription and quantitative PCR (RT-qPCR) 
Total RNA of EOC cell lines and EOC tumour samples was extracted with 
RNeasy mini kit or miRNeasy mini kit (Qiagen) according to manufacturer’s 
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protocol. For gene expression qPCR, 500ng mRNA was reverse-transcribed to cDNA 
using RT2 first strand kit (SAbiosciences, Qiagen) and subsequently mixed with 
SYBR green master mix (SAbiosciences, Qiagen) for qPCR analysis by ABI 7900HT 
(Life Technologies). Thermal cycling conditions were set as: 1 cycle of 95ºC 
incubation for 10 minutes for initial DNA denaturation and the activation of HotStart 
DNA Taq Polymerase, followed by 40 cycles of 95ºC for 15 seconds (denaturation) 
and 60ºC for 1 minute (primer annealing and extension). Primers were purchased 
from SAbiosciences (Qiagen), including five housekeeping genes B2M, HPRT1, 
RPL13A, GAPDH and ACTB that were used for normalization. Details of the primers 
are listed in Appendix I. For all RT-qPCR data, the mRNA expression level of each 
gene of interest was normalized to the expression of housekeeping genes and 
presented either as average 2-∆Ct, or as average fold change (2-∆∆Ct) with respect to 
control, from at least two biological replicates of the sample. For microRNA 
quantification, miScript II RT kit from Qiagen was used for reverse transcription. 
500ng of total RNA extracted with miRNeasy kit were used as template and miScript 
HiSpec Buffer was selected as the reaction buffer. After reverse transcription, 400 µl 
of nuclease-free water was added for dilution prior to qPCR analysis using miScript 
SYBR Green PCR kit and ABI 7900HT. For data normalization, RNU6-6P (RNU6-2) 
was used as internal control. Primer assays for microRNAs were purchased from 
SAbiosciences (Qiagen). Details of the primers are listed in Appendix I.  
 
2.6 Western blot analysis  
Cell lysates were harvested by RIPA buffer (#R0278, Sigma-Aldrich) added 
with protease inhibitor (#539134) and phosphatase (#524625) inhibitor cocktails from 
Calbiochem, Millipore. BCA assay (#23225, Thermo Scientific) was performed for 
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protein quantification. Lysates were resolved by standard reducing SDS-PAGE, 
transferred on PVDF membranes, blocked with 5% skim milk (Nacalai Tesque) and 
immunoblotted with specific antibodies: anti-GRHL2 (#HPA004820) from 
Atlas/Sigma; anti-E-cadherin (#610182) from BD Transduction Laboratories; anti-
ZEB1 (#3396) and anti-EEA1 (#3288) from Cell Signaling Technology; anti-
EPCAM/TROP1 (#MAB960) and anti-TROP2 (#AF650) from R&D Systems; anti-
Vimentin (#M7020) from Dako; anti-β-actin (#A1978) and anti-GAPDH (#G9545) 
from Sigma-Aldrich. Infrared dye-conjugated secondary antibodies from Li-COR 
Biosciences were used at 1:10000 dilution: IRDye 800CW goat anti-mouse or anti-
rabbit (#926-32210, #926-32211), IRDye 680LT goat anti-mouse or anti-rabbit 
(#926-68020, #926-68021) and IRDye 800CW donkey anti-goat (#926-32214). Blots 
were scanned using the Odyssey Infrared Imaging System (Li-COR). Images were 
converted to gray scale. 
 
2.7 Immunofluorescence staining 
Cells were grown on 13 mm or 15 mm glass coverslips (Paul Marienfeld 
GmbH & Co. KG) till 70–80% confluent, fixed with 4% paraformaldehyde for 10 
minutes, followed by membrane permeabilization with 0.05% triton-X for 5 minutes. 
The fixed cover slips were stored in 1x PBS at 4°C or directly proceed with 
immunostaining. The fixed cells were incubated with blocking buffer (3% BSA in 1x 
PBS) at room temperature for one hour followed by staining with primary antibodies 
(diluted in 1% BSA in 1x PBS) for 1 hour at 37°C in a humidified chamber or 
overnight at 4°C. The antibodies used include: anti-GRHL2 (#HPA004820) from 
Atlas/Sigma; anti-E-cadherin (#610182) from BD Transduction Laboratories; anti-N-
cadherin (#M142) from Takara Bio Inc.; anti-pan-Cytokeratin (#M3515) and anti-
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Vimentin (#M7020) from Dako; anti-β-Catenin (#8480), anti-phospho-Myosin Light 
Chain 2 (Ser19) (#3671), anti-LC3A (#4599), anti-EEA1 (#3288), anti-LAMP1 
(#9091), anti-RCAS1 (#12290) from Cell Signaling Technology. Alexa Fluor 488-
conjugated anti-mouse or anti-rabbit (#A11029, #A11034) and Alexa Fluor 594-
conjugated anti-mouse or anti-rabbit (#A11032, #A11037) from Invitrogen were used 
as secondary antibodies, incubation at room temperature for 1 hour in the dark. For F-
actin staining, Rhodamine phalloidin probe (#R415, Life Technologies) was used. 
After washing steps, stained cover slips were mounted onto glass slides by 
Vectashield mounting medium with/without DAPI (#H-1200, #H-1000) from Vector 
Laboratories. Images were taken by Nikon A1R confocal system or Zeiss AxioImager 
M2 epifluorescence imaging system. 
 
2.8 Gap closure migration assay, invasion assay and live-cell imaging 
 For gap closure migration assay, culture-inserts (#80209, Ibidi) were mounted 
onto different wells of multiwell culture plate. Cells were seeded into both chambers 
of the culture-inserts till 90 to 100% confluent, serum starved before removing the 
inserts. Non-attached cells were removed, and fresh Leibovitz’s L-15  media (#21083-
027, Life Technologies) supplemented with 20% FBS was added for time-lapse 
microscopy using Zeiss Axio Observer Z1 Live-imaging System with 37°C 
incubation. For invasion assay, cells were seeded into culture-inserts mounted onto 
each well of a 12-well plate. Upon removal of culture-inserts and non-attached cells, 
300 µl of pre-chilled BD Matrigel (#354234, BD BioScience) with the concentration 
of 8.9 mg/ml was layered on top of the attached cells. The gel was allowed to solidify 
by incubation at 37°C, 5% CO2 for 1 hour. 1 ml of L-15 media supplemented with 
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20% FBS was added prior to live-imaging. For image analysis, Wimscratch and 
ImageJ were used. 
 
2.9 Quantitative ELISA 
To quantify extracellular MMP2, MMP3 and MMP9 in cultured media, 
Quantikine ELISA kits from R&D Systems (#DMP2F0, #DMP300, #DMP900) were 
used. Cells were seeded onto 60 mm dishes overnight, changed with fresh media and 
incubated at 37°C, 5% CO2 for 24 hours. Cultured supernatants were harvested, 
filtered with 20 µm filter, and frozen in aliquots at -80°C. 100 µl of undiluted samples 
were used as input for the immunoassay according to the manufacturer’s protocol. 
Absorbance signals were detected by microplate reader (Tecan infinite 200). Standard 
curve was generated using the readouts of the serial diluted MMP standards (included 
in the kits). MMP levels in samples were calculated based on the standard curve. 
To quantitate ErbB3 expression and its phoshorylation,  25 µg of total protein 
lysates of EOC cell lines (SGOCL) were subjected to ELISA tests using PathScan 
Total HER3/ErbB3 Sandwich ELISA Kit (#7888) and PathScan Phospho HER3/ 
ErbB3 (panTyr) Sandwich ELISA Kit (#7890) from Cell Signalling Technology. 
Phospho-HER3/ErbB3 (Tyr1289) (21D3) rabbit monoclonal antibody (no. 4791 Cell 
Signalling Technology) was used as the detection antibody replacing the panTyr 
antibody in the Phospho Kit. The absorbance at 450 nm wavelength was measured 
using microplate reader (Tecan infinite 200). 
 
2.10 Anoikis assay 
 Anoikis resistance of control and GRHL2-knockdown OVCA429 cells was 
tested by seeding 3000, 6000 or 12000 cells into each well of 96-well plate of ultra-
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low attachment grade (#3474, Corning). Cells were incubated at 37°C, 5% CO2 and 
MTS assays (#G5430, Promega) were performed at day 0, day 2, day 4 and day 6 
according to standard protocol. The cells were incubated with MTS reagent mix for 2 
hours  and absorbance was read using a microplate reader (Tecan infinite 200).  
 
2.11 Spheroid invasion assay 
Control and GRHL2-knockdown OVCA429 cells were grown as spheroids 
following the protocol of 96 well 3D Spheroid BME Cell Invasion Assay from 
Cultrex (#3500-096-K) with slight modifications. Adherent cells grown under normal 
culture condition were trypsinized and harvested. From which, five thousand cells 
were mixed with Spheroid Formation ECM (provided in the kit) and seeded into each 
well of a round-bottom ultra-low attachment 96-well plate (#7007, Corning).  The 
plate was then centrifuged at 200 x g for 3 minutes and incubated at 37°C for 3 days 
(72 hours) to induce spheroid growth. After the assembled cells formed spheroids, 
BME matrix (Basement Membrane Extract) was added to each well (50 µl), followed 
by centrifugation at 300 x g, 4°C for 5 minutes. The plate was then incubated at 37°C 
for 1 hour to allow gel formation, after which 100 µl of cell culture media was added. 
The spheroids were grown under normal cell culture condition (37°C, 5% CO2) and 
were monitored every 3 or 4 days. Cells were stain for 1 hour with Calcein AM 
(#C3100MP, Life Technologies) to check their viability and with Ethidium 
Homodimer-1 (#E1169, Life Technologies) to check for dead cells. Images were 
taken by Zeiss AxioImager M2 epifluorescence imaging system. 
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2.12 Chromatin immunoprecipitation assays (ChIP-qPCR and ChIP-seq) 
Cells grown in 100 mm or 150 mm dishes were cross-linked by adding 
formaldehyde to a final concentration of 1% and incubated at room temperature for 10 
minutes. To quench the formaldehyde, glycine was added to a final concentration of 
0.125 M and incubated for 5 minutes. The fixed cells were rinsed twice with 1x TBS 
and harvested by scraping in SDS buffer (100 mM NaCl, 50 mM Tris-Cl at pH 8.1, 5 
mM EDTA, 0.5% SDS, 0.02% NaN3 and protease inhibitors). For lysis and shearing 
of DNA, the cells were sonicated by either Bioruptor® or Branson digital sonifier for 
7 to 10 pulses (20” on 20” off intervals). The size of chromatin fragments (200 bp to 
500 bp) was checked by agarose gel electrophoresis. Prior to immunoprecipitation, 
the chromatin samples were pre-cleared with blocked Protein G sepharose beads for 
one hour at 4°C. Inputs (2.5%) were collected and the rest of the pre-cleared samples 
were incubated with IgG control antibodies or anti-GRHL2 antibodies (#HPA004820, 
Sigma), 3 µg each, overnight at 4°C. The samples were then incubated with blocked 
Protein G sepharose beads for two hours at 4°C followed by a number of high 
stringency washes. The bound DNA was eluted, reverse cross-linked at 65°C 
overnight in 1% SDS, 0.1 M NaHCO3 and subsequently purified using QIAquick 
PCR purification kit from Qiagen. The purified samples and input controls were 
subjected to either qPCR analysis or deep sequencing. For ChIP-qPCR, the primer 
pairs used include: 
 
CDH1 intron 2  (forward) 5' TTCAAAAGATCCCCTGCGCT 3'  
(reverse) 5' AAGCCACAACAAACCCGTTC 3'  
RAB25 promoter  (forward) 5' CAGTGGGCTGTCTCTGAAGG 3' 
(reverse) 5' CTGAGAACAGGAAGAGCGGG 3'  
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CLDN4 promoter (forward) 5' GGGCCTCAAAAGTGCCTTTGTT 3’ 
(reverse) 5' GTGAGCAGACCAGTTCCTTCCA 3’ 
ZEB1 promoter_1 (forward) 5' CGGTCCCTAGCAACAAGGTT 3’  
(reverse) 5' TCGCTTGTGTCTAAATGCTCG 3'   
ZEB1 promoter_2 (forward) 5' GCCGCCGAGCCTCCAACTTT 3' 
(reverse) 5' TGCTAGGGACCGGGCGGTTT 3' 
 
To prepare for Solexa sequencing, ChIP-seq library was constructed using 
NEBNext® ChIP-seq sample preparation kit (E6200, New England Biolabs) according 
to the manufacturer’s protocol. Size-selection was performed either by gel extraction 
after agarose gel electrophoresis or by magnetic AMPure XP beads. Multiplexing 
sample preparation oligonucleotide kit (#PE-400-1001, Illumina) was used for index 
labelling. The samples were analyzed by Agilent 2100 Bioanalyzer prior to Solexa 
sequencing. ChIP-seq data was analyzed by MACS (Model-based analysis of ChIP-
seq) version 2.0.9. 
  
2.13 Expression microarray analysis 
Total RNA was extracted with either RNeasy mini kit or miRNeasy mini kit 
(Qiagen) and quantified using Nanodrop (Fisher Scientific). The RNA quality was 
checked on Agilent Bioanalyzer to ensure RIN value greater than seven. GeneChip® 
Human Gene 2.0 ST Array and GeneChip® miRNA 2.0 Array from Affymetrix were 
used for gene expression analysis and microRNA analysis respectively by Origen 
Laboratories. Microarray data were pre-processed and Robust Multi-array Average 
(RMA)-normalized using Affymetrix Power Tools 1.15.2 and annotation files version 
na.33.2. Probes that were detected significantly above background (DABG, p < 0.05) 
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in at least one sample were retained for further analysis. The gene expression levels of 
each transcript were averaged across exons based on the metaprobesets version r4 
annotation from Affymetrix. 
 
2.14 Statistical Analyses 
 Statistical differences in the mRNA expression levels of GRHL2 between the 
four subgroups of 42 EOC cells lines (biological duplicates for each cell line) were 
analyzed by Kruskal-Wallis test and Dunnet’s post-hoc tests using Prism 5 (GraphPad 
Software Inc.). The same statistical tests were used to analyze the differences in 
GRHL2 mRNA expression between the five molecular subtypes of 44 archived EOC 
patient samples. From the meta-analysis data of 1538 EOC tumours, Mann-Whitney 
U test was used to analyze the differences in GRHL2 mRNA expression between 
tumours of the Mes subtype and tumours of the non-Mes subtype. The overall patient 
survival of GRHL2-high tumours and GRHL2-low tumours were compared using log-
rank test. For RT-qPCR, unpaired Student’s t-tests were used to determine statistical 
changes in the average mRNA expression (from biological duplicates) of GRHL1, 
GRHL2, GRHL3, CDH1, CDH2, VIM, SNAI1, SNAI2, ZEB1, ZEB2, TWIST1, 
CLDN4, RAB25, TACSTD2, ERBB3, ELF3, EPS8, ST14, EPCAM, MAL2, ESRP1, 
ESRP2, EEA1, DRAM1, ARHGEF19, TERT and mature human microRNAs (miR-
200a-3p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-203a-3p, miR-205-5p) in 
GRHL2-knockdown cells compared to shLuc control cells. For ZEB1-overexpression 
experiment, unpaired Student’s t-test was used to analyze the changes in GRHL2 and 
ZEB1 mRNA expression (biological triplicates) in ZEB1-overexpressing cells 
compared to controls. The statistical changes in molecular subtype enrichment scores 
and EMT scores of GRHL2-knockdown cells were also checked by unpaired 
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Student’s t-tests. For migration and invasion assays, results were obtained from at 
least two independent experiments. Two-way ANOVA and Bonferroni post hoc tests 
were used to analyze the differences in percentage of cell-covered area. Changes in 
cell invasion were analyzed by unpaired Student’s t-tests. Results of MMP2 levels in 
conditioned media were obtained from two independent experiments, using unpaired 
Student’s t-tests for statistical analysis. For ChIP-qPCR experiments, unpaired 
Student’s t-tests were used to determine statistical significance in the binding of 
GRHL2 at selected DNA regions. The levels of ErbB3 protein expression and 
phosphorylation measured by ELISA (biological duplicates) in GRHL2-high and 








Grainyhead-like 2 regulates epithelial-mesenchymal 




 Epithelial ovarian cancer (EOC) is a heterogeneous disease associated with high 
mortality, mainly due to late diagnosis and widespread metastases to adjacent pelvic 
or abdominal organs (Jayson et al, 2014). Besides presenting itself as different 
histological subtypes, EOC shows high level of complex genetic alterations, which 
continues to challenge the development of effective targeted treatment. Recent efforts 
in dissecting the heterogeneity of EOC at the molecular level have implicated genes 
that are involved in epithelial-mesenchymal transition (EMT) as functional classifiers 
of EOC (Tan et al, 2013; Yang et al, 2013a; Gardi et al, 2014). Besides being an 
important developmental programme in morphogenesis, EMT provides a mechanistic 
explanation for the progression of carcinoma in gaining metastastic properties (Thiery, 
2002). In particular, the dissemination of EOC has been suggested to involve repeated 
rounds of EMT and MET (the reverse of EMT) which render plasticity and 
adaptability to the cancer cells (Ahmed et al, 2007). This is supported by increasing 
findings that associate EMT pathways with enhanced invasiveness, cancer stemness 
and chemoresistance in EOC (Huang et al, 2012b). Most of these pathways trigger 
EMT through the activation of several key EMT transcription factors including 
SNAI1/2 (Kurrey et al, 2005), TWIST1/2 (Kurrey et al, 2005; Ponnusamy et al, 
2010) and ZEB1/2 (Wang et al, 2014; Wu et al, 2011). These classic EMT 
transcriptional drivers are mostly repressors of the prototypic epithelial marker E-
cadherin (Thiery et al, 2009).  
 From a previous in-house study, classic and novel EMT-related genes were 
examined in EOC cell lines and tumours (Huang et al, 2013), among which 
Grainyhead-like 2 (GRHL2) emerges as a potential EMT transcription factor 
associated with the epithelial phenotype of EOC cells. Grainyhead-like 2 (GRHL2) is 
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one of the three mammalian orthologues of the Drosophila grainyhead (grh) 
(Wilanowski et al, 2002). The Grainyhead transcription factor family consists of two 
phylogenetic arms: the Grh subfamily and the LSF/CP2 subfamily, with the 
Drosophila genes grainyhead and gemini, as the respective ancestral genes 
(Wilanowski et al, 2002; Venkatesan et al, 2003; Traylor-Knowles et al, 2010). In the 
early, late and post embryonic development of Drosophila, grainyhead is essential for 
epithelial and epidermal morphogenesis (Bray and Kafatos, 1991; Narasimha et al, 
2008), wound healing (Mace et al, 2005), tracheal tube formation (Hemphälä et al, 
2003), maturation of central nervous system (Almeida and Bray, 2005) and 
maintenance of polarity in wing and hair (Lee and Adler, 2004). In the mammalian 
system, all three Grainyhead-like factors, Grhl1, Grhl2 and Grhl3 are required for 
normal embryonic development, of which Grhl2 and Grhl3 have important roles in 
neural tube closure (Wilanowski et al, 2008; Werth et al, 2010; Ting et al, 2003b). 
Studies in mice have shown that Grhl2 transcriptionally modulates the expression of 
Cdh1 (E-cadherin), Cldn 4 (Claudin 4), Rab25 and Nkx2-1, which are crucial for the 
differentiation and junctional maintenance of epithelial cells (Werth et al, 2010; 
Senga et al, 2012; Varma et al, 2012). Grhl2 also directly regulates the expression of 
G-protein exchange factor ARHGEF19 during epidermal wound healing (Boglev et al, 
2011). Some of these Grhl2 target genes have been validated in a study in human lung 
epithelium (Gao et al, 2013a). In zebrafish, the role of Grhl2b in regulating claudin b 
and epcam determines proper otic development and hearing function (Han et al, 
2011). This is in line with mutations found in human GRHL2 gene that are associated 
with hearing impairment (Peters et al, 2002; Vona et al, 2013; Van Laer et al, 2008). 
 In recent years, a number of studies have started to implicate GRHL2 in 
cancer progression. GRHL2 is shown to be overexpressed in oral squamous cell 
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carcinoma (OSCC) and confers growth advantage by positively regulating telomerase 
(Kang et al, 2009). In breast cancer, GRHL2 acts as an EMT suppressor (Cieply et al, 
2012) by forming a double negative feedback loop with the EMT driver ZEB1 
(Cieply et al, 2013; Werner et al, 2013; Xiang et al, 2012), and has significant roles in 
tumourigenesis (Werner et al, 2013; Xiang et al, 2012; Yang et al, 2013b). The role 
of GRHL2 in regulating tumour growth has also been demonstrated in gastric cancer 
(Xiang et al, 2013) and colorectal cancer (Quan et al, 2014). The aberration of 
GRHL2 expression in cancer has been shown to arise from genomic alterations. The 
genetic locus of GRHL2 resides in the 8q22.3 region that is frequently amplified in 
hepatocellular cancer, breast cancer, lung cancer, ovarian cancer and melanoma 
(Tanaka et al, 2008; Dompe et al, 2011). Within this 8q22.3 gene cluster, GRHL2 and 
UBR5 have been shown, through their respective proteins, to suppress death receptor-
induced apoptosis in cancer cells (Dompe et al, 2011).  
 To date, the functional roles of GRHL2 in EOC have yet to be elucidated. 
Besides the 8q22.3 amplification suggested in ovarian cancer (Dompe et al, 2011), 
data from TCGA (The Cancer Genome Atlas Research Network) also showed GRHL2 
amplification in about 8% to 22% cases of ovarian serous cystadenocarcinoma 
(Cerami et al, 2012; Gao et al, 2013b). Therefore, this study aims to explore the 
functions of GRHL2 in EOC, particularly in the regulation of EMT. It is hypothesized 
that GRHL2 is an EMT suppressor required for maintaining the epithelial phenotype 
of EOC. This chapter will describe the expression levels of GRHL2 in EOC cell lines 
and patient samples, as well as the functions of GRHL2 in regulating EOC phenotype, 





The expression of GRHL2 in EOC cell lines and tumours correlates with 
epithelial phenotype and is associated with better patient survival. 
 Based on the expression of E-cadherin, pan-cytokeratin and vimentin, a 
panel of 43 EOC cell lines, termed SGOCL, have previousy been characterized into 
four phenotypes forming an EMT Spectrum: Epithelial, Intermediate Epithelial 
(Intermediate E), Intermediate Mesenchymal (Intermediate M), and Mesenchymal 
(Huang et al, 2013). Utilizing this panel of cell lines (42 were used in this study), the 
mRNA level of GRHL2 was examined by RT-qPCR. The expression of GRHL2 was 
found to correlate negatively with the EMT Spectrum, with significant higher 
expression in the epithelial-like phenotype, Epithelial and Intermediate E; low to 
undetectable in the mesenchymal-like phenotype, Intermediate M and Mesenchymal 
(Figure 1A). This indicates that GRHL2 expression is exclusive in cells with an 
epithelial-like phenotype. The hallmark difference between the epithelial-like and 
mesenchymal-like phenotype along the EMT Spectrum is the expression of E-
cadherin (Huang et al, 2013). Therefore, western blot was performed in 38 
representative cell lines to validate the correlation between protein expression of 
GRHL2 and E-cadherin. Consistent with the RT-qPCR results, the protein levels of 
GRHL2 correlated with E-cadherin in most of the cell lines, with low or undetectable 
GRHL2 in most of the Intermediate M and Mesenchymal EOC cell lines (Figure 1B). 
This suggests that GRHL2 is likely to be involved in the maintenance of epithelial-
like phenotype in EOC. In addition to the SGOCL panel of cell lines, the expression 
of GRHL2 in EOC tumours was also examined. In a previously published work, meta-
analysis of expression microarray datasets from multiple repositories consisting of 
1538 EOC tumours was carried out. Five molecular subtypes - EpiA, EpiB, Mes, 
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StemA and StemB were identified based on gene expression profiling (Tan et al, 
2013). Among them, the Mes subtype is characterized by over-expressing EMT gene 
signatures and is associated with poor clinical outcomes. Referring to the in-house 
meta-analysis cohort, a significant lower expression of GRHL2 was observed in the 
Mes subtype (Figure 2A) compared to other subtypes (p < 0.0001). The overall 
survival (OS) data of patients with GRHL2-low and GRHL2-high tumours were 
compared, using a cutoff median matched with the expression in cell lines. GRHL2-
high tumours showed better survival outcome than GRHL2-low tumours (Hazard 
Ratio = 1.578; p = 0.0168) (Figure 2B). Independently, the expression pattern of 
GRHL2 was further validated by RT-qPCR using a collection of fresh frozen EOC 
tumours (JPKO, GSE30311). Among the five different molecular subtypes, the 
median transcript level of GRHL2 in Mes tumours was significantly lower compared 






































Figure 1. The mRNA and protein expression of GRHL2 in EOC cell lines. 
(A) Scatter plot showing normalized mRNA expression of GRHL2 (2-∆Ct) (y-axis) 
measured by RT-qPCR in the SGOCL panel of EOC cell lines with the four 
phenotypic subgroups, Epithelial, Intermediate Epithelial (Intermediate E), 
Intermediate Mesenchymal (Intermediate M) and Mesenchymal. Kruskal-Wallis and 
Dunnett’s post hoc tests were performed for statistical significance, ** p < 0.01; *** p 
< 0.001. (B) Western blots showing the protein expression of GRHL2, E-cadherin and 
GAPDH in 38 SGOCL cell lines (OVCA420, OVCAR3, Caov3, PEO1, OVCAR8, 
OV90, OV17R, IGROV1, OAW28, OVCA432, OAW42, FUOV1, OVCA433, 
JHOS3, PEO4, JHOS4, OV56, EFO-21, OVCAR5, OVCA429, JHOS2, Caov2, 
OVCAR2, UWB1.289, DOV13, CH1, OV7, SKOV3, HeyC2, Hey, A2780, OVK18, 
A1847, TOV112D, Colo720E, OVCAR10, HeyA8, Tyknu) representing the four 
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Figure 2. The mRNA expression of GRHL2 in EOC tumours and its association 
with patient survival. 
(A) Scatter plot showing the mRNA expression of GRHL2 (y-axis) in five molecular 
EOC subtypes: EpiA, EpiB, Mes, StemA and StemB (x-axis). Horizontal bars 
represent medians of expression in each group. Mann-Whitney U test showed 
significant difference between Mes subgroup and non-Mes subgroups, with p < 
0.0001. (B) Kaplan-Meier curves showing the overall patient survival (percent 
survival) of GRHL2-high (red) and GRHL2-low (low) groups. Hazard ratio (HR) = 
1.578 and log-rank test p = 0.0168. (C) Scatter plot showing normalized mRNA 
expression of GRHL2 (2-∆Ct) (y-axis) measured by RT-qPCR in 44 archived EOC 
samples classified by the five molecular subtypes EpiA, EpiB, Mes, StemA and 
StemB (x-axis). Kruskal-Wallis test followed by Dunnett’s post hoc tests were 
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Down-regulation of GRHL2 induces sequential EMT changes along the EMT 
spectrum in EOC cell lines. 
 To study the function of GRHL2 in EOC, stable knockdown of GRHL2 was 
performed using two different GRHL2-targeting shRNA hairpins (referred to as 
shGRHL2 #10 and shGRHL2 #12) on three EOC cell lines. Among the three cell 
lines used, two belong to the Epithelial phenotype: PEO1, OVCA420; and one is from 
the Intermediate E phenotype: OVCA429. shRNA sequences targeting luciferase 
(shLuc) and targeting no known genes (shNon) were used as controls. shLuc and 
shNon PEO1 and OVCA420 cells formed tight epithelial colonies with relatively 
smaller cell-sizes (Figure 3A, upper & middle panels). shLuc and shNon OVCA429 
cells, though still formed epithelial colonies, displayed a more spread-out morphology 
(Figure 3A, lower panel). This reflected the nature of OVCA429 cells of an 
intermediate phenotypic state. Compared to the two controls shLuc and shNon that 
formed tight colonies, GRHL2-knockdown PEO1 and OVCA420 cells were less 
compact and showed a loosen morphology within the epithelial colonies in both 
shGRHL2 sequences (Figure 3A, upper & middle panels). Interestingly, shGRHL2 
#10 OVCA429 cells showed a flattened “fried-egg-like” morphology while shGRHL2 
#12 OVCA429 cells displayed a more spindle-shaped mesenchymal-like morphology 
(Figure 3A, lower panel). The OVCA420 shGRHL2 #10 cells did not survive after 
subsequent passaging, thus experiments hereafter for OVCA420 involved only one 
stable knockdown line shGRHL2 #12. 
 As the endogenous expression of GRHL2 correlated with that of E-cadherin in 
EOC, the protein level of E-cadherin was examined in GRHL2-knockdown cells. In 
PEO1 and OVCA420, little or no change was observed in the protein expression of E- 



































Figure 3. GRHL2 is required for EOC cells to maintain epithelial morphology. 
 (A) Phase contrast images showing the morphologies of three EOC cell lines (PEO1, 
OVCA420, OVCA429) infected with control shRNAs (shLuc, shNon) and GRHL2-
targeting shRNAs (shGRHL2 #10, shGRHL2 #12). Images were taken with 10x 
objective with scale bars representing 100 µm. (B) Western blotting of GRHL2, E-
cadherin, and β-actin showing the knockdown efficiency of GRHL2 shRNAs and the 
expression of E-cadherin. The numbers below protein bands indicate normalized fold 
changes in band intensities with respect to shLuc for GRHL2 and E-cadherin. The 
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line OVCA429, E-cadherin was down-regulated significantly in both shGRHL2 #10 
and shGRHL2 #12 cells (Figure 3B, right column). This might account for the more 
prominent morphological changes observed in OVCA429 compared to the other two 
cell lines. As E-cadherin functions as an adhesion molecule at cell-cell adherens 
junction, its localization was checked by immunofluorescence (IF) staining with 
confocal microscopy. Interestingly, GRHL2-knockdown PEO1 and OVCA420 cells 
showed weaker fluorescence signals of E-cadherin distributed at cell-cell junctions, 
accompanied by the presence of a fraction of cytoplasmic E-cadherin that were 
uncoupled with β-catenin (Figure 4A & B). For OVCA429 cells, junctional E-
cadherin was no longer observed in both shGRHL2 #10 and shGRHL2 #12 cells, 
leaving only some cytoplasmic E-cadherin fluorescence signals visible around the 
nuclei (Figure 4C). This intriguing observation suggested that the manipulation of 
GRHL2 expression might abrogate the subcellular distribution of E-cadherin even in 
cells without significant morphological changes. Consistent with the protein 
expression results, GRHL2 knockdown in PEO1 and OVCA420 cells did not affect 
changes in the mRNA expression of E-cadherin gene, CDH1 (Figure 5A). However, 
knockdown of GRHL2 in the Intermediate E cell line OVCA429 significantly reduced 
the mRNA levels of CDH1 (Figure 5A). This result implied that the transcriptional 
regulation of E-cadherin is consistent with the changes in its subcellular distribution.  
In contrast to the suppressive roles of E-cadherin in tumour invasiveness 
(Vleminckx et al, 1991), the closely related Type-I cadherin, N-cadherin, is known to 
be pro-invasive (Hazan et al, 2000). From RT-qPCR analysis, the mRNA levels of 
CDH2, the gene coding for N-cadherin, and the mesenchymal gene VIM (Vimentin) 
were up-regulated after GRHL2 knockdown, especially in OVCA429 cells (Figure 
5A). For N-cadherin, the increment of protein expression was observed only in 
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OVCA429 shGRHL2 #10 (Figure 5C & E). For vimentin, the changes after knocking 
down GRHL2 varied, with stronger vimentin bands in western blot (Figure 5B) and 
enhanced IF signals of vimentin filaments observed in GRHL2-knockdown cells of 
PEO1 and OVCA429 (Figure 5D). Vimentin expression in OVCA420 cells were low 
or undetectable. Even though vimentin was up-regulated in PEO1 and OVCA429 
cells after GRHL2 knockdown, the expression of epithelial-associated cytokeratin 
filaments remained present (Figure 5F). The changes in E-cadherin, N-cadherin and 
vimentin showed that knocking down of GRHL2 induced phenotype changes in EMT. 
In short, based on the proposed EMT spectrum phenotypic classification (Huang et al, 
2013), PEO1 cells switched from Epithelial to Intermediate E after GRHL2 
knockdown by altering the subcellular distribution of E-cadherin and gaining 
vimentin; while OVCA429 switched from Intermediate E to Intermediate M via the 
loss of junctional E-cadherin and slight gain of vimentin (Figure 6). Despite changes 




















































































Figure 4. Down-regulation of GRHL2 affects the distribution of junctional E-
cadherin.  
Immunofluorescence staining of E-cadherin (red) and β-catenin (green) in GRHL2 
knockdown (shGRHL2 #10, shGRHL2 #12) and control (shLuc) PEO1 (A), 
OVCA420 (B) and OVCA429 (C) cells. Nuclei were stained blue (DAPI). Scale bars 
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Figure 5. Down-regulation of GRHL2 increases mesenchymal markers N-
cadherin and vimentin.  
(A) Bar charts showing the mRNA expression fold changes (y-axis) of GRHL2, E-
cadherin (CDH1), N-cadherin (CDH2) and vimentin (VIM) measured by RT-qPCR in 
control (white bars), shGRHL2 #10 (black bars) and shGRHL2 #12 (grey bars) cells. 
Unpaired t-tests were performed on the 2-∆Ct values for each gene and the statistical 
significance was indicated by asterisks, ** p < 0.01; *** p < 0.001.  
(B) Western blots showing vimentin, β-actin and GAPDH in controls (shLuc and 
shNon) and GRHL2-knockdown (shGRHL2 #10, shGRHL2 #12) PEO1 (upper 
panel), OVCA420 (lower left panel), and OVCA429 (lower right panel) cells. 
Numbers below protein bands indicate fold changes of band intensities relative to 
shLuc control. 
(C) Western blots showing N-cadherin and β-actin in controls (shLuc and shNon) and 
GRHL2-knockdown (shGRHL2 #10, shGRHL2 #12) OVCA429 cells.  
Immunofluorescence images of controls (shLuc and shNon) and GRHL2-knockdown 
(shGRHL2 #10 and shGRHL2 #12) cells showing the expression of vimentin (D), N-
cadherin (E), and pan-cytokeratin (F). White arrow indicates junctional N-cadherin 
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Figure 6. A simplified representation of EMT changes in GRHL2-knockdown 
EOC cells.   
A simplified diagram illustrating stepwise changes in EMT phenotype involving EMT 
markers E-cadherin, N-cadherin, cytokeratins and vimentin observed in the GRHL2-
knockdown cells of PEO1 and OVCA429.  
 
 
Cytoplasmic E-cadherin in GRHL2-knockdown EOC cells co-localized with 
autophagosomal marker LC3A. 
From the immunofluorescence staining described earlier (Figure 4), E-
cadherins were mostly distributed at cell-cell junctions in control cells whereas in 
GRHL2-knockdown cells, the E-cadherin signals at the junctions were partially 
affected in the Epithelial PEO1 and OVCA420 cells and substantially reduced in the 
Intermediate E OVCA429 cell. In addition, the cytoplasmic E-cadherin staining 
showed a prominent peri-nuclear pattern in GRHL2-knockdown cells. To verify the 
subcellular location of these non-junctional E-cadherins, organelle markers for early 
endosomes (EEA1), Golgi apparatus (RCAS1), lysosomes (LAMP1) and 
autophagosomes (LC3A) were used for double staining with E-cadherin. Confocal 
microscopy imaging showed that among the tested markers, most of the cytoplasmic 
E-cadherin co-localized with LC3A, while co-localization with other markers such as 
Golgi were sporadic (Figure 7A). The co-localization of cytoplasmic E-cadherin and 
LC3A was observed in GRHL2-knockdown cells of all three cell lines, and was 
especially evident in PEO1 and OVCA429 cells (Figure 7B). 
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Figure 7. The co-localization of cytoplasmic E-cadherin with various organelle 
markers in GRHL2-knockdown EOC cells. 
(A) Immunofluorescence images showing the staining of E-cadherin (green) along 
with four different organelle markers (red) in PEO1 shGRHL2 #12 cells. EEA1 (far 
left) marks early endosome; RCAS1 (middle left) (also known as EBAG9) marks 
Golgi apparatus; LAMP1 (middle right) marks lysosome; LC3A (far right) marks 
autophagosome. White arrows indicate co-localization (yellow). Scale bars represent 
50 µm. (B) Z-stack slices showing the co-localization (yellow) of LC3A (red) and 
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Knockdown of GRHL2 changed EMT signatures and resulted in molecular 
subtype switch in EOC.  
Among the three EOC cell lines, OVCA429 showed the most prominent 
phenotypic changes upon GRHL2 knockdown. This prompted the question whether 
manipulating GRHL2 expression would cause changes in the molecular subtype. 
Hence, the control and GRHL2-knockdown OVCA429 cells were selected for gene 
expression microarray to assess for transcriptomic changes. The gene expression data 
was then subjected to single-sample Gene Set Enrichment Analysis (ssGSEA, pmid: 
23257362) to determine the molecular subtype (pmid: 23666744) and EMT status, as 
applied in previous studies (Tan et al, 2013; Miow et al, 2014). Compared to the 
control (shNon), GRHL2-knockdown cells showed increased expression of genes that 
are usually down-regulated in the EpiA subtype; reduced expression of genes that are 
usually enriched in EpiA; and increased expression of signature genes that correlates 
with the Mes subtype (Figure 8A). From the computed enrichment scores, it was 
concluded that the molecular subtype of OVCA429 changed from EpiA to Mes for 
both shGRHL2 #10 and shGRHL2 #12 cells (EpiA to Non-EpiA, p = 0.0021; Non-
Mes to Mes, p = 0.000012) This was further confirmed by the changes in the EMT 
scores generated from an independent set of EMT signature genes, classifying control 
cell (shNon) as Epithelial with an average EMT score of -0.1013; shGRHL2 #10 and 
shGRHL2 #12 cells as Mesenchymal with average EMT scores of 0.1771 and 0.2099 
respectively (combined average score = 0.1968) (Figure 8B). Many affected genes 
were found to overlap in both signatures for molecular subtype and EMT scores 
(Figure 8A & B), which include Epithelial-related genes: CLDN3, KLK6, VGLL1, 
GALNT3, INADL, ZBED2, ESRP1, CDH1, LCN2, ITGB6; and Mesenchymal-related 
genes: ZEB1, IMPA1, CCDC88A. These genes may be the downstream targets that 
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are associated with the functional roles of GRHL2 in maintaining the epithelial 
phenotype of EOC cells. Among these genes, one transcriptional factor, ZEB1, 








  p = 1.2e-5 























































Figure 8. Knockdown of GRHL2 in OVCA429 cells induces molecular subtype 
change from EpiA to Mes.   
(A) Heatmap showing molecular subtype signature genes that were differentially 
expressed between OVCA429 control (shNon) and GRHL2 knockdown (shGRHL2 
#10, shGRHL2 #12) cells (fold change ≤ -0.8 or ≥ 0.8) based on the microarray gene 
expression data. Scatter plots showing molecular subtype enrichment scores from 
single sample Gene Set Enrichment Analysis (ssGSEA). (B) Heatmap showing 
differentially expressed EMT scoring genes from the microarray gene expression data 
of OVCA429 control (shNon) and GRHL2 knockdown (shGRHL2 #10, shGRHL2 
#12) cells (fold change ≤ -0.8 or ≥ 0.8). Scatter plots showing EMT enrichment scores 
from ssGSEA. Bars indicate mean values ± SEM. Unpaired t-tests were used to 
determine statistical significance. 
 
ZEB1 is one of several key transcription factors that are known to activate 
EMT. ZEB1 is also known to participate in the transcriptional regulatory loop with 
other EMT transcriptional drivers (Peinado et al, 2007). To validate the expression 
changes of ZEB1 revealed by the microarray analysis and to explore the expression 
changes of other transcription factors inflicted by GRHL2 knockdown, RT-qPCR was 
employed to detect the mRNA levels of EMT drivers SNAI1/2, ZEB1/2, TWIST1 and 
two other GRHL factors GRHL1 and GRHL3. All five classic EMT drivers were up-
regulated in OVCA429 after GRHL2 knockdown, among which, SNAI2, TWIST1 




















and ZEB1 showed similar increasing trends in PEO1 and OVCA420 although the 
statistical significance was not reached (Figure 9). GRHL1 and GRHL3 did not show 
consistent changes in PEO1 and OVCA420 but both were significantly down-



































Figure 9. Knockdown of GRHL2 affected the mRNA expression of other 
transcription factors. 
Bar charts showing the normalized mRNA expression (2-∆Ct) (y-axis) of five EMT 
transcriptional drivers (SNAI1, SNAI2, TWIST1, ZEB1 and ZEB2) and two other 
GRHL factors (GRHL1 and GRHL3) measured by RT-qPCR in control (white bars), 
shGRHL2 #10 (black bars), and shGRHL2 #12 (grey bars) cells of PEO1, OVCA420 
and OVCA429. Unpaired t-tests were performed for statistical significance, * p < 






































































































































































GRHL2 and ZEB1 form a double negative feedback loop in OVCA429 cells. 
 GRHL2 has recently been reported to form a double negative feedback loop 
with ZEB1 in breast cancer and colorectal cancer (Cieply et al, 2013; Werner et al, 
2013; Quan et al, 2014). As described above, the mRNA level of ZEB1 increased 
only significantly in OVCA429 after GRHL2 knockdown (Figure 10C), suggesting a 
potential role of GRHL2 as an upstream transcription suppressor for ZEB1 in EOC. 
Compatible with the RT-qPCR result, the up-regulation of ZEB1 protein expression 
was only detectable in both shGRHL2 #10 and shGRHL2 #12 of OVCA429 (Figure 
10A). To ascertain whether a GRHL2-ZEB1 reciprocal regulatory loop takes place in 
EOC, the expression of GRHL2 was examined after overexpressing ZEB1 in the same 
cell lines. GRHL2 and E-cadherin were down-regulated significantly in ZEB1-
overexpressing OVCA429 cells (Figure 10B), suggesting that GRHL2 and ZEB1 
negatively regulate each other in at least OVCA429 cells. This regulation, however, 
might not hold true in some EOC cell lines such as PEO1 and OVCA420 that may be 
intrinsically less plastic. Unlike OVCA429, neither knocking down GRHL2 in PEO1 
cause significant induction of ZEB1 expression nor over-expressing ZEB1 in PEO1 
had effect on the suppression of GRHL2 (Figure 10A & C). 
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Figure 10. The reciprocal negative regulation between GRHL2 and ZEB1 is 
more prominent in OVCA429 cells. 
(A) Western blots of ZEB1, β-actin, and GAPDH in control (shLuc, shNon) and 
GRHL2 knockdown (shGRHL2 #10, shGRHL2 #12) cells. (B) Western blots of 
ZEB1, E-cadherin, GRHL2, and β-actin in OVCA429 control and ZEB1-
overexpressing (ZEB1 #1, ZEB1 #2) cells. Numbers below protein bands indicate 
band intensities relative to shLuc control. (C) Bar charts showing the normalized 
mRNA expression (2-∆Ct) (y-axis) of GRHL2 (upper) and ZEB1 (lower) measured by 
RT-qPCR in PEO1 (grey bars) and OVCA429 (black bars) cells. Left panel: 
comparing control (shLuc) and GRHL2-knockdown (shGRHL2 #10, shGRHL2 #12) 
cells. Right panel: comparing vector control and ZEB1-overexpressing (ZEB1 #1, 
ZEB1 #3) cells. Unpaired t-tests were performed for statistical significance, ** p < 

















































































































































Knockdown of GRHL2 increases cell motility, reorganizes actomyosin, and 
promotes 2D migration. 
 One of the main features of cells that have undergone EMT is the gain of 
motility (Thiery, 2002). To study the changes in cell movement upon GRHL2 
knockdown, time-lapse live cell imaging was conducted, followed by cell-tracking 
analysis. Among the three cell lines, PEO1 has the lowest basal motility compared to 
OVCA420 and OVCA429 (Figure 11). Among shLuc control cells, the average speed 
of locomotion for PEO1 was 0.1384 µm/min compared to 0.2120 µm/min for 
OVCA420 and 0.4139 µm/min for OVCA429. After GRHL2 knockdown in all three 
cell lines, the average speed of locomotion in individual cells increased significantly 
compared to controls, indicating a gain in cell motility (Figure 11). Apart from the 
speed of locomotion, the displacement of cells representing the shortest distance from 
the origin to the last tracked time point was also compared. Most of the GRHL2-
knockdown cells showed increased displacement.   
 To further examine whether the more motile GRHL2-knockdown cells 
showed any difference in directional migration, a two-dimensional (2D) gap closure 
migration assay was carried out. Among the three cell lines, the inherently slow-
moving PEO1 cells did not show significant change in directional migration after 
GRHL2 knockdown (data not shown). On the other hand, loss of GRHL2 in 
OVCA420 and OVCA429 resulted in significant higher speed of gap closure (Figure 
12). Moreover, during the gap closure, individual detached cells were observed at the 
migrating front of GRHL2-knockdown cells for both OVCA420 and OVCA429, 
while the control cells still migrated collectively and remained attached to 
















Figure 11. Down-regulation of GRHL2 increases cell motility. 
Bar charts showing the speed of locomotion over the course of 11 to 18 hours (upper 
panels) and the net displacement (lower panels) of control (shLuc and shNon) and 
GRHL2-knockdown PEO1, OVCA420, and OVCA429 cells (sample size = 20) 
analyzed from time-lapse imaging. Statistical significance was determined by 





















































































































































































































































Figure 12. Down-regulation of GRHL2 promotes 2D migration of EOC cells. 
(A) Phase contrast images from 2D migration assays showing gap closure of control 
(shLuc and shNon) and GRHL2-knockdown OVCA420 (shGRHL2 #12) and 
OVCA429 (shGRHL2 #10, shGRHL2 #12) cells before (0 hour) and after 19 hours 
(OVCA429) or 22 hours (OVCA420). Yellow lines mark the edges of the initial gaps 
and scale bars represent 100 µm. (B) Line graphs showing the percentage of cells 
covering total area (y-axis) over time (x-axis) in control (shLuc, shNon) and GRHL2-
knockdown OVCA420 (shGRHL2 #12) and OVCA429 (shGRHL2 #10, shGRHL2 
#12) cells. Error bars indicated SEM. Statistical significance was determined by Two-
way ANOVA and Bonferroni post hoc tests. * p < 0.05; *** p < 0.001.  
0 hr 
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shLuc (control) shNon (control) shGRHL2 #12 
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 Besides the enhanced cell motility and migratory potential observed, 
GRHL2-knockdown cells were seen to have more single, detached cells at the 
migrating front compared to control cells, suggesting a change in the migratory 
behaviour. During cell migration, it requires coordination between actin filaments and 
myosin II to change the traction forces (Ridley et al, 2003). The changes in the 
activity of myosin II can be represented by the staining patterns of the phosphorylated 
myosin light chain 2 at the serine residue 19 (pS19-MLC2) (Reffay et al, 2014). 
Immunofluorescence staining of pS19-MLC2 and fluorescence labeling of F-actin (by 
phalloidin) were performed. Compared to control cells which showed a distribution of 
pS19-MLC2 at the edge of cell colonies, the pS19-MLC2 signals in GRHL2-
knockdown cells were more concentrated at the intercellular borders (Figure 13). The 
difference was especially apparent in OVCA420 cells. In addition, F-actin in GRHL2-
knockdown cells was less organized compared to control cells. Thus, GRHL2 could 
be involved in the regulation of actin cytoskeleton rearrangement and actomyosin 
contractility. Since suppression of actomyosin activity at cell-cell contacts have been 
implicated as a requirement for collective cell migration (Hidalgo-Carcedo et al, 
2011), the observed changes in GRHL2-knockdown cells suggested a potential 
disruption in collective cell migration. Taken together, these data suggested the roles 
of GRHL2 in cell motility and migration, potentially through the regulation of 






















































































































Figure 13. Actomyosin organization in PEO1, OVCA420 and OVCA429 after 
GRHL2 knockdown.  
Fluorescence images showing phosphorylation of myosin light chain 2 (ser19) 
(Phospho-MLC2) and F-actin (phalloidin) stainings in control and GRHL2-
knockdown (shGRHL2 #10, shGRHL2 #12) PEO1 (upper panels), OVCA420 
(middle panels), and OVCA429 (lower panels) cells. Scale bars represent 50 µm. 
 
 
Down-regulation of GRHL2 promotes cell invasion and increases the secretion of 
matrix metalloproteinase 2 (MMP2). 
 From the results of migration assays described earlier, OVCA420 and 
OVCA429 showed enhanced migration after GRHL2 knockdown. To study the cell 
invasiveness, a modified gap closure assay with the addition of a layer of Matrigel to 
cover the cultured cells was applied. OVCA420 cells showed low invasive potential, 
with slight increase in invasion in GRHL2-knockdown cells compared to the control 
(Figure 14A & B). In the case of OVCA429, GRHL2-knockdown cells were seen 
penetrating the Matrigel matrix more efficiently, at a faster rate compared to control 
cells (Figure 14A & B). Notably, at the invasive fronts, the GRHL2-knockdown 
OVCA420 cells displayed a collective front while the OVCA429 cells started to show 
single leading cells (Figure 14A). As cell invasion involves degradation of the 
extracellular matrix (ECM) by enzymes such as matrix metalloproteinases (MMPs), 
the levels of MMP2, MMP3 and MMP9 in the cultured media were measured by 
quantitative ELISA. The basal MMP2 secretion in the control OVCA420 and 
OVCA429 cells were low. In OVCA429, the levels of secreted MMP2 were 
significantly up-regulated in GRHL2-knockdown cells (Figure 14C), correlating to 
the increasing trend of invasiveness. Meanwhile, the secretion of MMP3 was not 
detected in all samples and MMP9 did not show consistent changes (data not shown). 
The endogenous expression of the MMP2 genes was interrogated by referring to the 
in-house microarray meta-analysis dataset of EOC tumours. The expression of MMP2 
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was shown to be highest in the Mes subtype of EOC (Figure 14D), further supporting 
MMP2 as a mesenchymal-associated MMP in EOC. These results suggested that 
down-regulation of GRHL2 in EOC cells contributed to tumour invasiveness, 
























































































Figure 14. Down-regulation of GRHL2 promotes invasion and up-regulates 
MMP2 secretion in EOC cells. 
(A) Phase contrast images from invasion assays in matrigel showing control (shLuc) 
and GRHL2-knockdown of OVCA420 (shGRHL2 #12) and OVCA429 (shGRHL2 
#10, shGRHL2 #12) cells before (0 hour) and after 46 hours (OVCA420) or 19 hours 
(OVCA429). Yellow lines mark the initial edges and scale bars represent 100 µm.  
(B) Bar chart showing the percentage of area invaded (y-axis) in OVCA420 (black 
bars) and OVCA429 (grey bars) cells. Error bars indicated SEM. Statistical 
significance was determined by unpaired t-tests, * p < 0.05; ** p < 0.01. Results were 
obtained from two independent experiments. (C) Bar chart showing the 
concentrations of MMP2 in the conditioned media (y-axis) of control (shLuc) and 
GRHL2-knockdown OVCA420 (black bars) and OVCA429 (grey bars) cells 
measured by quantitative ELISA. Unpaired t-tests were performed for statistical 
significance, ** p < 0.01. Results were obtained from two independent experiments. 
(D) Scatter plot showing the median levels (horizontal bars) of MMP2 mRNA 
expression (y-axis) in EOC tumours of different molecular subtypes (x-axis). Mann-
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Mann-Whitney U Test 
EpiA vs non-EpiA, p = 0.00414 
EpiB vs non-EpiB, p < 0.0001 
Mes vs non-Mes,  p < 0.0001 
StemA vs non-StemA, p < 0.0001 




Down-regulation of GRHL2 does not promote anoikis resistance and anchorage-
independent growth. 
In addition to enhanced cell motility, migration and invasiveness, another 
mesenchymal-related feature associated with cells that have undergone EMT is the 
resistance to anoikis (Frisch et al, 2013), a programmed cell death triggered when 
epithelial cells lack anchorage or support from extracellular matrix (Frisch and 
Francis, 1994). It has been reported that GRHL2 restores anoikis sensitivity and 
suppresses mammosphere formation in breast cancer cells (Cieply et al, 2012). To 
examine the role of GRHL2 in regulating anoikis in EOC, control and GRHL2-
knockdown OVCA429 cells were grown on ultra-low attachment (ULA) culture 
plates, and their growth was monitored by MTS assays every two days. Results 
showed that the cell viability of both control and GRHL-knockdown cells declined 
markedly from day two onwards and all cells did not survive after day four (Figure 
15A). To examine the role of GRHL2 in anchorage-independent growth, control and 
GRHL2-knockdown OVCA429 cells were grown as spheroids in a spheroid-forming 
environment on ULA plates which were subsequently coated with basement 
membrane extracts (BME). The spheroids for both controls and GRHL2-knockdown 
OVCA429 cells did not increase in size within two weeks, and showed mixture of 
calcein AM-positive live cells and ethidium homodimer-1 (EthD-1)-positive dead 
cells (Figure 15B). These data suggested that in EOC cells, GRHL2 may not be 














































Figure 15. Effects of GRHL2 knockdown on anoikis and spheroid growth. 
(A) Percentage of cell viability (y-axis) of control (shLuc, shNon) and GRHL2-
knockdown (shGHRL2 #10, shGRHL2 #12) OVCA429 cells grown on ULA culture 
plates examined by MTS assays at Day 0, 2, 4 and 6 (x-axis).  
(B) Phase contrast images of OVCA429 control (shLuc, shNon) and GRHL2-
knockdown (shGRHL2 #10, shGRHL2 #12) cells grown as spheroids for three days 
on ULA culture plate (Day 0) and subsequently embedded in BME. Serial images of 
spheroids at Day 4, 7, and 10 are shown. At Day 15, the spheroids were stained with 
calcein AM to detect viable cells and ethidium homodimer-1 (EthD-1) to label 
dying/dead cells. Scale bars represent 200 µm. 
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 Apart from being an important regulator of embryonic development, GRHL2 
has been implicated in several cancer models. Overexpression of GRHL2 has been 
described in oral squamous cell carcinoma while amplification of GRHL2 gene has 
been reported in HCC, breast cancer, lung cancer, ovarian cancer and melanoma 
(Tanaka et al, 2008; Dompe et al, 2011). In this study, the expression of GRHL2 in 
EOC was examined in a panel of phenotype-characterized cell lines and molecular 
sub-classified tumours. The levels of GRHL2 correlated with E-cadherin and 
epithelial phenotype, supporting its role as an epithelial signature transcription factor. 
Loss-of-function experiments further demonstrated the involvement of GRHL2 in the 
maintenance of epithelial phenotype, as down-regulation of GRHL2 in EOC cells led 
to partial or full EMT with increased motility, migratory and invasive properties. 
Hence, this study provides evidence, for the first time in EOC cells, that GRHL2 
regulates EMT. These results are consistent with recent published findings on breast 
cancer cells, which reported significant lower expression of GRHL2 in the claudin-
low and basal-B subtypes, and that GRHL2 functions as an EMT suppressor (Cieply 
et al, 2012; Werner et al, 2013). The flatten morphology observed in shGRHL2 #10 
EOC cells also matches the cell-flattening events reported in lung alveolar epithelial 
cells, likely to be caused by GRHL2 down-regulation during epithelial injury that 
might lead to idiopathic pulmonary fibrosis (Varma et al, 2012; Varma et al, 2014). In 
the EOC cell line OVCA429, although shGRHL2 #10 showed different cell shape 
compared to shGRHL2 #12 which were more spindle-like, down-regulation of 
epithelial marker E-cadherin and the up-regulation of EMT transcription driver ZEB1 
were consistent in both cells. The increased expression of N-cadherin, which is more 
prominent in shGRHL2 #10 cells, might explain the intact membranous β-catenin 
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observed at cell-cell junctions of shGRHL2 #10 cells, which is less obvious in the 
more scattered shGRHL2 #12 cells. More importantly, despite the discrepancy in cell 
morphology, the molecular profiles of both shGRHL2 #10 and shGRHL2 #12 cells 
had consistently switched from EpiA to Mes (mesenchymal), indicating the execution 
of  EMT that followed GRHL2 down-regulation. 
 Although GRHL2 is likely to suppress EMT in EOC cells, different cell lines 
displayed differential susceptibility to execute EMT when GRHL2 was down-
regulated. Despite changes in cell morphology and weakened distribution of E-
cadherin at cell-cell junctions after GRHL2 knockdown, the total E-cadherin 
expression in PEO1 and OVCA420 cells showed no difference. The Intermediate E 
cell line OVCA429, however, displayed significant reduction of E-cadherin after 
GRHL2 knockdown. On the other hand, the E-cadherin repressor ZEB1 increased 
remarkably in OVCA429 shGRHL2 cells at both mRNA and protein levels but only 
showed slight mRNA increment in PEO1 and OVCA420 upon GRHL2 knockdown. 
The mesenchymal marker vimentin filament protein was also up-regulated in 
knockdown cells of PEO1 and OVCA429 but not in OVCA420. These findings led to 
the speculation that epithelial-like EOC cell lines such as PEO1 and OVCA420 may 
be less susceptible to phenotypic changes mediated by GRHL2 knockdown, compared 
to OVCA429 which is already having an intermediate phenotype with considerable 
level of plasticity. Similarly, ectopic expression of ZEB1 in OVCA429 resulted in 
significant reduction of GRHL2, a phenotype not executed in PEO1. These suggest 
that the transcriptional regulation of E-cadherin (activation) and ZEB1 (repression) in 
epithelial cells is likely more tightly controlled compared to cells in intermediate 
EMT stages.  
 91 
 On the other hand, down-regulation of GRHL2 resulted in increased cell 
motility in all three EOC cell lines. Although OVCA420 did not show significant 
changes in phenotypic markers like in OVCA429, enhanced cell migration and 
invasiveness was observed in both cell lines after GRHL2 knockdown. These suggest 
that the loss of E-cadherin or up-regulation of vimentin does not necessarily precede 
changes in cell behaviour that involves cytoskeletal remodeling such as directional 
migration. In fact, other modes of EMT induction such as TGF-β1 treatment has been 
shown to promote morphologic changes and actin rearrangement in many epithelial 
cells that do not commit to full EMT execution defined by losing E-cadherin and 
zonula occludens (ZO)-1 (Brown et al, 2004). Moreover, it has been reported that 
other epithelial cell types such as human bronchial epithelial cells would lose their 
epithelial barrier integrity after functional inactivation of GRHL2 even though E-
cadherin expression remained unchanged (Gao et al, 2013a). This is because GRHL2 
regulates, directly or indirectly, many other genes that are associated with EMT. 
Besides the widely studied EMT-related genes CDH1, CDH2, VIM and ZEB1, genes 
that may be involved in GRHL2 regulation in EOC cells (based on microarray 
analysis) include tight junction-related CLDN3, CLDN7, and INADL; cell adhesion-
related CDH3 and EPCAM; fibroblast growth factor genes FGF2 and FGF5; cell 
migration-related genes CCDC88A and ITGB6; cell surface receptor genes TACSTD2 
and ERBB3 as well as other EMT-related genes: ESRP1, RAB25, ST14, VGLL1, 
IMPA1, and SERPINE1. Some of these genes, such as RAB25, EPCAM, ERBB3, and 
ESRP1 have previously been implicated as GRHL2 targets in other tissues (Senga et 
al, 2012; Werner et al, 2013; Gao et al, 2013a; Xiang et al, 2012). 
 Inferring from the cell behaviour changes in knockdown experiments, 
GRHL2 may regulate cell motility, migration and invasion. These roles appear to be 
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relevant to the evolutionarily conserved role of Grainyhead family in wound-healing 
(Wang and Samakovlis, 2012). The ancestral gene grainyhead is required for 
epidermal wound-healing in Drosophila through direct regulation of cuticle repair 
genes (Mace et al, 2005). Similarly, the murine Grhl3 is required for epidermal 
differentiation and wound-repair via direct regulation of two important genes: 
Transglutaminase1 (TGM1) which encodes a cross-linking enzyme (Ting et al, 2005), 
and ARHGEF19 which encodes a Rho guanine nucleotide exchange factor that 
activates RhoA, thus allowing Grhl3 to modulate actin polymerization as part of the 
planar cell polarity (PCP) signaling pathway (Caddy et al, 2010). Among the two 
genes, ARHGEF19 but not TGM1, is reported in a mouse study, to be the direct target 
of Grhl2, which might explain the redundant roles shared by Grhl2 and Grhl3 in 
eyelid closure (involving actin polymerization at leading edge) during embryonic 
development (Boglev et al, 2011; Yu et al, 2008). These studies suggest that GRHL2 
and GRHL3 are likely to regulate re-epithelialization during initial phase of wound 
closure, and the down-regulation of the latter in human keratinocytes was shown to 
impair wound healing (Caddy et al, 2010). In contrast, knockdown of GRHL2 in EOC 
cells, as shown in this study, resulted in enhanced cell migration and invasion. From 
the migration assay, the gap closure rate increased significantly after GRHL2 was 
down-regulated in both OVCA420 and OVCA429 cells. Moreover, these knockdown 
cells were more scattered, have higher motility and showed potential disruptions in 
collective cell migration. This is in line with the findings from a mouse study, which 
reported that Grhl2 knockdown in murine lung epithelial cells resulted in impaired 
collective cell migration (Varma et al, 2012). When cultured in ECM, GRHL2-
knockdown cells, especially OVCA429, displayed increased invasiveness, coupled 
with an up-regulation of MMP2 secretion. From these data, it is speculated that in the 
 93 
context of cancer, reduction in GRHL2 might affect the ability of epithelial cells to 
migrate collectively, but instead, allowing them to gain motility as single cells with a 
mesenchymal-like migratory and invasive potential. As this study only focuses on 
GRHL2, the involvement of GRHL1 and GRHL3 which may share related functions, 
can not be ruled out. 
 Given the drawback that shRNA-mediated silencing may show off-target 
effects, this study is short of rescue experiments which have yet to be successfully 
demonstrated. However, the use of two shRNA controls and two different shGRHL2 
constructs in three EOC cell lines helps ensure consistency in the associated 
phenotype and lowers the concern for off-target effects. To complement the 
knockdown results, attempts have also been made to overexpress GRHL2 in GRHL2-
low mesenchymal like EOC cells (Appendix IV). However, at this point of writing, 
no reversal of cell morphology has been observed (Figure C). Nevertheless, existing 
experimental data in this study have highlighted the EMT-related functions of 
GRHL2 in EOC with respect to cell morphology, gene expression, cell motility, 
migration, and invasion. On the other hand, the roles of GRHL2 in anoikis resistance, 
cancer stemness, and tumourigenicity have remained elusive in EOC. In breast cancer 
cells, GRHL2 has been reported to suppress anoikis resistance and mammosphere 
formation (Cieply et al, 2012). This suggested a tumour suppressive role of GRHL2, 
as overcoming anoikis is an important mechanism for tumor survival and progression 
(Guadamillas et al, 2011). However, our experimental data does not support the role 
of GRHL2 in this aspect, as knockdown of GRHL2 did not provide any growth 
advantage to EOC cells in an anchorage-independent setting. In normal culture, 
OVCA429 shGRHL2 #10 cells showed slower growth compared to control cells (data 
not shown), a phenotype yet to be confirmed. The possibility of GRHL2 acting as a 
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tumour suppressor in EOC can only be surmised from the patient survival data that 
showed a positive correlation between GRHL2 expressions and the overall survival. 
Meanwhile, preliminary results from mouse xenograft studies (data not shown) 
showed no dominating role of GRHL2 in enhancing the EOC tumorigenicity in nude 
mice, although conclusive data is still awaited. In fact, the function of GRHL2 in 
carcinogenesis has remained contradictory among different cancer types. In breast 
cancer, Cieply et al suggested GRHL2 as a tumour suppressor that inhibits tumour 
initiation, promotes chemosensitivity, and suppresses stem cell characteristics (Cieply 
et al, 2013). Five other studies implicated GRHL2 as a potential oncogene that 
promotes tumour growth and metastasis (Xiang et al, 2012; Yang et al, 
2013b; Werner et al, 2013; Dompe et al, 2011; Leth-Larsen et al, 2012). Besides in 
breast cancer, the roles of GRHL2 in hepatocellular carcinoma (HCC) (Tanaka et al, 
2008), oral squamous cell carcinoma (OSCC) (Kang et al, 2009) and colorectal 
carcinoma (Quan et al, 2014) are also suggested to be oncogenic, with potential 
regulation of telomerase activity in OSCC (Kang et al, 2009). In contrast, GRHL2 is 
reported to suppress tumour growth in gastric cancer by inducing apoptosis (Xiang et 
al, 2013). In summary, the ambiguous role of GRHL2 in regulating tumour growth, in 
EOC as well as in other cancers, requires further clarification through investigation 
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 Transcriptional targets of Grainyhead-like 2 in  
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4.1 Introduction  
 From the in vitro experimental results mentioned in previous chapter, GRHL2 
was shown to negatively regulate EMT in EOC. As a transcription factor, the 
functional roles of GRHL2 are likely to involve direct transcriptional activation or 
repression of a myriad of genes. Gene expression analysis comparing control and 
GRHL2-knockdown cells pinpointed many genes that showed differential expression 
after GRHL2 knockdown, including the epithelial signature gene CDH1 and EMT 
driver gene ZEB1. GRHL2 has previously been shown, in mouse (Werth et al, 2010) 
and human bronchial epithelial cells (Gao et al, 2013a), to bind to the intronic 
enhancer of CDH1. ZEB1 has also been reported to be a direct target gene of GRHL2 
in mammary epithelial cells (Cieply et al, 2012). Besides validating known targets, 
this study aims to identify other putative target genes that are directly regulated by 
GRHL2 in EOC. To investigate the DNA-binding of transcription factors, techniques 
such as electrophoretic mobility shift assay (EMSA) or chromatin 
immunoprecipitation (ChIP) are commonly used. ChIP assay serves as an effective 
method for identifying transcription factor binding sites either at a global scale 
coupled with high-throughput DNA sequencing (ChIP-seq), or at specific sites by 
PCR/qPCR (ChIP-PCR/qPCR) (Collas, 2010). In this chapter, transcriptional targets 
regulated by GRHL2 in EOC explored by ChIP assay with an anti-GRHL2 antibody 
will be described. Employing both ChIP-seq and ChIP-qPCR techniques, this study 
validated some of the known GRHL2 target genes and simultaneously identified 
many novel potential GRHL2 targets in EOC. Combining gene expression data and 
ChIP analysis, direct transcriptional targets of GRHL2 were examined and discussed, 




Genome-wide analysis of DNA-binding of GRHL2 in EOC cells 
 To identify direct transcriptional targets of GRHL2 in EOC cells, ChIP-seq 
experiments were carried out on three EOC cell lines that showed high endogenous 
expression of GRHL2, among which OVCAR3 and PEO1 belong to the Epithelial 
phenotypic group; while OVCA429 belongs to the Intermediate E phenotype. The 
ChIP samples were prepared and sequenced following the pipeline processing by 
Solexa/Illumina’s protocol and peaks were called by using MACS (Model-based 
analysis of ChIP-seq) (Zhang et al, 2008) with p-value cutoff set at 1.00e-03. This 
yielded large sets of GRHL2-bound peaks, about 10k, 40k and 70k peaks for 
OVCAR3, PEO1 and OVCA429 cells respectively. After normalization to input 
controls, top peaks with false discovery rate (FDR) adjusted q-value < 1.0002e-33 
were analyzed (2000 peaks for OVCAR3, 5000 peaks for PEO1, 8000 peaks for 
OVCA429). By mapping the ChIP-seq peaks with the sequences based on the human 
genome hg19 version, the majority of GRHL2 binding sites were found to occupy 
non-promoter DNA regions . Consistent in all three cell lines, about 10% of the peaks 
resided at ±5 kilobases (kb) away from the nearest transcription start sites (TSS) while 
majority of the peaks (~ 80%) were located at 5 kb to 500 kb upstream/downstream of 
TSS (Figure 16). This suggested that GRHL2 not only occupies promoter regions, but 
also binds to other regulatory elements such as enhancer regions at distal sites.  
To obtain a functional overview of the binding sites, the ChIP-seq peaks were 
subjected to gene ontology (GO) analysis by using GREAT (Genomic Regions 
Enrichment of Annotations Tool) (McLean et al, 2010), with the basal gene 
regulatory domain assigned as 5 kb upstream, 2 kb downstream, plus 1000 kb 
extension. In the GO category of biological process, associated GO terms such as 
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“skin development” (Figure 17) matched with reported functional roles of GRHL2 in 
keratinocyte differentiation (Chen et al, 2012). Interestingly, genes involved in actin 
filament bundle assembly were implicated, which might be relevant to the potential 
roles of GRHL2 in cytoskeletal remodelling described in Chapter III. From the GO 
analysis, many of the GRHL2 target genes were found to be associated with cellular 
components that are related to cell-cell adhesion, such as zonula adherens in 
OVCAR3 and  OVCA429 and desmosome in PEO1 and OVCA429 (Figure 17). 
Interestingly, genes annotated as clathrin coat of coated pits or endocytic vesicles 
were also found in PEO1 and OVCA429. This suggested that GRHL2 might also 
regulate clathrin-mediated endocytosis. These genes could also be related to the 
functions of GRHL2 in regulating cell-cell junctions and epithelial features. Other 
common GO annotated pathways included gamma-glutamyl cycle (OVCAR3 & 
OVCA429), Rap1 signalling (PEO1 & OVCA429), p38 signalling (PEO1 & 
OVCA429), α6β4 integrin signaling (PEO1 & OVCA429), as well as transcriptional 
targets of TAp63 (all three lines). The associated genes in each category are listed in 

































Figure 16. The distribution of GRHL2-bound peaks from ChIP-sequencing. 
Bar charts depict the distribution of GRHL2 ChIP-seq peaks grouped according to 
their distance to the transcription start site (TSS) of nearby genes annotated in the 
UCSC hg19 database (Goldman et al, 2013). Only ChIP-seq peaks with FDR adjusted 
q-value <1.0002e-33 in OVCAR3, PEO1 and OVCA429 cells (2000, 5000 and 8000 




















































Figure 17. Gene ontology (GO) analysis of GRHL2 ChIP-seq peaks 
Bar charts indicate GO terms that showed significant association with the GRHL2 
ChIP-seq peaks (Binomial test p < 0.005 and FDR adjusted Q-value < 0.05 for both 
Binomial and Hypergeometric tests) in OVCAR3, PEO1 and OVCA429. GO terms 
from three categories were plotted based on fold enrichment: biological process 
(blue), cellular components (green) and pathway commons (red).  
0 2 4 6 
Validated transcriptional targets 






labyrinthine layer blood vessel 
development 
negative regulation of protein 
kinase B signaling cascade 
Fold enrichment 
OVCAR3 
GO Biological Process 
GO Cellular Component 
Pathway Commons 
0 1 2 3 
a6b1 and a6b4 Integrin signaling 
Validated transcriptional targets of 
TAp63 isoforms 
p38 signaling mediated by MAPKAP 
kinases 
stearate biosynthesis I (animals) 
gamma-glutamyl cycle 
NAD biosynthesis II (from tryptophan) 
Rap1 signalling 
desmosome 
clathrin coat of endocytic vesicle 
zonula adherens 
actin filament bundle assembly 




α6β1 and α6β4 integrin signalling 
0 1 2 3 
Hypoxic and oxygen homeostasis 
regulation of HIF-1-alpha 
Validated transcriptional targets 
of TAp63 isoforms 
Alpha6Beta4Integrin 
FoxO family signaling 
p38 signaling mediated by 
MAPKAP kinases 
Rap1 signalling 
Apoptotic cleavage of cell 
adhesion proteins 
clathrin coat of coated pit 
desmosome 
ER-nucleus signaling pathway 
membrane raft organization 
Fold enrichment 
PEO1 
        α6β4 integrin 
 101 
 For subsequent analysis, ChIP-seq peaks that fulfill the criteria of MACS 
scores ≥ 25, enrichment ≥ 5 and distance ± 100 kb to the nearest TSS were shortlisted 
as GRHL2 binding sites with good level of confidence, and the associated genes 
(upstream and/or downstream of the sites) were collated as potential GRHL2 target 
genes. This yielded approximately 1500 peaks in OVCAR3, 6500 peaks in PEO1, and 
9400 peaks in OVCA429, among which 1140 peaks corresponding to 956 associated 
genes were found to overlap across all three EOC cell lines (Figure 18A). By 
annotating the peaks with HOMER (Hypergeometric Optimization of Motif 
EnRichment) (Heinz et al, 2010), 7 to 12% of the GRHL2 binding sites were found to 
reside in gene promoters; 19 to 23% in intergenic regions; 20 to 26% in introns; ≤ 5% 
in CpG-island; ≤ 2% in exons; ≤ 1% in 5’UTR/3’UTR; and 40 to 41% in 
other/unknown regions (Figure 18B). Overall, OVCA429 of the Intermediate E 
phenotype had the most number of GRHL2 binding sites associated with the most 
number of genes, compared to PEO1 and OVCAR3 of the Epithelial phenotype. In 
addition, many of these putative target genes showed more than one GRHL2 binding 
sites across the gene coding/non-coding regions. This suggested that the occupancy of 
GRHL2 at cis-regulatory elements (promoters/enhancers) may involve long-distance 

































Figure 18. DNA-binding sites of GRHL2 in EOC cells and the associated DNA 
elements. 
(A) Venn diagram indicating the number of GRHL2 ChIP-seq peaks with MACS 
scores ≥ 25, enrichment ≥ 5 and distance ± 100 kb to the nearest TSS, overlapped or 
unique in OVCAR3, PEO1 and OVCA429 cells. (B) Pie charts showing the 
percentage of GRHL2 binding sites classified based on annotated genomic elements 



















































DNA-recognition motif of GRHL2 in EOC cells 
 
 The members of Grainyhead transcription factor subfamily have been 
reported to share conserved DNA-binding domain and similar DNA-recognition motif 
(Wilanowski et al, 2002). Based on the binding sites at response elements, the DNA-
binding sequence for Drosophila grh was suggested as the palindromic 8 bases 
AACCGGTT with different levels of variability (Dynlacht et al, 1989; Harrison et al, 
2010). This binding motif was well-conserved in the mammalian GRHL consensus 
generated by CASTing (cyclic amplification and selection of targets) (Wilanowski et 
al, 2008; Ting et al, 2005; Boglev et al, 2011). Although most of the GRHL2 binding 
sites at target genes followed the core consensus motif, GRHL2 may recognize DNA 
sequence that deviates from the reported consensus, such as the promoter of TERT 
(Chen et al, 2010) and NKX2-1 (Varma et al, 2012). By aligning the Grh/GRHL 
consensus with some of the reported GRHL2 binding sites, it was shown that within 
the conserved sequence, an invariant motif of cytosine and guanine separated by two 
bases CNNG is likely to be the main feature recognized by GRHL2 (Figure 19A). To 
examine the DNA-binding sequence of GRHL2 in EOC cells, approximately 700 
ChIP-seq peaks with highest MACS scores from each of the three EOC cell lines 
were subjected to MEME-ChIP analysis (Multiple Expectation Maximization for 
Motif Elicitation) using MEME Suite (Bailey et al, 2009). Generated de novo from in-
house ChIP-seq data, the DNA-binding motif of GRHL2 in EOC cells contained the 
ACCDGYY sequence similar to the GRHL consensus, with two core CNNG motifs 
occurred in repeat, spaced by five bases (Figure 19B). From TOMTOM motif 
analysis (MEME suite), the GRHL2 binding motif was found to share similarities 
with the binding motifs of Tfcp2l1, the murine version of human TFCP2L1 (paralog 
of GRHL2), and the chicken ZEB1 (Gallus gallus) (Figure 19C). In addition, the 
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CNNG repeated motifs within GRHL2 binding consensus also share resemblance 
with the DNA-binding motifs of p53 transcription factor family members (Figure 
19C), which have previously been suggested to be phylogenetically related to 
Grh/CP2 family based on protein structure and folding (Kokoszynska et al, 2008). 
This is consistent with the finding of TAp63 GO annotated pathway shown in all 








































Figure 19. Analysis of DNA-binding motifs of GRHL2 
(A) DNA-binding motifs of Grainyhead subfamily members from published literature 
with respective references. The motif sequences are presented as logos, some obtained 
by WebLogo (Crooks et al, 2004). Black arrows mark the invariant C and G bases 
that are conserved in almost all motifs. (B) From the in-house GRHL2 ChIP-seq data 
of three EOC cell lines, the DNA-binding motif of GRHL2 was generated by MEME-
ChIP analysis. E-value represents p-value multiplied by the number of tested 
candidate. Black arrows mark the invariant C and G bases. (C) DNA-binding motifs 
of transcription factors Tcfcp2l1 (murine), ZEB1 (chicken), TP53 and TP63 (human) 
(ChIP-seq-derived) were obtained from JASPAR database (Mathelier et al, 2014). 
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GRHL2 binds to the regulatory elements associated with CDH1, CLDN4, RAB25 
and ZEB1 
 Grhl2 has previously been shown in a mouse study to bind to the intronic 
enhancer of Cdh1 (E-cadherin) and the promoter region of Cldn4 (claudin 4) for 
transcriptional activation of the two genes (Werth et al, 2010). In a separate mouse 
study of liver progenitor cells, Grhl2 is involved in tight junction maintenance 
through its regulatory binding at the promoter region of Rab25, which encodes a 
small GTPase involved in recycling of membrane proteins such as claudin 4 (Senga et 
al 2012). Besides these three epithelial-related genes, the mesenchymal-related gene 
ZEB1 was also shown to be a direct target gene of GRHL2 in mammary epithelial 
cells (Cieply et al, 2012). To validate whether these genes are directly regulated by 
GRHL2 in EOC cells, GRHL2 ChIP-qPCR by using specific primers designed for 
these reported regions was carried out (Figure 20B).  
 From the ChIP-qPCR results of PEO1 and OVCA429 (Figure 20A), 
significant enrichment was detected in the intron 2 region of CDH1 at 7.6 kb 
downstream of TSS (Figure 20B), which matched the conserved GRHL2 binding site 
reported by Werth et al (Figure 19). Consistent with the ChIP-qPCR result, the same 
binding site was detected by ChIP-seq in OVCAR3, PEO1 and OVCA429 (Table 1). 
Interestingly, besides the common binding site, two additional ChIP-seq peaks were 
specifically detected further downstream within the intron 2 region of CDH1 in 
OVCA429.  
 In GRHL2 ChIP-qPCR, enrichment was shown at the reported -7 to +177 
promoter region (Figure 20B) of CLDN4, but did not reach statistical significance due 
to low efficiency of primer pairs (Figure 20A). However, the site (which contained 
the conserved binding motif) matches with one of several peaks detected in GRHL2     
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Figure 20. The occupancy of GRHL2 at the regulatory elements of CDH1, 
CLDN4, RAB25 and ZEB1 genes detected by ChIP-qPCR. 
(A) Bar charts showing the results of GRHL2 ChIP-qPCR in PEO1 and OVCA429 
using primer pairs that flanked reported GRHL2 binding sites in intron 2 of CDH1 
and in the promoter regions of CLDN4, RAB25 and ZEB1 respectively. Signals of IgG 
control and ChIP samples were normalized to input DNA and presented as % input 
with SEM from biological duplicates. Unpaired t-tests were performed and asterisks 
represent significance compared to IgG control, * p < 0.05. No significant enrichment 
was detected by both primer pairs for ZEB1 promoter. (B) Box shows the starting and 
ending of DNA sequences flanked by the primer pairs of respective genes with the 
GRHL2 binding motif in red. Numbers refer to distance (in base pairs) relative to TSS 
of UCSC ref seq genes (Goldman et al, 2013). For ZEB1, the distance relative to TSS 
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TTCAAAAGATC-------CAGCAAACCAGCCAAACCAGTTTCT-------GTTGTGGCTT CDH1 intron 2 
+7572 +7770 +7606 
GGGCCTCAAAAG-------AGGAATCCAGAGAAACTGGTCAGG---------TCTGCTCAC  
-7 +177 +28 
CLDN4 promoter 
CGGTCCCT--------TGTCGTAAACCAGGTGCGG--------CACAAGCGA  ZEB1 promoter 
GCCGCCGAGCCTCCAACTT--------AACCGCCCGGTCCCTAGCA  
-2091 / -128  -1908 / +55 -2008 / -45  








CAGTGGGC-------ACACCAACCTGTCGAACCTGTCTGACGTC--------TGTTCTCAG  -191 
-10 -94 
RAB25 promoter  
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ChIP-seq in both PEO1 and OVC429 cells (Table 1). Another ChIP-seq peak was 
found near the promoter of CLDN4, at the 3’UTR region, and was detected in all three 
EOC cell lines. This GRHL2 binding site has yet to be validated by ChIP-qPCR. In 
total, five GRHL2 binding sites associated with CLDN4 were identified in EOC, 
among which two sites were common in all three tested cell lines; two sites 
overlapped in PEO1 and OVCA429; and one site unique to OVCA429. These binding 
sites varied from ~ 5.6 kb upstream of TSS down to the transcription termination site 
of CLDN4 (+2.6 kb).  
For RAB25, there was only one GRHL2 binding site found within the 
promoter region (Table 1), with a GRHL2 binding motif similar to the sequence 
reported in mouse (Senga et al, 2012) and its enrichment validated by ChIP-qPCR 
(Figure 20A). On the other hand, no binding of GRHL2 was detected at the reported 
promoter region of ZEB1 from both ChIP-qPCR (Figure 20A) and ChIP-seq (Table 
1). A single ChIP-seq peak with relatively low enrichment/score was found 32 kb 








Table 1. The binding sites of GRHL2 at the regulatory elements of CDH1, 
CLDN4, RAB25 and ZEB1 genes identified by ChIP-seq. 
Table showing GRHL2 ChIP-seq peaks associated with CDH1, CLDN4, RAB25 and 
ZEB1 in OVCAR3, PEO1 and OVCA429. Distance to TSS was counted based on 
peak summit.  refer to ChIP-seq peaks covering regions that matched the binding 
sites flanked by respective primer pairs (used in ChIP-qPCR) shown in Figure 20. 
 
Gene Cell line No. of Peaks 
Peak 







CDH1 OVCAR3 1 282 25 68.02 7602 Intron 2  
PEO1 1 594 126 231.28 7621 Intron 2  
OVCA429 3 749 179 260.42 7624 Intron 2  
616 35 51.96 41716 Intron 2  
253 32 39.12 52942 Intron 2  
         
CLDN4 OVCAR3 2 205 33 50.77 -5672 Intergenic  
328 37 56.93 1525 3’ UTR  
PEO1 4 326 73 58.37 -5668 Intergenic  
658 62 51.32 45 5’ UTR  
578 203 162.32 1514 3’ UTR  
299 34 34.06 2659 TTS  
OVCA429 5 395 158 173.75 -5680 Intergenic  
317 73 65.97 -1140 Intergenic  
678 126 87.29 20 5’ UTR  
586 174 84.38 1509 3’ UTR  
488 25 25.85 2639 TTS  
         
RAB25 OVCAR3 1 379 113 86.93 -82 Promoter  
PEO1 1 466 174 163.49 -92 Promoter  
OVCA429 1 520 205 149.12 -87 Promoter  
         
ZEB1 OVCA429 1 286 25 18.19 32704 Intron 1  
TSS=Transcription start site;  TTS=Transcription termination site;  UTR=Untranslated region 






Putative target genes of GRHL2 showed differential expression after GRHL2 
knockdown. 
 To examine whether the genes enriched with GRHL2 binding were 
transcriptionally regulated by GRHL2, the expression data obtained from gene 
expression microarray analysis of control and GRHL2-knockdown OVCA429 cells 
(Figure 7, Chapter III) was cross-analyzed with the GRHL2 ChIP-seq data of 
OVCA429 (Figure 21). Putative GRHL2 target genes that showed consistent reduced 
expression after GRHL2 knockdown included membrane receptor genes TACSTD2, 
GPRC5A; tight junction gene INADL; membrane traffic-related genes RAB25, 
SYNGR2; metastasis-associated gene MACC1; and phospholipase-encoding PLA2G7. 
On the other hand, putative GRHL2 target genes that showed consistent increased 
expression after GRHL2 knockdown include endosomal trafficking gene EEA1; 
protein folding/transport-related gene HSP90B1; member of the arrestin family 
ARRDC3; zinc finger protein-coding ZNF700; and autophagy-associated gene 
DRAM1.  
RT-qPCR was employed to validate the expression changes in selected 
putative GRHL2 target genes that might be associated with EMT in EOC (Figure 22). 
CLDN4, which showed GRHL2 binding at its promoter region (based on ChIP-seq) 
(Table 1), and RAB25, which showed GRHL2 binding at its validated promoter 
(based on ChIP-seq and ChIP-qPCR) (Figure 20 and Table 1), were confirmed by RT-
qPCR to have reduced expression after GRHL2 knockdown in OVCA429 (Figure 
22). Four other epithelial-related genes with GRHL2 bound to their respective 
promoter regions, including TACSTD2, ERBB3, and ELF3 (Table 2), were also 
markedly down-regulated following GRHL2 knockdown (Figure 22), except for 
EPS8, which showed a relatively modest down-regulation. Another group of                
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Figure 21. Cross-analysis of GRHL2 ChIP-seq and gene expression microarray 
data of GRHL2 control/knockdown in OVCA429. 
(A) Volcano plot indicating genes that were enriched with GRHL2 binding (based on 
ChIP-seq in OVCA429) and had differential expression after GRHL2 knockdown 
(based on gene expression microarray of OVCA429 discussed in Chapter III). 
Potential target genes of GRHL2 were represented as green dots (positively regulated 
by GRHL2) and red dots (negatively regulated by GRHL2) corresponding to the 




epithelial-related genes that showed reduced expression after GRHL2 knockdown, 
such as ST14, EPCAM, MAL2, ESRP1 and ESRP2, were mainly genes with GRHL2 
binding sites at intronic enhancers or distal intergenic regions. Besides serving as a 
transcriptional activator, GRHL2 is also likely to have transcriptionally repressive 
roles on the direct regulation of genes such as EEA1 and DRAM1, evident by the 
increased gene expression followed GRHL2 knockdown and the enrichment of          
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Figure 22. mRNA expression of putative GRHL2 target genes in OVCA429 
control and GRHL2-knockdown cells analyzed by RT-qPCR. 
Bar chart showing the mRNA expression of CLDN4, RAB25, TACSTD2, ERBB3, 
ELF3, EPS8, ST14, EPCAM, MAL2, ESRP1/2, EEA1, DRAM1, ARHGEF19 and 
TERT analyzed by RT-qPCR in control (shLuc, white) and GRHL2-knockdown 
(shGRHL2 #10, black; shGRHL2 #12, grey) OVCA429 cells. The fold change (2-
∆∆Ct) of each gene was calculated with respect to shLuc as control. Unpaired t-tests 
were performed on the 2-∆Ct values and asterisks represent statistical significance, n.s. 
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Table 2. The putative GRHL2 target genes in EOC cells with their respective 
GRHL2 binding sites identified by ChIP-seq. 
Table showing GRHL2 ChIP-seq peaks associated with TACSTD2, EEA1, ERBB3, 
ST14, ELF3, ESRP1/2, ARHGEF19, DRAM1, EPCAM, MAL2 genes detected in 
OVCAR3, PEO1 and OVCA429, with their respective peak length, MACS score, fold 
enrichment, distance to TSS and genomic annotation. Distance to TSS was counted 
based on peak summit.  
 
 
Gene Cell line No. of Peaks 
Peak 






TACSTD2 OVCAR3 1 328 91 70.01 209 5’ UTR 
PEO1 3 226 40 46.35 4607 Intergenic 
611 240 143.86 192 5’ UTR 
230 28 13.43 -15203 Intergenic 
OVCA429 3 292 53 44.06 4614 Intergenic 
796 272 176.66 195 5’ UTR 
362 38 37.61 -42930 Intergenic 
        
EEA1 OVCAR3 1 233 27 41.54 -488 Promoter 
PEO1 1 505 109 87.16 -493 Promoter 
OVCA429 1 608 149 54.19 -474 Promoter 
        
ERBB3 OVCAR3 1 617 31 60.64 -213 Promoter 
PEO1 1 1167 149 132.82 -248 Promoter 
OVCA429 2 1224 197 157.48 -247 Promoter 
334 59 72.99 6197 TTS (variant s) 
        
ST14 OVCAR3 1 269 39 60.01 412 Intron 1 
PEO1 3 360 42 50.35 -13185 Intergenic 
421 73 57.68 391 Intron 1 
311 27 21.59 6790 Intron 1 
OVCA429 3 466 46 45.53 -13216 Intergenic 
359 67 32.49 413 Intron 1 
273 26 30.7 6793 Intron 1 
ELF3 OVCAR3 4 241 67 103.09 -2240 Intergenic 
490 45 69.24 -158 Promoter 
355 92 70.78 24416 Intergenic 
377 132 187.1 35892 Intergenic 
PEO1 4 607 191 114.54 -2235 Intergenic 
705 111 80.39 -155 Promoter 
342 195 154.07 24414 Intergenic 
493 220 75.39 35895 Intergenic 
OVCA429 6 541 205 99.42 -2239 Intergenic 
499 118 116.79 -149 Promoter 
453 149 54.19 24416 Intergenic 
543 241 175.31 35890 Intergenic 
455 29 21.1 46803 Intergenic 
252 40 51.96 90650 Intergenic 
        
ESRP1 OVCA429 1 290 52 25.22 16087 Intron 4 
        
ESRP2 OVCAR3 1 585 119 176.05 2019 Intron 3 
PEO1 1 575 101 121.14 2031 Intron 3 
OVCA429 1 819 158 114.94 2029 Intron 3 
        
ARHGEF19 OVCAR3 1 292 71 54.62 -138 Promoter 
PEO1 1 293 41 75.26 -137 Promoter 
OVCA429 1 486 136 65.95 -147 Promoter 
        
DRAM1 PEO1 2 280 38 24.93 194 5’ UTR 
482 72 112.75 17581 Intron 1 
OVCA429 3 392 64 55.42 191 5’ UTR 
398 69 50.19 17597 Intron 1 
193 26 37.83 31251 Intron 4 
        
EPCAM PEO1 1 675 87 100.82 -29143 Intergenic 
OVCA429 1 664 82 114.38 -29133 Intergenic 
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MAL2 PEO1 4 458 31 29.13 -64135 Intergenic 
428 73 35.02 -7461 Intergenic 
672 145 69.56 -3015 Intergenic 
254 40 23.99 -1070 Intergenic 
OVCA429 1 403 66 76.21 -3024 Intergenic 
        
EPS8 PEO1 1 574 108 43.18 -136 Promoter 
OVCA429 1 784 114 82.93 -145 Promoter 
TSS=Transcription start site;  TTS=Transcription termination site;  UTR=Untranslated region 
 
GRHL2 binding at their promoter regions. ARHGEF19, a previously identified 
GRHL2 target gene (Boglev at al 2011; Gao et al, 2013a) with enrichment of GRHL2 
binding at the promoter region, showed inconsistent expression changes in OVCA429 
GRHL2-knockdown cells. TERT, another target gene known to be regulated by 
GRHL2 directly and epigenetically (Kang et al, 2009; Chen et al, 2010), was not 
associated with any GRHL2 ChIP-seq peaks identified in this study. As its expression 
was not consistently affected by GRHL2 knockdown, GRHL2 might have little role in 
the transcriptional regulation of TERT in EOC. 
Among the differentially expressed target genes validated by RT-qPCR in 
OVCA429, the protein levels of EEA1, EPCAM and TACSTD2 in control and 
GRHL2-knockdown PEO1, OVCA420 and OVCA429 cells were checked by western 
blotting (Figure 23A). Although the respective promoters of EEA1, EPCAM, and 
TACSTD2 were enriched with GRHL2 binding (based on ChIP-seq), no significant 
changes was detected in all three proteins in PEO1 shGRHL2 cells. In OVCA420, 
there was an increased protein level of EEA1 in shGRHL2 #12 cells after GRHL2 
knockdown, while no changes were observed in EPCAM and TACSTD2. In 
OVCA429, the up-regulation of EEA1 was only apparent in shGRHL2 #10 cells; 
while the down-regulation of EPCAM and TACSTD2 were significant in both 
shGRHL2 #10 and shGRHL2 #12 cells, consistent with the RT-qPCR results. 
The qPCR results also confirmed that the ERBB3 expression was significantly 
down-regulated in GRHL2-knockdown OVCA429 cells (Figure 22).  The change in 
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ErbB3 protein expression in GRHL2-knockdown cells has yet to be determined. 
However, from the quantitative ELISA data of the entire SGOCL panel, the protein 
level of total and phosphorylated ErbB3 (phosphorylation at Y1289) correlated 
significantly with the expression of GRHL2 in EOC cells (Figure 23B). This suggests 


































Figure 23. Differential protein expression of putative GRHL2 target genes in 
GRHL2-high vs. GRHL2-low cells.  
(A) Western blots showing the protein levels of EEA1, EPCAM and TACSTD2 in 
PEO1 (left) OVCA420 (middle) and OVCA429 (right). Numbers below protein bands 
indicate normalized band intensities relative to shLuc control. (B) Bar charts showing 


















































OVCA429 OVCA420 PEO1 
EEA1 
β-actin 




 1.0     1.4     0.2    0.2        1.0     0.9    0.7          1.0     2.0     1.9     1.6       
TACSTD2 
β-actin 
 1.0      0.8     0.3    0.2        1.0     1.5     1.0          1.0     1.1      0.9     0.6      
*** ** 























































(right) in EOC cells measured by quantitative ELISA. 37 cell lines of the SGOCL 
collection (no data for FUOV-1) were grouped into GRHL2-high (black bars) and 
GRHL2-low (white bars) based on GRHL2 protein expression analyzed by western 
blot (refer to Chapter III). Mann-Whitney U test and student t-test showed similar 




GRHL2 directly regulates microRNAs such as MIR200B and MIR203A in EOC 
cells. 
 The GRHL2 ChIP-seq data in EOC cells revealed thousands of GRHL2 
binding sites associated with protein-coding genes as well as non-coding RNA genes. 
In recent years, mounting studies have found that non-protein-coding RNAs such as 
microRNAs (miRNAs) play essential roles in regulating post-transcriptional gene 
expression, not only in normal physiological contexts, but also in disease progression 
(He and Hannon, 2004). To identify potential miRNA genes directly regulated by 
GRHL2, the expression of miRNA was profiled by microarray (Affymetrix miRNA 
2.0) comparing OVCA429 control v.s. GRHL2-knockdown cells, followed by cross-
analysis with the ChIP-seq data. Potential miRNA targets of GRHL2 were screened 
by shortlisting only miRNAs associated with GRHL2 binding sites and showed 
consistent changes in both OVCA429 shGRHL2 #10 and shGRHL2 #12 cells 
compared to control (Figure 24). MIR203A, MIR200B and MIR205 emerged as 
potential targets positively regulated by GRHL2, with substantial down-regulated 
expression (log2 fold of 4.3, 3.4, 3.5 respectively) after GRHL2 knockdown. From 
the ChIP-seq data, MIR203A had a GRHL2 binding site at its promoter region that 
was consistent in OVCAR3, PEO1 and OVCA429 cells (Table 3). MIR200B also 
showed GRHL2 binding at the CpG island 3.8 kb upstream, which was matched to 
the previously characterized promoter region of a single polycistronic primary 
transcript encoding three miRNAs (miR-200b, miR-200a, and miR-429) (Bracken et 
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al, 2008). Meanwhile, a GRHL2 binding site was found at ~ 1.3 kb downstream of 
MIR205 gene (in both PEO1 and OVCA429) at the transcription termination site of its 
host gene, MIR205HG. In OVCA429, four other GRHL2 binding sites associated 
with MIR205HG were detected, among which three were further upstream at 
intergenic regions and one at the promoter of MIR205HG.  
 On the other hand, miRNA genes that might be negatively regulated by 
GRHL2 included MIR21, MIRLET7G, MIR1908, and MIR4284 which showed 
increased expression after GRHL2 was knocked down in OVCA429 cells (Figure 24). 
It is interesting to note that MIR21 has been reported to be a target gene directly 
repressed by GRHL3, a paralogue of GRHL2 (Bhandari et al, 2013); while the gene 
product miR-21 has also been shown to directly inhibit GRHL3 transcript through 
binding at its 3’UTR, thus forming a double negative feedback regulation (Darido et 
al, 2011). Since GRHL2 could form dimers with GRHL3 (Ting et al, 2003a), they 
may share similar target genes such as MIR21. However, none of the GRHL2 ChIP-
seq peaks identified in this study matched the reported GRHL3 binding site at the 
promoter of MIR21 (Table 3). Instead, the GRHL2 binding site nearest to MIR21 was 
at -3.7 kb, which overlapped with an intronic region of an adjacent gene VMP1. Other 
associated binding sites were found further away at intergenic regions. Similarly, the 
GRHL2 ChIP-seq peaks at the vicinity of MIRLET7G, MIR1908 and MIR4284 were 
associated with elements of other adjacent genes. Therefore, the repressive roles of 
GRHL2 on these genes might not go through direct transcriptional regulation and 
remained to be further explored. 
 Among the miRNA targets of GRHL2, MIR203A, MIR200B and MIR205, 
each of them have recently been implicated to have regulatory roles in EMT (Moes et 
al, 2012; Gregory et al, 2008). As the three neighbouring genes MIR200B, MIR200A, 
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and MIR429 share the same primary transcript (Bracken et al, 2008), the miRNA 
products for these three genes should show similar expression trends. Indeed, from 
the miRNA expression array, the transcript levels of the three miRNA genes were 
consistently reduced in GRHL2-knockdown OVCA429 cells (Figure 25A). To further 
verify the expression changes, the levels of miR-200a-3p and miR200b (both 5p and 
3p) were tested by RT-qPCR and the results confirmed a significant down-regulation 
of the mature miRNAs in both shGRHL2 #10 and shGRHL2 #12 cells (Figure 25B). 
Similar down-regulated expression trends were observed in two other members of the 
miR-200 family, including miR-200c (microarray and RT-qPCR) and miR-141 
(microarray), despite no GRHL2 binding was found associated with MIR200C or 
MIR141 genes. It is possible that GRHL2 positively regulate all five members of the 
miR-200 family, either directly (miR-200a, miR-200b and miR-429) or indirectly 
(miR-200c and miR-141). In addition, RT-qPCR showed significant reduction of 
miR-203a-3p and miR-205-5p in GRHL2-knockdown cells, thus supporting them as 
target miRNA genes of GRHL2. Taken together, GRHL2 not only regulates protein-
coding genes, but also modulates multiple miRNA genes that could be responsible for 




















































Figure 24. Cross-analysis of GRHL2 ChIP-seq and miRNA expression 
microarray data of GRHL2 control/knockdown in OVCA429. 
Volcano plot showing microRNA-coding genes that were enriched with GRHL2 
binding (based on ChIP-seq in OVCA429) and had consistent differential expression 
in both shGRHL2 #10 and shGRHL2 #12 cells (based on GeneChip® miRNA 2.0 
microarray in OVCA429). Potential targets of GRHL2 were represented as green dots 
(positively regulated by GRHL2) and red dots (negatively regulated by GRHL2) 
corresponding to the ChIP-seq MACS score (y-axis) and expression fold change (x-
axis), both in log2 transformed values. Genes highlighted in yellow were miRNAs 
with good detection above background (DABG) signals ( p <0.05) in microarray. 
 
 



















































Table 3. The binding sites of GRHL2 associated with microRNA genes. 
Table showing GRHL2 ChIP-seq peaks at the vicinity of MIR203A, MIR203B, 
MIR200B, MIR205, MIR205HG, MIR21, MIRLET7G, MIR1908, MIR4284 genes in 
OVCAR3, PEO1 and OVCA429 cells. Distance to the respective RNA genes was 
counted from the peak summit. Rows with matching colours indicate peaks that 
overlapped at similar DNA regions. 
 
Gene Cell line No. of Peaks 
Peak 






MIR203A OVCAR3 2 253 54 41.54 -993 Promoter 
551 194 208.73 -369 Promoter 
PEO1 1 1090 223 133.73 -375 Promoter 
OVCA429 1 1189 205 163.87 -372 Promoter 
        
MIR203B OVCA429 1 386 25 36.37 -2904 Intergenic 
        
MIR200B OVCAR3 2 325 45 11.54 -3846 CpG 
202 25 12.82 -2296 CpG 
PEO1 1 458 51 61.17 -3859 CpG 
OVCA429 1 653 41 29.82 -3863 CpG 
        
MIR205 PEO1 1 258 33 60.57 1259 TTS of 
MIR205HG OVCA429 1 291 59 21.46 1273 
MIR205HG OVCA429 3 343 65 89.47 -68539 Intergenic 
294 41 38.73 -18767 Intergenic 
446 38 44.62 -12752 Intergenic 
MIR205HG/ 
MIR205 OVCA429 1 399 37 38.45 
23 (MIR205HG) Promoter of 
MIR205HG -3287 (MIR205) 
        
MIR21 OVCAR3 1 189 33 60.09 -3796 Intron 10 of 
gene VMP1 PEO1 2 801 127 233.12 -3798 
337 38 45.58 5180 Intergenic 
OVCA429 4 521 37 59.15 -11695 Intergenic 
884 230 334.62 -3793 Intron 10 of gene VMP1 
349 88 99.94 5167 Intergenic 
417 43 20.85 16100 Intergenic 
        
MIRLET7G PEO1 1 243 39 46.78 2821 Intron 3 of 
WDR82 OVCA429 1 500 148 255.93 2837 
        
MIR1908 OVCA429 1 467 38 40.3 -117 Promoter of  gene FADS2 
        
MIR4284 OVCA429 1 293 27 19.35 -4685 Intron 3 of gene STX1A 


















miR-200a-3p hsa-miR-200a_st -2.5501 -4.4951 -3.5226 0.9143 
miR-200a-5p hsa-miR-200a-star_st -2.9038 -1.8138 -2.3588 0.3143 
      
miR-200b-3p hsa-miR-200b_st -3.3550 -3.4100 -3.3825 0.8286 
precursor of 
miR-200b hp_hsa-mir-200b_x_st -1.2102 -1.0752 -1.1427 0.7714 
      
miR-429 hsa-miR-429_st -0.5309 -0.5409 -0.5359 0.4571 
      
miR-200c-3p hsa-miR-200c_st -2.2310 -2.7360 -2.4835 0.7333 
miR-200c-5p hsa-miR-200c-star_st -2.1956 -2.6356 -2.4156 0.9143 
precursor of 
miR-200c hp_hsa-mir-200c_st -1.4083 -2.0183 -1.7133 0.8286 
      
miR-141 hsa-miR-141_st -4.6551 -5.6601 -5.1576 0.8286 
precursor of 
miR-141 hp_hsa-mir-141_st -0.4612 -0.6362 -0.5487 0.8286 
      
miR-203 hsa-miR-203_st -3.0891 -5.5841 -4.3366 0.8286 
      
miR-205-5p hsa-miR-205_st -4.2439 -2.7839 -3.5139 0.4952 
miR-205-3p hsa-miR-205-star_st -1.2111 -1.4111 -1.3111 0.6667 
precursor of 












Figure 25. Differential expression of mature miRNAs in OVCA429 control and 
GRHL2-knockdown cells. 
(A) Table showing the log2 fold expression changes (< 0 means down-regulation) of 
miR-200 family members, miR-203 and miR-205 detected from GeneChip® miRNA 
2.0 microarray in shGRHL2 #10 and shGRHL2 #12 OVCA429 cells with respect to 
control (shNon). Only probesets with good detection above background (DABG) 
signals (p <0.05) are shown. Spearman Rho indicates correlation with GRHL2 
expression. (B) Bar chart showing the fold expression change of mature human 
microRNAs  miR-200a-3p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-203a-3p 
and miR-205-5p in GRHL2-knockdown (shGRHL2 #10, black bars and shGRHL2 
#12, grey bars) OVCA429 cells compared to control (shLuc, white bars) measured by 
RT-qPCR. Unpaired t-tests were performed on the average 2-∆Ct values obtained from 




































The results gathered from Chapter III and this chapter support a role of 
GRHL2 as a potential EMT player in EOC through direct transcriptional control of 
multiple genes. With a genome-wide approach, this study provides a detailed analysis 
of GRHL2 binding sites describing the interaction of GRHL2 with the regulatory 
elements (promoters or enhancers) of its target genes. This analysis suggested that 
GRHL2 recognizes a conserved yet diversified DNA sequence with two core CNNG 
motifs, often occurring in tandem with 5 bases as spacer. Interestingly, it resembles 
the DNA-binding sequence of LSF/CP2 subfamily, as well as the p53 transcription 
factor family, both of which recognize DNA with a direct CNNG repeat usually 
spaced by 6 bases. Members of the two families also share similarities in protein 
folding and binding to DNA as tetramers (Kokoszynska et al, 2008; Shirra et al, 
1994). This raises the question whether the bipartite GRHL2 binding motifs observed 
in EOC cells signify tetramerization of GRHL2 during protein-DNA interaction. In 
this regard, GRHL2 has been shown to form homodimers as well as heterodimers 
with other GRHL factors, but not with the paralogous LSF/CP2 factors (Wilanowski 
et al, 2002; Ting et al, 2003a). The possibility of GRHL2 occupying DNA elements 
in the form of tetramers, with or without the involvement of other transcription factors, 
would require further investigation. A possible connection between GRHL2 and p63, 
a member of the p53 family, also exists, as GRHL2 and p63 shares not only similar 
DNA-binding motif and some common target genes (GO list in Appendix III), but 
also EMT suppressive roles through the direct regulation of miR-205 (Tran et al, 
2013; Olsen et al, 2013). This may warrant future works to determine if the 
resemblance involves any functional crosstalk or is merely due to a shared ancestral 
origin between the two transcription factors (Kokoszynska et al, 2008).  
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 Besides binding to the promoter regions of its potential target genes, GRHL2 
was found to bind to intronic or intergenic DNA away from annotated TSS. This 
suggests that GRHL2 modulates gene expression not only by controlling gene 
promoter activities, but also by acting on distal enhancers. The latter may involve 
long-distance DNA interaction between the multiple GRHL2-bound sites, such as 
through chromatin looping. Transcription factor bound at enhancer elements may 
regulate the promoter activity of its target gene through chromatin looping (Marsman 
and Horsfield, 2012), as demonstrated by the transcriptional control of E-cadherin 
gene by Grhl2 in a mouse study (Werth et al, 2010). Nevertheless, these GRHL2 
binding events would only be functional if the expressions of associated genes are 
affected. Thus, the data from ChIP-seq was cross-analyzed with the microarray 
expression profiling from GRHL2-knockdown cells, followed by validation of 
relevant transcriptional targets of GRHL2 in OVCA429 cells. Some of the EMT-
related GRHL2 targets include the known target gene CDH1, which encodes the 
epithelial signature adhesion molecule E-cadherin; ZEB1, one of the classic EMT-
inducing transcription factor gene; CLDN4, an important tight junction gene; RAB25, 
which is involved in membrane protein trafficking; two paralogous genes EPCAM 
and TACSTD2, each encoding a cell surface glycoprotein, which were recently 
suggested to be involved in tight junction regulation (Lei et al, 2012; Nakatsukasa et 
al, 2010); and ERBB3, a member of the epidermal growth factor receptor (EGFR) 
family, the expression of which is shown to negatively correlate with EMT phenotype 
in EOC cells (Huang et al, 2013). Some of these target genes showed GRHL2 binding 
at their promoters (RAB25, TACSTD2 and ERBB3) while some of them showed 
binding at non-promoter regions (EPCAM and ZEB1). It is yet to be explored how 
GRHL2 regulates the transcription of target genes via long-distance DNA interaction 
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from the distal enhancer sites. Future studies employing techniques such as chromatin 
conformation capture (3C) (Dekker et al, 2002), ChIP-3C, or ChIA-PET (chromatin 
interaction analysis using paired-end tag sequencing) (Fullwood and Ruan, 2009) 
would help to understand the three-dimensional chromatin interactions involved in 
GRHL2 regulation of its target genes. 
 With three EOC cell lines OVCAR3, PEO1 and OVCA429, this study 
validated the direct binding of GRHL2 at the intron 2 of E-cadherin gene CDH1, a 
large intron (~ 63 kb) associated with a marker of active enhancers (H3K27ac) and 
harbors many transcription factor binding sites (Rosenbloom et al, 2013). 
Importantly, this intron 2 of CDH1 has previously been characterized as an enhancer 
required for  transcriptional activation and maintenance of E-cadherin expression in 
epithelial cells during mouse embryogenesis (Stemmler et al, 2003; Stemmler et al, 
2005). The occupancy of GRHL2 at this intronic enhancer region is likely to account 
for the transcriptional modulation of E-cadherin in EOC cells. Indeed, as mentioned 
in Chapter III, knockdown of GRHL2 in OVCA429 resulted in significant reduced 
expression of E-cadherin, at both mRNA and protein levels. The effect, however, was 
cell line-dependent, as knockdown of GRHL2 in PEO1 and OVCA420 showed little 
changes in E-cadherin abundance. It remains unclear whether this was due to 
incomplete silencing of GRHL2 by the shRNAs, or the epigenetic modification of the 
E-cadherin gene at intron 2 in PEO1 and OVCA420 cells that might be inherently 
different from OVCA429 cells. Since two additional GRHL2-binding sites at CDH1 
intron 2 were detected in OVCA429 but not in OVCAR3 and PEO1 (Table 1), 
variability in chromatin architecture is likely to exist across different EOC cell lines, 
which might have caused varied accessibility to GRHL2 binding and hence the 
observed difference in the regulation of E-cadherin expression. The differences of the 
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H3K27ac modification at these intronic regions among these cells warrant further 
investigation. Besides changes in protein expression, in GRHL2-knockdown cells, the 
stability of E-cadherin at cell-cell junctions were seen affected, accompanied by the 
presence of E-cadherin in the autophagosomal compartment (Chapter III). These 
suggest that, in addition to the regulation at the transcriptional level, GRHL2 may 
have other roles in the distribution of E-cadherin proteins. This potential function of 
GRHL2 may be mediated through other GRHL2 target genes such as RAB25 and 
SYNGR2 which are involved in protein recycling (Senga et al, 2012; Janz and Südhof, 
1998) or the autophagy regulator gene DRAM1, which has also been shown to have 
roles in regulating cell migration and invasion (Galavotti et al, 2013). 
In breast cancer cells, the EMT transcriptional driver ZEB1 and GRHL2 have 
been demonstrated to directly repress each other through binding at their respective 
promoters (Cieply et al, 2012; Cieply et al, 2013 Werner et al, 2013). This double 
negative feedback regulation has also been suggested in colorectal cancer (Quan et al, 
2014). However, in EOC cells, no direct interaction of GRHL2 was found at the 
promoter region of ZEB1, from data of both ChIP-seq (in OVCAR3, PEO1 and 
OVCA429 cells) and ChIP-qPCR (PEO1 and OVCA429 cells). Only one GRHL2 
binding site was shown, in OVCA429 cells, to be associated with the first intron of 
ZEB1 gene, the enhancer activity of which is not known. Although GRHL2 does not 
occupy the promoter of ZEB1 in EOC cells, their reciprocal repressive relationship 
does exist, which was evidenced by the up-regulation of ZEB1 upon GRHL2 
knockdown and the down-regulation of GRHL2 upon ZEB1 overexpression (shown 
in Chapter III). The more prominent effect of the reciprocal regulation seen in 
OVCA429 cells compared to PEO1 raises the question whether the ZEB1 intronic 
binding by GRHL2, unique to OVCA429, is involved in the regulation. As 
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mentioned, techniques such as 3C may be useful to search for possible physical 
interactions between this unique GRHL2 binding site at intron 1 and at the promoter 
region of ZEB1.  
If GRHL2 does not directly repress ZEB1 in EOC cells, indirect control 
mechanisms are likely to operate, as GRHL2 may regulate ZEB1 post-
transcriptionally through some of its microRNA targets, such as the miR-200 family 
members and miR-205. These miRNAs have been reported, in MDCK cells, to 
suppress EMT by directly repressing ZEB1 and ZEB2 (Gregory et al, 2008). In 
particular, the miR-200 family members which consists of miR-200a, miR-200b, 
miR-200c, miR-141 and miR-429, have been shown to form double negative 
feedback regulation with ZEB1, exerting opposite influence on EMT (Brabletz and 
Brabletz, 2010). Among the five members, GRHL2 binds to the common promoter of 
the three co-regulated MIR200B/MIR200A/MIR429. Thus, the results from this study 
and reported findings suggest that ZEB1 interacts with GRHL2 through at least two 
possible modes, one via reciprocal direct repression on its promoter activity, the other 
involves a separate reciprocal negative regulation (direct/indirect) through  miR-200 
family members. The latter is more likely to take place in EOC, and the balance of 
this GRHL2-miR-200-ZEB1 regulation may determine the epithelial integrity of the 
cells. Besides miR-205 and the miR-200 family, another direct GRHL2 target, miR-
203A has been shown to form a negative feedback loop with SNAI1 (Moes et al, 
2012). This then implies that GRHL2 not only activates E-cadherin by acting on its 
intron 2 enhancer activity, but may also regulate E-cadherin indirectly through the 
miR-203/SNAI1 axis. Indeed, in OVCA429, a significant up-regulation of SNAI1 
was found in GRHL2 knock-down cells. This further supported the pivotal role of 
GRHL2 in controlling the balance between the miRNAs and their targets.  
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To summarize, the direct regulation of GRHL2 on MIR200B, CDH1 and ZEB1 
in different EOC cells is illustrated in Figure 26. Collectively, this work proposed 
that, in EOC cells, the transcriptional roles of GRHL2 involve various miRNAs that 
form complex regulatory networks between epithelial marker E-cadherin and EMT 
inducers such as ZEB1 and SNAI1 (Figure 27). The involvement of miRNAs and the 
presence of negative feedback loops suggest that GRHL2 may be part of a redundant 









































Figure 26. A simplified representation of GRHL2 regulation on MIR200B, ZEB1  
and CDH1. 
In both PEO1 and OVCA429 control cells, GRHL2 occupies the promoter of 
miR200B and the intronic enhancer of CDH1 (E-cadherin) for activation of the genes. 
ZEB1 is either not expressed or expressed at minimal levels repressed by miR-200b. 
OVCA429 is different from PEO1 in that GRHL2 has additional binding sites at the 
intronic regions of ZEB1 and CDH1 with unknown functions. When GRHL2 is down-
regulated, partial EMT takes place in PEO1 while full EMT is executed in OVCA429, 
indicated by the up-regulation of ZEB1 and the down-regulation of E-cadherin. At 
this point, ZEB1 transcriptionally represses MIR200B and CDH1 by direct binding to 
their promoters.  

























































Figure 27. Proposed regulatory network involving GRHL2 and other players in 
EMT.  
The suppressive roles of GRHL2 in EMT involve direct/indirect regulation of E-
cadherin and ZEB1 through miRNAs, forming a complex regulatory network. 
Symbols in red represent regulatory roles of GRHL2 that were supported by the data 
























5.1 Transcriptional regulation of GRHL2 
 Functionally conserved as a transcription factor, the mammalian GRHL2 has 
been shown to directly activate or repress a variety of genes (Table V, Chapter I). In 
this study, the aim to identify GRHL2 target genes in EOC cells, at a genome-wide 
scale, was achieved by three means. First, microarray gene expression analysis was 
employed to identify genes that showed differential expression between OVCA429 
control and GRHL2 knockdown cells (Chapter III). Second, cross-linked EOC cells 
were subjected to GRHL2 ChIP-seq analysis to identify genes associated with 
GRHL2 binding in vivo (Chapter IV). Third, a combined analysis of the two 
mentioned experiments were conducted and supplemented by validation on GRHL2 
binding (ChIP-qPCR) and gene expression changes (RT-qPCR or/and western blot) 
for several target genes of interest. Hence, genes that show GRHL2 binding at 
promoters or known enhancers, and have differential expression upon GRHL2 
knockdown, are likely to be direct functional targets of GRHL2 in EOC. These 
include targets potentially activated by GRHL2: CDH1, CLDN4, RAB25, TACSTD2, 
ERBB3, EPS8, MIR200B and MIR203A; and those potentially repressed by GRHL2: 
DRAM1 and EEA1. For future works, reporter assays will be useful to validate the 
role of GRHL2 on the promoter/enhancer activity of these genes. Other putative direct 
targets such as ZEB1, ESRP1/2, EPCAM, ST14, MAL2 and MIR205 require further 
elucidation on their direct interaction with GRHL2, as the associated binding sites, in 
EOC cells, were found to reside at intronic or intergenic elements. Otherwise, they 
may be considered as indirect targets of GRHL2, along with other genes not bound by 
GRHL2 but were down-regulated/up-regulated upon GRHL2 knockdown, such as 
CDH2, VIM, MMP2 and MIR200C. Nevertheless, the possibility of these genes being 
de-regulated as a passenger effect cannot be ruled out. Finally, there is another large 
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set of genes enriched with GRHL2 binding but show no expression changes affected 
by GRHL2 knockdown. Future exploration will be required to ascertain whether these 
GRHL2 DNA-binding events are non-functional in a tissue-specific manner, or may 
contribute functionally by assisting or blocking the interaction of other transcription 
factors or cofactors. Since GRHL2-mediated gene regulation may crosstalk with other 
pathways, it is also possible that alternate mechanisms may compensate the effects of 
GRHL2 knockdown in the expression of these associated genes.  
 
5.2 GRHL2, microRNAs and epigenetics 
 Besides targeting protein-coding genes, GRHL2 was shown in this study to 
regulate non-coding RNA genes such as microRNAs (Chapter IV). Putative miRNA 
that are positively regulated by GRHL2 include the EMT-associated miR-200 family, 
miR-203 and miR-205, among which GRHL2 was found to occupy the shared 
promoter of MIR200B/MIR200A/MIR429 (Bracken et al, 2008) and the promoter of 
MIR203A. As these miRNAs form negative regulatory loops with other EMT inducers 
such as ZEB1 and SNAI1 (Brabletz and Brabletz, 2010; Moes et al, 2012), the 
miRNA regulation by GRHL2 substantiates its role as a transcriptional suppressor of 
EMT. From supplemental experiments (Appendix V), transfection of miRNA mimics 
of miR-200a and miR-200b but not miR-203a and miR-205 were able to rescue the 
protein expression of E-cadherin in both shGRHL2 #10 and shGRHL2 #12 
OVCA429 cells (Figure DB). Interestingly, only cells transfected with miR-200b 
revert their morphologies back to a more epithelial-like colonies-forming phenotype 
(Figure DA). Thus, these data suggest that GRHL2 involves in the EMT regulation of 
EOC cells mainly through the GRHL2-miR-200-ZEB1-E-cadherin networks.  
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 The notion whether miRNA itself is an epigenetic mechanism is not clear, but 
the direct involvement of GRHL2 in miRNA regulation may suggest an indirect 
regulatory role of GRHL2 in epigenetics. This is because one of the putative GRHL2 
targets, miR-200a has been shown to form a negative feedback regulatory loop with a 
class III histone deacetylase, SIRT1 (Eades et al, 2011). Besides, other studies have 
also demonstrated the involvement of GRHL2 in histone modifications and DNA 
methylation. In mouse kidney collecting duct cells, the loss of Grhl2 resulted in 
reduced active histone marks (H3K4 tri-methylation and H3-K9/14 acetylation) at 
specific sites of the E-cadherin promoter (Werth et al, 2010). In human keratinocytes, 
up-regulation of GRHL2 inhibited the recruitment of histone demethylase Jmjd3 to 
the promoters of epidermal differentiation complex genes, resulting in an elevated 
level of repressive histone mark (H3K27 tri-methylation) at the respective promoters 
(Chen et al, 2012). Apart from histone modifications, GRHL2 is also reported to 
inhibit DNA methylation at the 5’ CpG island of telomerase gene (TERT), possibly by 
hindering the activity of DNA methyltransferase DNMT1, thus maintaining the 
expression of TERT (Chen et al, 2010). Collectively, data from this and existing 
studies present opportunities to investigate the potential influence of GRHL2 on the 
miRNA regulation and the epigenome of cancer cells. Another aspect worth exploring 
is how the intrinsic epigenetic state of cells would determine/affect the transcriptional 
functions of GRHL2, especially in the regulation of EMT. Notably, it has been 
suggested that the plasticity of cells at different phenotypic stages may depend on the 
progressive epigenetic remodelling, involving histone modifications and DNA 
methylation on EMT-related genes (Tam and Weinberg, 2013). Therefore, within a 
cancer type such as EOC that shows heterogeneous EMT phenotypes, different 
epigenetic landscapes may exist when cancer cells undergo oncogenic EMT. Further 
 134 
works are in progress to examine how the existing epigenetic modifications, in cell 
lines with different phenotypes, may interfere with the DNA-binding of GRHL2 to 
the regulatory elements of EMT-related genes. Besides being involved in epigenetic 
regulation, GRHL2 itself is also regulated by epigenetic modification. A recent 
finding shows that DNA methylation events in GRHL2 exon–intron regions are 
associated with the transcript expression of GRHL2 (Carmona et al, 2014). Therefore, 
the regulation of GRHL2 by other modes of epigenetic control such as histone 
modifications may also be worth investigating.  
 
5.3 GRHL2 and EMT  
 EMT is a critical morphogenetic programme that takes place in embryonic 
development as well as adult pathologies such as cancer (Thiery, 2002). GRHL2, an 
evolutionarily conserved transcription factor, is also involved in normal development, 
pathophysiology and cancer (discussed in Chapter I). Although no study has directly 
implicate GRHL2 in EMT during embryonic development, the requirement of 
GRHL2 for complete neural tube closure and epithelial differentiation through its 
transcriptional regulation on cell adhesion component E-cadherin (Werth et al, 
2010; Rifat et al, 2010; Pyrgaki et al, 2011) suggests a possible EMT suppressive role 
for this transcription factor. In the context of cancer, this suppressive role of GRHL2 
in oncogenic EMT has been demonstrated in breast cancer cells (Cieply et al, 
2012; Werner et al, 2013; Xiang et al, 2012). Increasing evidence show that GRHL2 
not only transactivates a variety of genes required for epithelial maintenance (Werth 
et al, 2010; Senga et al, 2012; Gao et al, 2013a), but also forms a double negative 
feedback regulation with ZEB1, one of the classic EMT transcription drivers that 
repress E-cadherin (Cieply et al, 2012; Cieply et al, 2013; Werner et al, 2013; Quan 
 135 
et al, 2014). In keeping with the reported findings, the results from this study 
supported the hypothesis that GRHL2 is critical for maintaining the epithelial 
integrity of EOC, as down-regulation of GRHL2 in EOC cells resulted in partial or 
full EMT (Chapter III), likely through direct or indirect regulation of EMT-related 
genes (Chapter III and IV). The binding of GRHL2 at the intronic enhancer region of 
E-cadherin gene was validated, while the transcriptional activating role of GRHL2 on 
E-cadherin expression was shown to be cell line-dependent, being more apparent in 
the intermediate E cell line OVCA429. The double negative feedback loop between 
GRHL2 and ZEB1 was also demonstrated in OVCA429 and the data suggests that 
miRNAs from the miR-200 family and miR-205 may be involved in this GRHL2-
ZEB1 regulatory loop. Meanwhile, another GRHL2 target, miR-203 may link GRHL2 
to the regulation of SNAI1, another key EMT transcription activator. For future 
studies, rescue experiments with miRNA mimics will be useful to further elucidate 
their interactions in this network and the associated EMT-related functions.  
Another prospect that may be worth exploring is the potential role of GRHL2 
in the post-transcriptional regulation of E-cadherin, or other adhesion molecules, 
through its target genes associated with protein trafficking (RAB25), endocytosis 
(EEA1), or autophagy (DRAM1). Rab25, in particular, has been reported to promote 
localization of Cldn4 to tight junctions in mice, a mechanism contributing to the 
regulatory roles of Grhl2 in the lumen expansion of cholangiocytes (Senga et al, 
2012; Tanimizu and Mitaka, 2013). Since cytoplasmic E-cadherin was observed to 
co-localize with the autophagosome marker LC3A in EOC cells, it may also be 
relevant to explore the possible connection between GRHL2, autophagy, and EMT. 
The requirement of GRHL2 in maintaining epithelial integrity of EOC cells 
suggest the potential of GRHL2 in activating MET (the reversal of EMT) in EOC 
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cells harbouring the mesenchymal traits. In breast cancer, Cieply et al showed that 
ectopic expression of GRHL2 in MDA-MB-231 induced MET-like morphological 
changes accompanied by an up-regulation of E-cadherin and down-regulation of 
ZEB1 and vimentin (Cieply et al, 2012). Werner et al also reported similar MET-like 
morphology in GRHL2-overexpressing MDA-MB-231 cells with an up-regulation of 
E-cadherin but no change in its downstream target ERBB3 (Werner et al, 2013). In 
mouse lung E10 cells, overexpression of Grhl2 resulted in increased E-cadherin but 
also with modest up-regulation of mesenchymal markers vimentin and α-SMA 
(Varma et al, 2012; Varma et al, 2014). For EOC cells, preliminary attempts have 
been made to overexpress GRHL2 in mesenchymal-like EOC cells. However, the 
experiments did not show any prominent morphological changes related to MET (data 
not shown). Further works are in progress to identify potential molecular changes 
incurred by the up-regulation of GRHL2. Compared to the more widely-studied EMT 
induction, relatively little is known about the transcriptional activation of MET, which 
may contribute to the adaptation of disseminated cancer cells at secondary sites 
(Thiery, 2002). Future studies on GRHL2-mediated MET in EOC or other cancer may 
help shed light on EMT/MET-associated tumour metastasis. 
 
5.4 GRHL2 and EOC 
 In recent years, a number of studies have implicated the suppressive role of 
GRHL2 in oncogenic EMT, while its role in regulating tumour growth may differ 
depending on cancer types (Discussion, Chapter III). Along with HCC, breast cancer, 
lung cancer and melanoma, ovarian cancer is reported to show frequent amplification 
at GRHL2-encoding gene locus 8q22.3, (Tanaka et al, 2008; Dompe et al, 2011). 
Since the reported data was analyzed in unclassified tumours, the amplification of 
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GRHL2 may not reflect an up-regulation of GRHL2 in all tumour subtypes. By 
examining GRHL2 expression in breast cancer cell lines and tumours of different 
subtypes, Cieply et al reported an overall up-regulation of GRHL2 in breast cancer 
cells compared to normal tissues, but a significant down-regulation of GRHL2 in two 
mesenchymal-associated subtypes, the claudin-low and basal-B (Cieply et al, 2012). 
Using a similar approach, this project examined the expression level of GRHL2 in 
phenotype-characterized EOC cell lines and molecular subtyped EOC tumours. The 
results showed that the expression of GRHL2 correlated with E-cadherin, and was 
significantly down-regulated in EOC cell lines of mesenchymal phenotype, as well as 
EOC tumours of Mes (mesenchymal) subtype. Functional studies demonstrated that 
down-regulation of GRHL2 in EOC led to a gain in EMT features accompanied by 
increased migratory and invasive potential. Therefore, it can be concluded that among 
the heterogeneous EOC cells, GRHL2 serves as a potential epithelial signature, the 
expression pattern of which may help to define the epithelial/mesenchymal phenotype, 
and that the loss of GRHL2 is associated with cells that are undergoing or have 
undergone EMT. Interestingly, the EMT phenotype induced by GRHL2 knockdown 
in this study was shown to be heterogeneous among the Epithelial and Intermediate E 
cell lines. Changes in molecular expression and invasive potential mediated by 
GRHL2 were generally more prominent in the intermediate E cell line OVCA429 
compared to epithelial cell lines PEO1 and OVCA420 (Chapter III). This supports the 
existence of an EMT spectrum in EOC cells (Huang et al, 2013), within which, cells 
that show Intermediate E phenotype are likely to have higher EMT potential 
compared to cells with Epithelial phenotype.  
The results of this study proposed a correlation between the loss of GRHL2 
and the progression of EMT in EOC, which is likely to take place during cancer 
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dissemination. The role of GRHL2 in early tumour formation, however, remains 
unclear. Compared to normal ovary tissues, an overall up-regulation of GRHL2 in 
EOC is valid based on two observations. First, referring to the latest data from TCGA 
(The Cancer Genome Atlas Research Network), about 8% (dataset of TCGA, Nature, 
2011) or 22% (provisional dataset of TCGA) of ovarian serous cystadenocarcinoma 
cases showed amplification in GRHL2 (Cerami et al, 2012; Gao et al, 2013b). Second, 
most of the EOC cell lines with Epithelial or Intermediate E phenotypes showed up-
regulated GRHL2 (mRNA and protein) when compared to normal immortalised 
ovarian surface epithelial (IOSE) cells which have little/non-detectable expression of 
GRHL2 (data not shown). However, unlike other cancers, the origin of EOC, 
especially the most common serous histotype, has remained debatable, with two 
possible tissue precursors: OSE cells that rarely express E-cadherin and are associated 
with mesenchymal properties; and fallopian tube fimbriae cells that have high levels 
of E-cadherin (Auersperg, 2013; Auersperg et al, 1999). Since the expression of 
GRHL2 correlates with E-cadherin, oviduct fimbriae cells may also have high 
expression of GRHL2, and hence, in comparison, GRHL2 may no longer be 
considered up-regulated in EOC cells. This remains speculative as the expression of 
GRHL2 in fimbriae cells have yet to be verified and warrants future investigation. If 
the up-regulation of GRHL2 in early tumourigenesis is valid, it is possible that 
GRHL2 follows the proposed E-cadherin model in EOC, which suggested an 
increment of E-cadherin as OSE transform into benign tumours, followed by a 
decreasing trend of E-cadherin as benign tumours gain malignant potential to form 
carcinomas (Vergara et al, 2010). It also mirrors the injury-induced lung fibrosis 
model proposed by Varma et al, which suggested an up-regulation of GRHL2 in 
injured alveolar epithelial cells at early phase, followed by a progressive loss of 
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GRHL2 as the cells become flatten and subsequently adopt myofibroblastic 
characteristics (Varma et al, 2014). Given the notion that cancer could be an 
overhealing wound (Schäfer and Werner, 2008), GRHL2, an orthologue of wound 
healing gene grainyhead, may be required for proper wound healing upon epithelial 
injuries, and de-regulation of this transcription factor may contribute to fibrosis or 
cancer at different stages.  
The conflicting roles of GRHL2 in regulating tumour growth demands further 
clarification. Existing studies in other cancer types have reported both oncogenic and 
tumor suppressive potential of GRHL2, possibly involving death receptor-mediated 
apoptosis (Dompe et al, 2011); maintenance of telomerase activity (Kang et al, 2009); 
and regulation of c-Myc and Bcl-2 (Xiang et al, 2013). In EOC, preliminary data 
suggest that GRHL2-knockdown cells showed slower growth rate and no enhanced 
tumorigenicity in the mouse xenograft model (data not shown). Future works will be 
carried out to further clarify the tumour initiation function of GRHL2 in EOC.  
 
5.5 Concluding Remarks 
 Taken together, this present work has provided some insights into the potential 
roles of transcription factor GRHL2 as a gatekeeper of the epithelial state and a 
negative regulator of EMT in EOC. The information obtained and the conclusions 
drawn from this present work has also provided some mechanistic explanation of the 
intrinsic heterogeneity related to EMT that has been observed in EOC. Understanding 
the diverse role of GRHL2 in the transcriptional and epigenetic control may open up 
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Table VIII. List of primers.  
Details of the primers purchased from Qiagen and used for RT-qPCR in this study. 
 
Gene  Catalog no. Ref Seq Accession no. Reference position (base pairs) 
ACTB PPH00073E NM_001101.3 1222 
B2M PPH01094E NM_004048.2 381 
GAPDH PPH00150E NM_002046.3 1287 
HPRT1 PPH01018B NM_000194.2 974 
RPL13A PPH01020B NM_012423.2 940 
GRHL1 PPH19832A NM_198182.2 2007 
GRHL2 PPH18929F NM_024915.3 2192 
GRHL3 PPH12149A NM_198174.2 1303 
ZEB1 PPH01922A NM_030751.5 451 
ZEB2 PPH09021B NM_014795 4012 
SNAI1 PPH02459B NM_005985 475 
SNAI2 PPH02475A NM_003068 842 
TWIST1 PPH02132A NM_000474.3 783 
CDH1 PPH00135E NM_004360.3 4219 
CDH2 PPH00636F NM_001792.3 1141 
VIM PPH00417E NM_003380.3 1797 
CLDN4 PPH07330D NM_001305.3 1282 
RAB25 PPH12800E NM_020387.2 1051 
TACSTD2 PPH05688A NM_002353.2 788 
ERBB3 PPH00463B NM_001982.3 623 
ELF3 PPH09786C NM_004433.4 1240 
EPS8 PPH07120A NM_004447 2602 
ST14 PPH09550A NM_021978.3 2320 
EPCAM PPH05720A NM_002354.2 637 
MAL2 PPH10025A NM_052886.2 2609 
ESRP1 PPH088556A NM_017697.3 1256 
ESRP2 PPH18162A NM_024939.2 2207 
EEA1 PPH07165A NM_003566 4305 
DRAM1 PPH19768F NM_018370.2 1112 
ARHGEF19 PPH22922A NM_153213.3 2502 
TERT PPH00995E NM_198253.2 1072 
 
Gene  Name of gene product Catalog no. Stem loop sequence 
RNU6-6P U6 snRNA 6, 
pseudogene 
MS00033740 - 
MIR200A hsa-miR-200a-3p MS00003738 CCGGGCCCCUGUGAGCAUCUUACCGGACAGUGCUGGAUUU 
CCCAGCUUGACUCUAACACUGUCUGGUAACGAUGUUCAAAGGUGACCCGC 
MIR200B hsa-miR-200b-3p MS00009016 CCAGCUCGGGCAGCCGUGGCCAUCUUACUGGGCAGCAUUG 
GAUGGAGUCAGGUCUCUAAUACUGCCUGGUAAUGAUGACGGCGGAGCCCUGCACG 
 hsa-miR-200b-5p MS00009023 CCAGCUCGGGCAGCCGUGGCCAUCUUACUGGGCAGCAUUG 
GAUGGAGUCAGGUCUCUAAUACUGCCUGGUAAUGAUGACGGCGGAGCCCUGCACG 
MIR200C hsa-miR-200c-3p MS00003752 CCUCGUCUUACCCAGCAGUGUUUGGGUGCGGUUGGGAGU 
CUCUAAUACUGCCGGGUAAUGAUGGAGG 
MIR203A hsa-miR-203a-3p MS00003766 GUGUUGGGGACUCGCGCGCUGGGUCCAGUGGUUCUUAACA 
GUUCAACAGUUCUGUAGCGCAAUUGUGAAAUGUUUAGGACCACUAGACCCGGCGG
GCGCGGCGACAGCGA 
MIR203B hsa-miR-203b-5p MS00042217 GCGCCCGCCGGGUCUAGUGGUCCUAAACAUUUCACAAUUG 
CGCUACAGAACUGUUGAACUGUUAAGAACCACUGGACCCAGCGCGC 












Figure B. Control and GRHL2-knockdown cells at the migrating front during 
gap closure. 
Phase contrast images showing the migrating front of control and GRHL2-
knockdown OVCA420 and OVCA429 cells. Arrows indicate individual, detached 
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Table IX. Gene ontology (GO) terms and the associated genes.  
GO analysis of GRHL2 ChIP-seq peaks using GREAT version 2.0.2.   
 
OVCAR3   
# Ontology Term Name Genes 
GO Biological Process 
negative regulation of 
protein kinase B signaling 
cascade 
DAG1, EPHA2, KLF4, PHLDA3, PLEKHA1, PTEN, PTPRJ, SLC9A3R1 
GO Biological Process labyrinthine layer blood vessel development CYR61, FBXW8, HS6ST1, JUNB, NSDHL, OVOL2, PLCD3, PLGLB1 
GO Biological Process skin development APC, COL3A1, COL5A1, DSP, ERRFI1, GJB3, GNAS, IRF6, JUP, KRT9, OVOL1, PDGFA, PTCH2, SHH, SUFU, TCF7L2, TFAP2A, TFAP2C 
GO Cellular Component zonula adherens CAMSAP3, CTNNA1, JUP, KIFC3, PLEKHA7, PVRL2 
Pathway Commons gamma-glutamyl cycle GCLM, GGT1, GGT2, GGT5, GGT6, GGT7 
Pathway Commons mTOR signalling AKT2, CAB39L, EIF4EBP1, EIF4G1, MTOR, PPM1A, PRKAG2, RHEB, RPTOR, STK11, STRADA 
Pathway Commons PKB-mediated events AKT2, CAB39L, EIF4EBP1, EIF4G1, MTOR, PPM1A, PRKAG2, RHEB, RPTOR, STK11, STRADA 
Pathway Commons Validated transcriptional targets of TAp63 isoforms 
BTRC, CABLES1, DICER1, DST, EVPL, FDXR, GADD45A, GPX2, ITGB4, 
JAG1, NOC2L, PMAIP1, PRKCD, S100A2, SHH, TFAP2C, TRAF4, YWHAQ 
 
PEO1   
# Ontology  Term Name  Genes 
GO Biological Process membrane raft organization CAV2, CAV3, CD2, DLG1, DOCK2, MAL, PPT1 
GO Biological Process ER-nucleus signaling pathway 
AMFR, ARHGEF10L, ATF6, ATG10, CASP12, CCND1, DERL1, EIF2A, 
EIF2AK4, ERN1, GSK3B, IFNG, INSIG1, LMNA, NFE2L2, PAK1, PPP1R15B, 
SCAP, SREBF1, SREBF2, VCP, XBP1 
GO Cellular Component desmosome B4GALT1, CTNNB1, DSC1, DSC2, DSC3, DSG1, DSG2, DSG3, DSP, EVPL, JUP, KAZN, PERP, PKP1, PKP2, PPL 
GO Cellular Component clathrin coat of coated pit AP2M1, AP2S1, CLTA, CLTB, EGFR, EPS15, LDLRAP1, PICALM, SGIP1, SLC18A3 
Pathway Commons 
Hypoxic and oxygen 
homeostasis regulation of 
HIF-1-alpha 
BHLHE40, BHLHE41, CITED2, COPS5, CREB1, CUL2, CXCL12, EGLN2, 
EGLN3, EP300, ETS1, FECH, FOS, FURIN, HDAC7, HIF1A, HIF3A, HK1, HK2, 
HSP90AA1, ID2, ITGB2, JUN, LEP, MCL1, NCOA1, NCOA2, NDRG1, NPM1, 
NT5E, PGM1, PLIN2, RBX1, RORA, SLC2A1, SMAD3, TCEB2, TFRC 
Pathway Commons Validated transcriptional targets of TAp63 isoforms 
BBC3, CABLES1, CLCA2, DHRS3, DICER1, DST, EP300, EVPL, GADD45A, 
GDF15, GPX2, HBP1, IGFBP3, ITGA3, ITGB4, JAG1, MDM2, PERP, PMAIP1, 
PML, PRKCD, S100A2, SERPINB5, SHH, SPATA18, TFAP2C, TP63, TRAF4, 
VDR, YWHAQ 
Pathway Commons FoxO family signaling 
BCL2L11, BCL6, CAT, CSNK1A1, CSNK1D, CSNK1G3, CTNNB1, EP300, 
FASLG, FBXO32, FOXO1, FOXO3, GADD45A, KAT2B, MAPK10, MAPK8, 
MAPK9, RALA, RALB, RBL2, SFN, SGK1, USP7, YWHAB, YWHAG, YWHAH, 
YWHAQ, YWHAZ 
Pathway Commons Alpha6Beta4Integrin 
CLCA1, CLCA2, DSP, DST, EGFR, EIF4EBP1, ERBB2, FYN, GRB2, ITGB4, 
MBP, MET, MMP7, PAK1, PIK3CB, PIK3CG, PLEC, PRKCA, PRKCD, PTK2, 
SFN, SMAD2, VIM, YWHAB, YWHAH, YWHAQ, YWHAZ 
Pathway Commons p38 signaling mediated by MAPKAP kinases 
CREB1, ETV1, HSPB1, MAPK11, RAF1, SFN, SRF, TCF3, TH, YWHAB, 
YWHAG, YWHAH, YWHAQ, YWHAZ 
Pathway Commons Rap1 signalling RAF1, RAP1GAP, RAP1GAP2, RAPGEF3, RAPGEF4, SIPA1, YWHAB, YWHAZ 




OVCA429   
# Ontology  Term Name  Gene 
GO Biological Process actin filament bundle assembly 
ACTN1, ACTN4, ADD1, ADD2, ARRB1, CALD1, CDC42, CUL3, ELN, ESPN, 
EZR, FSCN1, GAS7, LCP1, LIMA1, NEDD9, PAWR, PTK2B, SORBS1 
GO Biological Process 
positive regulation of 
hormone metabolic 
process 
ARNT, BMP6, CYP17A1, GATA3, HIF1A, IGF1R, LHCGR, PAX8, POR, WNT4 
GO Cellular Component desmosome B4GALT1, CTNNB1, DSC1, DSC2, DSC3, DSG1, DSG2, DSG3, DSP, EVPL, JUP, KAZN, PERP, PKP1, PKP2, PKP3, PKP4, PPL 
GO Cellular Component zonula adherens CAMSAP3, CTNNA1, CTNNB1, JUP, KIFC3, PLEKHA7, PVRL2, SORBS1 
GO Cellular Component clathrin coat of endocytic vesicle AP2A2, AP2S1, EGFR, EPN2, EPS15, LDLRAP1, PICALM, SGIP1, SLC18A3 
Pathway Commons Validated transcriptional targets of TAp63 isoforms 
ABL1, BBC3, BTRC, CABLES1, CDKN1A, CLCA2, DHRS3, DICER1, DST, 
EP300, EVPL, GADD45A, GDF15, GPX2, HBP1, IGFBP3, IKBKB, ITGA3, 
ITGB4, JAG1, MDM2, NOC2L, NQO1, PERP, PMAIP1, PML, PRKCD, S100A2, 
SERPINB5, SHH, SMARCD3, SP1, SPATA18, TFAP2C, TP53I3, TP63, TRAF4, 
VDR, WWP1, YWHAQ 
Pathway Commons a6b1 and a6b4 Integrin signaling 
CD9, CDH1, EGF, EGFR, ERBB2, ERBB3, GRB2, IL1A, ITGB4, MET, MST1R, 
PIK3CA, PIK3R1, PRKCA, RPS6KB1, RXRA, SFN, SHC1, YWHAB, YWHAG, 
YWHAH, YWHAQ, YWHAZ 
Pathway Commons Rap1 signalling RAF1, RAP1A, RAP1B, RAP1GAP, RAP1GAP2, RAPGEF3, RAPGEF4, SIPA1, YWHAB, YWHAZ 
Pathway Commons p38 signaling mediated by MAPKAP kinases 
CREB1, ETV1, HSPB1, MAPK11, MAPK14, MAPKAPK2, MAPKAPK3, RAF1, 
SFN, SRF, TCF3, TH, YWHAB, YWHAG, YWHAH, YWHAQ, YWHAZ 
Pathway Commons gamma-glutamyl cycle ANPEP, GCLM, GGCT, GGT1, GGT2, GGT5, GGT6, GGT7, GSS 
Pathway Commons stearate biosynthesis I (animals) 
ACOT4, ACOT7, ACSBG1, ACSBG2, ACSL1, ACSL3, ACSL5, ELOVL1, 
ELOVL6, SLC27A2 

































Figure C. GRHL2 overexpression in SKOV3, OV56 and HeyA8 cell lines. 
(A) Western blots showing the protein expression of E-cadherin, GRHL2 and β-actin 
in parental, empty vector (EV) control, and GRHL2-overexpressing cells of three cell 
lines: SKOV3, OV56, HeyA8. Numbers below protein bands indicate fold changes of 
band intensities relative to parental cells. (B) Phase contrast images showing the cell 
morphologies of SKOV3, OV56, HeyA8 cells infected with empty vector (EV) 
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Figure D. Phenotype rescue by miRNA mimics in GRHL2-knockdown 
OVCA429 cells. 
(A) Phase contrast images showing the cell morphologies of GRHL2-knockdown 
OVCA429 cells (shGRHL2 #10 and shGRHL2 #12) transfected with miRNA mimics 
of negative control, miR-200a, miR-200b, miR-203a and miR-205. Scale bars 
represent 100 µm. (B) Western blots showing the protein expression of ZEB1, 
GRHL2, E-cadherin, Vimentin (Vim) and GAPDH in GRHL2-knockdown OVCA429 
cells (shGRHL2 #10 and shGRHL2 #12) transfected with miRNA mimics of negative 
control, miR-200a, miR-200b, miR-203a and miR-205. 
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